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 “Never doubt that a small group of thoughtful, 
committed citizens can change the world; indeed, it’s the only thing that ever has.” 
 
    ~ Margaret Mead  
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Abstract 
Institutional policy processes (whether pre-legislative, legislative, post-legislative or 
administrative) in the European Union (EU) are probably among the most commonly 
misrepresented and misunderstood processes in Europe. The relationship between 
institutional actors and the general public, (mis-) informed and influenced by media outlets, 
is often hindered by high levels of distrust and by barriers to communication. 
One issue that has attracted considerable concern has been the role of vested interests, 
represented by large teams of lobbyists, in the development of legislation and regulations. 
This has led some to characterise the EU as having been captured by “big business”, to the 
detriment of Europe’s citizens. Yet while there is extensive circumstantial evidence of the 
ability of these interests to exert influence, for example through meetings with key decision-
makers, and in a few cases from the inclusion of specific features in legislation (or a failure to 
legislate), it is more difficult to quantify such influence.  
One approach that has been considered to offer potential in this regard is quantitative text 
analysis (QTA). This refers to the application of one or more methods for drawing statistical 
inferences from text samples. In contrast, qualitative text analysis methods are comparatively 
more inductive, non-statistical and exploratory. QTA has been used to show a progressive 
shift away from language used in public health submissions on EU tobacco legislation towards 
that used by the industry. 
This study begins with the premise that industry, and especially multinational corporations, 
and possibly other stakeholder groupings (e.g. trade organizations, industry front groups) use 
particular vocabulary, evidence, position-taking and semantic shifts to influence the policy 
process. Business case language and economic perspectives dominate over a narrative 
featuring public health or ethical concerns. The study then explores the scope to use QTA as 
a tool to “interrogate” the subject (the text submitted to a public consultation), to examine 
and assess the content of public consultation documents and to evaluate the policy position 
of stakeholders as well as their evolution. Finally, it asks whether a more sophisticated 
package of tools, including QTA of policy briefs, mission statements or policy papers, can 
complement traditional methods such as stakeholder analysis to provide a more robust 
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assessment that can protect public institutions against misuse and misrepresentation of 
scientific evidence in public consultations. 
I do this by investigating the experience of public consultations in influencing the evidence 
base for institutional policy-making in the field of health, aiming to identify who stands to 
benefit from public consultations and whether they achieve an advantage. I propose that QTA 
could help to foster a dialogue between groups weakly or rarely represented in public health 
consultations and institutional knowledge systems, and focus attention on the role of public 
consultations in challenging power hierarchies between public health activists, industry 
professionals and regulatory affairs practitioners as risk managers.  
I undertake QTA in three separate health-related case studies in which some variant of public 
consultation took place.  
This study looks at:  
a) the experience of public consultation applied to a draft scientific opinion by the European 
Food Safety Authority (on the chemical compound acrylamide),  
b) the process of consultation on the findings of an externally commissioned study on 
pharmaceutical pricing policy in Europe and  
c) the draft text sequence of an important piece of EU legislation as it progressed through the 
co-decision procedure, the application of rights of patients in cross-border healthcare, i.e. 
Directive 2011/24/EU. 
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Chapter 1. The corporate determinants of health, and why they 
matter 
There is growing interest in what have been termed the corporate determinants of health. 
This interest builds on findings from research in a number of initially disparate fields, including 
the environment, working conditions, chemical safety, and marketing of a variety of products 
that impact directly on health, such as tobacco, alcohol, and energy dense foods. Those 
working in each of these fields have recognised that the political economy of corporate 
interests may influence the greater public good (Wiist, 2010). There is a growing concern that 
powerful economic interests play a major role in shaping the environment in which health-
related decisions are made, whether by individuals, in their purchasing choices, habits or 
socially acceptable practices, or by public authorities, in their decisions about measures such 
as marketing authorisations, taxation or regulation.  
 
The overconsumption of tobacco, sugar, fat and salt is engendering a rising prevalence of 
major chronic diseases, spiralling health care costs and declining population health and 
productivity (Millar, 2013). Marketing products that are damaging to health and the 
environment, at prices that do not account for these damaging effects, often targeting 
consumers that are ill-informed and susceptible (e.g., children or socio-economically 
vulnerable groups such as those with low education) is contributing to negative externalities 
(e.g. further poverty, pollution or climate change). It furthermore contributes to rising health 
inequities (Millar, 2013). The latter translate into further socio-economic inequalities 
perpetuated through generations as health, education and economic productivity are 
intrinsically inter-related (Onarheim et al., 2016).  
 
The “commercial determinants” of health and health inequity 
These developments reflect a growing concentration of power in the hands of multinational 
corporations, many with annual turnovers far in excess of all but the richest countries. 
Globally, higher intake of unhealthy foods correlates strongly with higher tobacco and alcohol 
sales, providing evidence that trade liberalisation and other policies promoted by these 
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corporations benefit industries producing different unhealthy commodities (Stuckler et al., 
2012). Moreover, the activities of these corporations are one crucial component of the 
‘commercial determinants’ of health, which, in broad terms, describe the economic and 
political institutions that structure the production, distribution, and sale of unhealthy 
commodities (Kickbusch et al., 2016).  
 
From the earliest days of what would now be called epidemiology it was clear that some 
people enjoyed much better health than others and that these inter-group gaps were related 
to the circumstances in which they were born and lived their lives (Marmot et al., 2008). In 
other words, people were placed in positions in a stratification system because of the 
circumstances in which they were born. Health inequality is acted out through various 
mechanisms – one of them being the ways in which corporate power is deployed, for example 
via marketing of health-damaging products. I start from the premise that industries producing 
tobacco, alcohol and energy-dense foods, in shaping the ‘commercial determinants’ of health, 
contribute to the proliferation of health inequalities, to the detriment of a better health-
informed, more meritocratic society. Health inequalities deserve further scrutiny beyond this 
brief mention here, not least via the examination of the root causes of ill health. Presently, 
health inequality as a phenomenon could benefit from further investigation into the paucity 
of evidence connecting health-related habits to lifestyle choices and social class transmission 
through the generations. 
 
This introductory chapter covers different points of interpretation of the role of industry and 
notes its influence on health policy. It equally serves as a reference chapter for the rest of the 
thesis discussing the implications of this role, and particularly those aspects of the role 
involved in the interplay with public policy affecting health, with the ultimate goal of reducing 
health inequalities. 
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Tactics used by corporations 
The tobacco, food, and alcohol industries stand opposed, in many instances, to the aims of 
the public health community, and in too many instances industry has been able to slow (and 
in some cases even stop) action on non-communicable diseases. Crucially, corporations use a 
wide range of tactics to tilt the playing field in their favour: most notably, corporations such 
as tobacco companies use philanthropic contributions and public relations strategically to 
gain political influence (Tesler and Malone, 2008). Detailed research to identify charitable 
causes deemed attractive to elected officials helped various lobbies and industries to target 
their charitable contributions and thus exert leverage to achieve their legislative objectives. 
Business alliances and multinational corporations fund industry front groups that pose as 
consumer or patient groups or think tanks and use names that seem bland and supportive of 
public health, free choice, pluralism, etc. (e.g. the Center for Media and Democracy) (Wiist, 
2010). Corporate Social Responsibility measures also divert attention away from enforceable 
standards and compliance with laws.  
 
The influence of industry spreading through research networks is also noteworthy. 
Manipulation of scientific research and information is now widely employed by industry, and 
it can translate into undue influence on universities – for example, via partnerships with 
corporations to fund an institute bestowing university-conducted confidential research and 
the rights to license the research results (Wiist, 2010). Another common tactic entails funding 
studies which, by design, will fail to detect a significant effect of a public health measure (e.g. 
standardised packaging) on smoking prevalence (Laverty et al., 2014, Diethelm and McKee, 
2014) or supporting studies where the power to detect an effect is low. 
 
Since the tactics discussed above have recently received considerable attention in the 
literature, a number of comprehensive and robust taxonomies of schemes employed by 
vested interest groups exist. I have used a recent paper categorising and listing unhealthy 
industry tactics (Moodie, 2017b) as the backbone of other influential work I reviewed as part 
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of my literature review, in a quest to showcase the wealth and depth of tactics unveiled as at 
work in policy-making, fully documented in specialist literature. Table 1 illustrates tactics 
assembled by Rob Moodie, drawing on a summary from the following sources: Oreskes and 
Conway’s “Merchants of Doubt” (Oreskes and Conway, 2010), Wiist’s “The Corporate 
Playbook, Health, and Democracy: The Snack Food and Beverage Industry’s Tactics in 
Context” (Wiist, 2011) and Freudenberg’s “Lethal but Legal” (Freudenberg, 2014), supported 
by further examples identified by the author. 
Table 1-1 “What Public Health Practitioners Need to Know About Unhealthy 
Industry Tactics” 
1. Attack 
legitimate 
science 
1.1 Accuse 
science of 
deception or 
uncertainty, 
calling it “junk 
science” or “bad 
science”, 
claiming 
manipulation to 
fulfil political 
aims. 
Seeding doubt has previously been labelled 
as a “denialist technique”; first popularised 
by the American Hoofnagle brothers, it 
involves the use of rhetorical arguments to 
give the appearance of legitimate and 
unresolved debate about matters generally 
considered to be settled. The term can be 
traced to people who deny the existence of 
the Holocaust, but it has been applied much 
more widely (McKee and Diethelm, 2010). 
More specifically, this tactic has been 
labelled “identification of conspiracies”: 
denialists argue that scientific consensus 
arises not as a result of independent 
researchers converging on the same view 
but instead because researchers have 
engaged in a complex and secretive 
conspiracy. They are misusing the peer 
review process to suppress dissent rather 
than fulfil its legitimate role of excluding 
16 
 
work that is devoid of evidence or logical 
thought (McKee and Diethelm, 2010). 
 1.2 Insist that 
there are many 
causes to a 
problem and 
that addressing 
just one of them 
will have 
minimal impact. 
Undermining the case for public health 
action has been equally labelled  as 
“denialism”; for instance, the tobacco 
industry maintained for many years that it 
was unaware of research about the toxic 
effects of smoking, especially passive 
smoking (Diethelm et al., 2005). 
 1.3 Exaggerate 
the uncertainty 
in any scientific 
endeavour to 
undermine the 
status of 
established 
corpora of 
scientific 
knowledge. 
The tobacco, energy, arms and chemical 
industries work to make sure debate is kept 
alive by developing false dichotomies 
(Moodie, 2017a). 
 1.4 Use 
corporate-
funded studies. 
Well documented in the past (Diethelm and 
McKee, 2014) and also focusing on stroke-
related alcohol consumption (McCambridge 
and Hartwell, 2015a). Also, a working paper 
at the University of Zurich evaluating plain 
packaging on smoking prevalence of minors 
in Australia, unsurprisingly used data and 
methods  that would fail to detect any 
expected effect. (Diethelm et al., 2005). 
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2. Attack and 
intimidate the 
scientists 
2.1 Seed doubt 
by attacking the 
authenticity and 
integrity of the 
author. 
A classic tactic is the naming of 
environmentalists as “watermelons” (green 
on the outside and red on the inside) to 
transfer fear and hate of communism on the 
environmentalist movement (Moodie, 
2017a). 
 2.2 Infiltrate 
scientific groups 
and monitor 
exponents. 
The tobacco industry introduced serious bias 
that probably influenced scientific and 
public opinion in Germany, based on 
network analysis of the industry’s links to 
scientific establishments; science was 
distorted in five ways: suppression, dilution, 
distraction, concealment and manipulation 
(Grüning et al., 2006). 
 2.3 Create 
enough doubt to 
forestall 
litigation and 
regulation. 
One common tactic is to always demand 
more proof. Another is to flood public 
officials with freedom of information 
requests based on unlimited legal resources 
(Collin and Hill, 2013). 
 2.4 Promote 
self-regulation 
and voluntary 
codes 
Companies present themselves as socially 
responsible actors, at pains to stress their 
commitment to tackling alcohol-related 
harm – many highlighting measures they 
had taken or programs they had endorsed to 
this end (Hawkins and Holden, 2013). 
3. Create arms-
length front 
organisations 
3.1 Create front 
groups or run 
projects through 
them 
(“information 
“Information laundering” is a term used to 
describe how “alternative science” is 
“cleansed”, just as money is, to create the 
impression that the claims being put 
forward were scientific (Moodie, 2017a). 
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laundering”), 
especially law 
firms that can 
avoid scrutiny 
because of 
“attorney-client 
privilege” 
The “attorney-client privilege” has been 
recently quoted in the press in relation to 
lobbying opportunities in Brussels (Wermke, 
2017). 
 3.2 Create 
research 
institutes or 
think tanks that 
can create their 
own scientific 
studies (and 
publish findings 
selectively) 
Coca-Cola evidence:  a group that was set up 
to promote debate about “energy balance” 
in an effort to combat obesity closed down 
after it was found that its funder, Coca-Cola, 
had a hand in some of its decision making 
(Kmietowicz, 2015b). 
Further evidence of selective publication 
(Lexchin et al., 2003), in that research 
funded by drug companies was more likely 
to have outcomes that favour the sponsor’s 
product than research funded by other 
sources. Explanations include the selection 
of an inappropriate comparator to the 
product being investigated and publication 
bias (Lexchin et al., 2003). 
4. Manufacture 
false debate and 
insist on 
balance 
4.1 Create a 
controversy and 
instil distortion 
of truth 
For instance, by insisting that alcohol 
advertising helps consumers choose 
between brands (Petticrew et al., 2017b). 
 4.2 Divert 
attention from 
harm, focusing 
on CSR, or on 
Scepticism about reliance on CSR 
programmes to achieve social policy 
objectives extends far beyond tobacco 
control (Collin, 2012). Confirmed by 
19 
 
other issues as 
the problem 
literature on community alcohol 
partnerships (Petticrew et al., 2017a). 
The limits of CSR were discussed at length in 
a dedicated paper (Fooks et al., 2013). 
5. Frame key 
issues in highly 
creative ways 
5.1 No need to 
look for a 
solution 
(problem too 
complex) 
Insisting that the problem is  in and of itself 
very complex and so cannot have a simple 
solution (Moodie, 2017a). 
 5.2 Invoke time: 
premature to 
suggest 
remedies 
Denialists highlight any scientific 
disagreement (whether real or imagined) as 
evidence that the entire topic is contested, 
and argue that it is thus premature to take 
action – also known as “manufacture of 
doubt” (McKee, 2010). 
 5.3 Insist 
technology will 
obviate need for 
regulation 
Assuring the public that technological 
advances will obviate the need for 
regulation, insisting that the marketplace is 
the only way to solve the problem (Moodie, 
2017a). 
 5.4 Invoke 
personal or 
parental 
responsibility: 
no need for a 
nanny state 
The central “Stop Out of Control Drinking” 
Diageo funded “responsible drinking” 
campaign in Ireland (Diageo being an alcohol 
producer) employed a narrative around 
“attitudes, motivations, and behaviours” 
and the involvement of psychologists has 
strong resonances with the tobacco industry 
“sociological program,” which recruited 
behavioural scientists to develop a tobacco 
industry narrative around individual 
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smokers’ motivations (Petticrew et al., 
2016). Similarly, other studies stress 
individual responsibility and risk 
management – with “responsible drinking” 
as an industry-affiliated term (Maani Hessari 
and Petticrew, 2017). 
 5.5 Use 
colourful 
imagery 
The controversial “Out of control” drinking 
campaign in Ireland – a focus on culture, 
peers and the family (Petticrew et al., 2016). 
 5.6 Use 
scaremongering 
(fear factor) as a 
tool for change 
of policy. 
Many invoke the power of fear to drive 
nonsensical policies  (Moodie, 2017a). 
 5.7 De-escalate: 
diminish the 
severity of the 
problem or 
admit that it is a 
serious one, but 
not a life-
threatening one 
Other methods of misrepresentation include 
using “red herrings” (deliberate attempts to 
divert attention from what is important), or 
building “straw men” (misrepresentation of 
an opposing view so as to make it easier to 
attack) (McKee, 2010). Also, use excluded 
middle fallacies (in which the “correct” 
answer is presented as one of two extremes, 
with no middle way). Thus, passive smoking 
causes either multiple forms of cancer or 
none, and as it can be shown not to cause 
some it must, it is argued, cause none 
(McKee, 2010). 
 5.8 Use 
flattering 
comparators: 
Also, the use of false analogies (for example, 
because both a watch and the universe are 
extremely complex, the universe must have 
21 
 
the problem is 
serious, but less 
severe than 
other problems 
that should 
receive priority 
been made by some cosmic watchmaker) 
(McKee, 2010). 
 5.9 Cost to fix 
the problem too 
high, benefits of 
the problem 
have not been 
considered and 
other options 
await 
Across the last century, major tobacco 
companies successfully embedded the 
cigarette into nearly every aspect and arena 
of culture, worldwide, in order to keep 
smoking “normal” and its promotion 
acceptable (Wiist, 2010). 
 5.10 Harness the 
power of 
language: be 
sure to use 
certain 
language, in the 
face of 
uncertain 
language on the 
other side  
Use pejorative language repeatedly e.g. 
“overregulation”, “nanny state”, “excessive 
regulation”, “unnecessary red tape” 
(Moodie, 2017a). 
6. Finance industry 
disinformation 
campaigns 
6.1 Fund such by 
using novel 
techniques (co-
opt celebrities, 
sympathetic 
expert 
“Message force multipliers” are expert 
witnesses paid by the industries they 
represent (Moodie, 2017a). 
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witnesses, 
sponsor 
conferences 
challenging 
scientific 
consensus and 
align with other 
issues e.g. anti-
tax groups). 
7. Influence the 
political agenda 
7.1 Donate to 
political parties 
across the 
political 
spectrum 
SABMiller engaged the influential think-tank 
Demos to produce reports on binge 
drinking, which were heavily promoted 
among policy makers at key stages during 
the development of the UK government’s 
2012 alcohol strategy – this was an effort to 
marginalise peer-reviewed literature 
(Hawkins and McCambridge, 2014). 
 7.2 Mobilise 
representatives 
from unhealthy 
industries 
around the 
policy table, for 
standard setting 
or guideline 
development 
In using fake experts, the tobacco industry 
coined the term “Whitecoats” for those 
scientists who were willing to advance its 
policies regardless of the growing scientific 
evidence on the harms of smoking (McKee, 
2010). 
 7.3 Invest in 
paid lobbyists. 
The creation of front organisations, kept at 
arms’ length from the mother company – 
e.g. via prestigious public relations agencies 
(e.g. Hill and Knowlton) and via legal firms 
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who avoid scrutiny through the client-
attorney privilege, discussed above (Moodie, 
2017a). 
 7.4 Make 
“friends” in 
important and 
influential 
government 
roles (by 
targeting their 
advisers, 
recruits or 
senior officials 
leaving office). 
The Center for Responsive Politics ‘s 
Revolving Door project intends to identify 
professionals whose career  trajectory has 
taken them from Capitol Hill, the White 
House and Cabinet offices to K Street, and 
vice versa. Its database is the most 
comprehensive source to help the citizens 
learn who’s who in the Washington 
influence industry (Wiist, 2010). 
 7.5 Aim to 
reduce 
government 
budgets for 
regulatory, 
scientific or 
policy activities 
against the 
corporate 
interest. 
The industry engages in covert intelligence 
activities aimed at undermining public 
health, which it refers to as “the anti-
tobacco industry”, continuously testing the 
limits of the law (Wiist, 2010). 
  
Table 1-1 documents in detail a taxonomy of unhealthy industry strategies to dominate the 
regulatory playing field, to the detriment of the average consumer. At the same time, the 
tactics listed, echoed in specialist literature via dedicated case studies or further 
investigations, serve well the policy need for transparency. They thus identify tactics and sub-
techniques that are ripe for future scrutiny, preparing the ground for a system of checks and 
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balances that may counter such distortion or untruth and level the playing field for more 
effective regulatory measures. The non-direct dominance and confrontation tactics employed 
by various industries are more and more uncovered via the field of corporatology, the study 
of harmful industries. In the budding field of corporatology, framing issues are key in that 
industry-affiliated terms, such as “responsible drinking”, become strategically ambiguous, not 
clearly defined with relation to any particular level of alcohol consumption, and hence 
allowing for multiple interpretations (Maani Hessari and Petticrew, 2017). We now move to 
discuss power elites (who create and shape meaning in interpretation), their discourse and 
its health implications. 
Power elites and health 
 
The relationship between power and health is complex, consisting of vectors of constructs 
and systems of power that produce inequities at multiple levels. Analysing the influence of 
transnational power elites across different, albeit linked dimensions, is essential to better 
grasp the operationalization of power in shaping global health. Power elites often advocate 
for a diminishing role of the state via less progressive taxation yet simultaneously for an 
increase in its role as a source of state subsidies to them, such as access to basic science 
research undertaken in government facilities or research funding, and a protector of their 
intellectual property rights. Thus, they contribute to a skewed, contradictory, self-centred 
approach that fails to improve society beyond the status quo. 
 
This thesis will look explicitly at the role of power elites, the contradictions of the concepts 
and positions they espouse and what can be done practically to give a voice to the unheard 
and power to the powerless.  
Defining the narrative 
Language is central to expressing political opinion. However, this is both an advantage and a 
challenge: mass communication has created powerful platforms that have become the 
vehicle for an impressive volume of text underpinning narratives in current use. At the same 
time, ownership of mass media has long been a source of power (such as the case of Rupert 
Murdoch, the Media Mogul).  Power elites have the ability to frame the dominant narratives 
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of the moment on the determinants of health – for example, whether obesity, diabetes, heart 
disease, COPD, or cholesterol levels linked to food intake and other health-related behaviours 
are framed as issues pertaining to individual choices or societal characteristics anchored in 
the community (Johnson-Cartee, 2005). They also directly influence these determinants 
through their marketing activities, their expert advice to consumers or other actors as well as 
how people work, go about their lives and seek pleasure (such as whether alcohol use, 
substance abuse and tobacco are acceptable social norms). Power elites can influence 
people’s belief construct on how society should examine habits and handle interactions with 
their most pressing health threats, using the discourse that they choose.  
Setting the rules 
Power elites can influence regulatory bodies by placing their advisors on committees or by 
creating revolving doors that enable officials to move into lucrative consultancies or front 
groups (e.g. research institutes) or public affairs consultancies, for example once they have 
retired. They capture elected officials in office, who vote for the interests of their elite funders 
(Gilens and Page, 2014).  Power elites also shape health decisions through their tremendous 
influence on how and where decisions are made and the creation of mechanisms that ensure 
that they will survive and prosper. They deploy their research methods and concrete, 
technical expertise to define global standards, exemplified by the manner in which the 
tobacco industry set the standards for measuring the constituents of cigarette smoke, 
including design of the machines used for this purpose or the predominance of corporate-
minded scientists representing agri-food industries at the Codex Alimentarius meetings. 
Last but not least, the purpose of the thesis is not to simply add to the literature on the 
behaviour of corporations that have stakes in public health policy but to develop a tool to 
understand the positions of the different forces, public and private, better. In this perspective, 
decision-making is improved and actors help the playing field to evolve, rendering manners 
of engagement more equitable and more transparent. 
 
This section began by noting that the activities of Multinational Corporations are subject to 
the influence of health policies in a number of ways. These include legislative and regulatory 
measures, such as bans or restrictions on marketing or use of certain products and imposition 
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of technical standards, some of which may be linked or incorporated into trade deals, creating 
what have been termed “non-tariff barriers to trade”. The next chapters will then show how 
corporations have a strong interest in influencing these policies, given the potential to impact 
on their growth and profitability. This can involve arguing for such measures to operate on a 
voluntary rather than a statutory basis, linking conditionalities or shaping the technical 
aspects of the legislation and regulation. It can also include seeking to shape public and 
political opinion about the legitimacy of taking any government action at all, such as the 
tobacco industry’s opposition to smoking bans. This is important because many corporations 
are now larger, economically, than many states and the larger a corporation’s revenue and 
the greater the regulatory pressures placed on it, the greater will be its political activity 
(Hansen et al, 2004). In this way, this Chapter has set the scene for the rest of the thesis. 
The next chapter will look concretely at how structures and processes for decision-making 
offer opportunities for influence to be exerted. I will then revisit table 1-1 to delve deeper 
into what is currently known about how industries have exerted influence in the field of health 
and how this corporate influence has been studied previously. Thereafter, the methods and 
research question chapter will take centre stage, followed by the results of the three case 
studies, their conclusions and corresponding discussion.  
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Chapter 2. Why is the European Union a target for corporations?  
The European Union is a prime target for transnational corporations because of the size of its 
market (circa 500 million people) and because its policies have wide-ranging effects, either 
direct (regulations) or following their transposition into national law (directives). Thus, to take 
two examples, within the European single market, the EU has competency for marketing 
authorisations for nearly all foodstuffs and pharmaceuticals, both areas of great commercial 
interest to major corporations, but also with substantial implications for human health.  
This section will describe the key European institutions as set out in the Treaty of Lisbon (the 
European Commission, the European Parliament and the Council of Ministers) and show why 
they represent targets for corporate influence. It will describe how these institutions operate, 
setting out the stages in the Ordinary Legislative Procedure, the standard procedure for 
passing legislation applicable in the EU. This will show how amendments introduced by the 
European Parliament and the positions of the Member States expressed in the Council 
debates offer opportunities for influence from various interest groups to be exerted. This 
section will give the reader a solid grounding in the EU legislative process and the scope to 
influence it, thus providing context for the remainder of the thesis. 
The European Institutions   
Before considering the influence of corporations at a European level it is necessary to 
introduce the European institutions, those bodies responsible for policy, legislation, and 
regulation. Their roles have evolved over time but are governed by the most recent European 
Treaty, which, at the time of writing, is that signed at Lisbon on 13 December 2007 by the 
heads of state and government of the then 27 EU Member States (Croatia only joined the EU 
in July 2013), and entering into force on 1 December 2009. The Lisbon Treaty sought to ensure 
that the functioning of the European Union reflected changes following the two waves of 
enlargement which had taken place since 2004 and which increased the number of EU 
Member States from 15 to 27. The Lisbon Treaty was drafted as a replacement for the 
Constitutional Treaty, which was rejected by French and Dutch voters in referenda in 2005.  
The Treaty of Lisbon recognises the following entities as fully-fledged institutions: 
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· The European Council, made up of the Heads of State or of Government of the EU and 
the President of the European Commission, meeting at least twice a year, setting the 
overall direction for the European Union; it does not normally adopt legal acts formally 
binding the Member States but issues declarations containing guidelines for future 
Community actions (Moussis, 2007). 
· The Council of Ministers (the Council), composed of a representative of each Member 
State at ministerial level, authorised to commit the government of that Member State. In 
practice, the Council of Ministers meets in ten different formations (also called 
configurations), each addressing a particular area. Thus, health issues will be discussed by 
the EPSCO Council (Employment, Social Policy, Health and Consumer Affairs Council), 
comprising health ministers from the Member States. Working groups comprising 
national experts and health attachés prepare meetings of the EPSCO Council, which are 
usually at Ministerial level. The preparatory work for the EPSCO configuration is done via 
five working groups specialising in health, social questions and food safety: the 
Pharmaceuticals and Medical Devices Council Working Group, the Working Party on Social 
Questions, the Working Party on Public Health, the Senior Working Party on Public Health 
and the Working Party on Foodstuffs (Council of the European Union, 2017). 
· The European Parliament (EP), consisting of 751 members elected by direct universal 
suffrage, allocated broadly in proportion to a Member State’s population (e.g. following 
the accession of Croatia to the EU, Germany has 96 seats and the UK has 73 seats); the EP 
has legislative, political, supervisory, and budgetary functions. 
· The European Commission, composed of the College of Commissioners (1 per Member 
State) and the Commission services, composed of multinational departments of civil 
servants, is the institution that has the right to initiate proposals for Community decision-
making (this right is however not exclusive, since The Treaty of Lisbon gives citizens the 
possibility to influence the initiatives of the Commission, under certain conditions). The 
Commission is also the guardian of the Treaties and of all the Community’s legislation. 
Therefore, it has the task of ensuring that the Member States fulfil their obligations and 
appropriately apply the provisions of the Treaties and of secondary legislation. For this, it 
has investigative power and can refer a Member State to the European Court of Justice if 
it considers that there is a case of infringement of Community legislation (Moussis, 2007).  
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· The Court of Justice of the European Union (actually a number of bodies but usually 
referred to as its main constituent, the European Court of Justice), seated in Luxembourg, 
is responsible for providing a coherent and uniform interpretation of European law, and 
for ensuring that Community law is observed in a uniform manner. The Court plays an 
important role in the European process by clarifying ambiguous legal provisions, which 
are sometimes the result of pressure to reach agreement between law-makers with 
various national interests (Moussis, 2007).  
Beyond these institutions, the Lisbon Treaty recognises the status of “advisory bodies” to the 
Economic and Social Committee and to the Committee of the Regions. Other entities such 
as the European Central Bank and the Court of Auditors are also recognised as “other 
institutions and advisory bodies”, yet their role does not grant them the status of a fully-
fledged institution (Moussis, 2007). 
Some national politicians have criticised what they see as the “democratic deficit in the EU”. 
For example, they argue that Members of the European Parliament are remote from their 
constituents and they portray the EU policy and legislative process, involving the Council, the 
European Parliament and the Commission as lacking legitimacy (McKee et al., 2010). Many of 
these arguments are based on misunderstandings or, in some cases repeated 
misrepresentations. However, sustained by hostile media, in some countries these arguments 
have been used by some politicians to undermine the legitimacy of the European institutions. 
There is, however, a debate about the most appropriate level at which to take action, with 
differing views about whether a problem can most effectively be addressed at a European or 
national level. This has given rise to the principle of subsidiarity, where decisions are taken at 
the lowest level commensurate with their ability to address the issue in question. In addition, 
even where there are shared problems in some areas, the diversity of national contexts has 
made it especially difficult to create binding European legislation. This is especially true in the 
area of social policy where, although there are many common principles, there are also many 
differences of detail in the way that Member States organise their social protection and health 
systems. Thus, Tamara Hervey argues that a response to the problem of “social Europe” has 
been new forms of governance, i.e. a range of processes and practices that have a norm-
setting or regulatory dimension but do not operate primarily or at all through the 
conventional mechanisms of command-and-control-type legal institutions (Letsas and 
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O'Cinneide, 2011). Command-and-control responses are considered problematic since the 
treaties restrict the competence of the European institutions in areas such as health services. 
However, the interface between health services and other areas that are fully within the 
competence of the European institutions, such as the single market and, in particular, free 
movement of goods, such as pharmaceuticals, and services, such as some providers of 
healthcare, is often unclear or contested. This previously led to several cases where the 
European Court of Justice has had to resolve uncertainties, such as those affecting patient 
mobility, in those cases arising from lack of clarity in the legislation, although these particular 
issues have since been clarified in a directive on cross-border healthcare. Therefore, the 
binding nature of EU internal market law and gaps in equally binding EU social law have led 
to new governance processes, such as the Open Method of Coordination (OMC). The OMC is 
used in the social security field, via the regular meetings of the Administrative Commission, 
made up of at least one specialist representative per Member State and the European 
Commission discussing bilaterally and multilaterally the entitlements and reimbursements in 
the field of social security. The ongoing review of the Social Security Regulations, Regulations 
(EC) No 883/2004 and their implementing acts, within the context of the Labour Mobility 
Package, is testimony to how social questions (e.g. invalidity pensions, posting of workers and 
family benefits regulation) remain a thorny issue. The Labour Mobility Package is to be 
adopted by 2019. 
EU Decision-making  
The co-decision procedure, the EU’s standard decision-making procedure, is known as 
‘Ordinary Legislative Procedure’. In a seminal paper on the subject, David Bostock argued that 
“co-decision is a complex procedure whose unwritten rules and behavioural norms have 
developed, are still developing and are not easy quickly to grasp” (Bostock, 2002). Moreover, 
he notoriously quipped: “if all EU negotiation is a dark mystery, legislative co-decision is a 
blacker shade of dark” (Bostock, 2002). The great majority of co-decision files fall within the 
remit of policies dealing with the Internal Market, e.g. Transport, Energy, Environment, 
Research, Consumer Protection, Culture, Education and Health and Food Safety. 
As depicted graphically in Figure 2-1 below, it is the Commission that proposes new 
legislation, consulting interested parties such as non-governmental organisations, local 
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authorities and representatives of industry and civil society. Groups of experts give advice on 
technical issues. Citizens, businesses and organisations can participate in the consultation 
procedure via the website “Public consultations” (European Commission, 2017b). National 
parliaments can formally express their reservations if they feel that it would be better to deal 
with an issue at national rather than at EU level. The Commission’s proposals must then be 
agreed by the Council and the Parliament, proposing amendments as appropriate. If the 
Council and the Parliament cannot agree upon amendments, a second reading takes place. In 
the second reading, the Parliament and Council can again propose amendments. Parliament 
has the power to block the proposed legislation if it cannot agree with the Council. If the two 
institutions agree on amendments, the proposed legislation can be adopted. If they cannot 
agree, a conciliation committee tries to find a solution (EUR-LEX, 2017). Both the Council and 
the Parliament can block the legislative proposal at this final reading. The two readings offer 
ample opportunities for interest groups to influence the tone, quality and quantity of 
amendments introduced by Members of European Parliament. Sessions of the European 
Parliament and some Council sessions are broadcast live online. 
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Figure 2-1 The Ordinary Legislative Procedure (the Co-decision procedure)  
 
Source: (Parliament, 2017) 
From a theoretical perspective, the story of hard regulation, as depicted above, can be 
understood in terms of a struggle between competing civil society and corporate coalitions 
(Smith et al., 2015). Although one cannot rule out the possibility of industry’s genuine 
commitment to self-regulation for the common good, there is now overwhelming evidence 
that self-regulation or soft regulation discourse (as opposed to hard regulation in terms of 
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binding rules to be observed) should be approached critically and seen as an opportunistic 
tactical adaptation to policy change (Peeters and Gilmore, 2015, Knai et al., 2015, Savell et al., 
2016, Martino et al., 2017). Civil society groups believe in the need for greater EU regulation 
to guard against social and environmental harms (including harm to health), whilst corporate 
advocates believe that regulation of economic actors at EU level should be as limited as 
possible so as to safeguard free market ideals and promote competitiveness (Smith et al., 
2015). 
The Better Regulation Policy 
When Commission President Jean-Claude Juncker took office in 2015, he announced that he 
would implement a “better regulation” policy. Following many years of internal and external 
deliberation within the Commission and beyond it, with the evaluation community further 
afield, the Secretariat-General of the European Commission issued a set of guidelines that 
were subsequently endorsed by the College of Commissioners on how to implement a better 
regulation policy. A key component of this policy was the creation of a Regulatory Scrutiny 
Board (RSB), composed of senior European Commission officials and resource persons 
external to the Commission services, responsible for the quality control of impact 
assessments and, inter alia, the stakeholder consultation process. The members of the RSB 
are expected to adopt a challenge function, scrutinising the quality of the impact assessments 
and of the consultation process. Interestingly, the RSB or Impact Assessment Board does not 
include any representative from the Directorate-General or department responsible for 
health (Smith et al., 2015), nor did it do so in the past. This is notable, since sources indicate 
that the Board was deliberately chosen to reflect the main categories of impacts assessed as 
important by the European Commission (Radaelli and Meuwese, 2008). However, it has since 
been revealed that the tobacco industry and other corporate interests were able to exert 
considerable influence on the approach taken to impact assessment (Smith et al., 2010b), 
which now displays many of the characteristics known to favour corporate influence (Smith 
et al., 2010a). 
The rationale for open, public stakeholder consultation and how it came about 
As mentioned above, the Commission holds the right of initiative (not merely politically, like 
the European Parliament but also practically), also known as the right to draw up proposals 
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for legislation and policy. Luchetta and Akse argue that, since the Commission is not directly 
elected and does not therefore have a broad political mandate from the people of Europe, its 
legitimacy relies to an important extent on the quality of its actions and the substance of its 
deliverables, in the shape of legislative and policy proposals (Luchetta and Akse, 2014). The 
impact assessment (IA) policy and corresponding process is a step in that direction, 
introduced around the years 2000-2005, as a Lisbon Treaty obligation for all Member States, 
and not merely for the EU or its main institutions.  
Notwithstanding the serious concerns about its approach to impact assessment, the 
Commission has set itself the goal of basing all important legislative and policy decisions on 
sound analysis supported by the best data available. Impact assessments should collect and 
analyse evidence for political decision-makers, notably the College of Commissioners, on the 
advantages, disadvantages and trade-offs of possible policy options by assessing their 
potential social, economic and environmental impacts.  
The 18-month preparation process for Impact Assessments is depicted graphically in Figure 
2-2. An intrinsic part of the Commission’s internal decision-making procedure, the duration 
of the IA provides external stakeholders with ample opportunities to make their involvement 
count. 
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Figure 2-2     The ‘average’ timeline of an impact assessment  
 
 
 
Source: European Commission: www.ec.europa.eu 
 
The public consultation process (further described in Appendix D) was scaled up and given 
more prominence following adoption of the Commission’s Better Regulation Guidelines, in 
2015. This was portrayed as a means to counter what the Commission argued was undue 
delay in the passage of proposed legislation by the European Parliament and Council, 
involving the passage of multiple amendments introduced during successive readings of the 
legislative proposals. The public consultation exercise is presented as a means by which the 
European Commission can understand, consider, and address stakeholder views before the 
final proposal is submitted to the European Parliament and to the Council. This is portrayed 
as offering the considerable advantage of being more efficient, increasing the quality of the 
regulatory output, and reducing the risk of regulatory capture by vested interests. Thus, in 
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the European Commission, public consultation was mainstreamed as part of the impact 
assessment work. 
Public consultation is thus presented as a key regulatory tool to foster transparency, 
efficiency, effectiveness, accountability and interaction with interested members of the 
public (Rodrigo and Amo, 2006). Consultation is viewed as helping regulators balance 
opposing interests or bring into play expertise and the perspectives for alternative actions of 
those directly affected. It is also seen as a means to apply quality checks, identify unintended 
effects, assess administrative burdens and, last but not least, it can also identify synergies and 
contradictions between regulations from different parts of government.  
Voluntary compliance can be another positive side-effect of public consultation, according to 
the OECD. Compliance can be enhanced by announcing regulatory changes in a timely manner 
and by increasing the sense of legitimacy and shared ownership that motivate affected parties 
to comply with them. Of course, all these arguments are based on the questionable 
assumption that public consultations, by virtue of their openness, reduce the potential for 
capture by vested interests. This is an assumption that will be tested in this thesis. 
The European Commission seeks to avoid such capture, and to optimise its relations with 
stakeholders by applying four general principles (European Commission, 2014a): 
(1) Participation: consulting as widely as possible, being inclusive; 
 (2) Openness and Accountability: rendering the consultation process and how it has affected 
policy-making transparent to the general public and to those involved; 
 (3) Effectiveness: consulting at an appropriate time, when stakeholder views can still make a 
difference, respecting proportionality (a principle established in European law where any 
action must go far enough to achieve its aim but no further) and specific restraints; 
 (4) Coherence: ensuring consistency of consultation processes across all services as well as 
evaluation, review, and quality control. 
According to the European Commission, these principles are complemented by five Minimum 
Standards that all consultations must respect (European Commission, 2014a): 
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  A. Clear content of the consultation process (Clarity): Consultation material including 
the strategy document itself should be clear, concise and include all necessary information to 
facilitate responses; 
  B. Consultation of target groups (Targeting): When defining the target group(s) in a 
consultation process, the Commission should ensure that all relevant parties have an 
opportunity to express their opinions and have an active voice in the process; 
  C. Publication: The Commission should organise appropriate awareness-raising 
publicity and adapt its communication channels to meet the needs of all target audiences. 
Without excluding other communication tools, (open public) consultations should be 
published on the internet and announced at the “single access point”; 
  D. Time limits for participation (Consultation period): The Commission should provide 
sufficient time for planning and responses to invitations and written contributions; 12 weeks 
is a minimum; 
  E. Acknowledgement of feedback (Feedback): Receipt of contributions should be 
acknowledged and contributions published. Publication of contributions on the “single access 
point” replaces a separate acknowledgment if published within 15 working days. Results of 
(open public) consultations should be published and displayed on websites.  
There are considerable similarities between the approaches of the OECD and the European 
Commission, indicating synergies and mutual influence. 
A critical analysis of public consultation – what works, what does not, what concerns remain 
The design of this process is considered its strength. Its use of an online platform renders it 
publicly available, easily accessible, and convenient to monitor/follow. Also, the deadlines 
(minimum 3 months) are generally considered reasonable. However, there are concerns that 
the process may open the door to capture by vested interests during the consultation process. 
Coordinated lobbying and the creation of lobbying coalitions among interest groups may 
present the authorities with a ready-made solution (Jensen, 2015) and thus amplify the voice 
of powerful corporations compared to citizens’ grassroots organisations or civic purpose 
driven NGOs.  
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Further concerns relate to other aspects of transparency. Not all public consultations publish 
their input documents fully online – sometimes summaries drafted internally or by external 
consultants are the norm. Moreover, the weight given to the concerns raised is also unclear, 
essentially leaving this part of the process a black box. Peeters and Gilmore show that a 
seminal study dating back to 1999 by the Institute of Medicine in the US was pivotal in shaping 
tobacco industry discourse on harm reduction. Transnational tobacco companies adopted the 
concept “harm reduction” in response to the study, developed a CSR strategy around it and 
proceeded to deploy it extensively in corporate messaging (Peeters and Gilmore, 2015) to 
secure reputational benefits. The paper illustrates how discourse and container concepts such 
as “harm reduction” can be seen as opportunistic tactical adaptations to policy change rather 
than a genuine commitment to harm reduction. Care should be taken that vital wins hitherto 
secured are not undermined or reversed by efforts from the tobacco industry to 
inappropriately influence policy (Peeters and Gilmore, 2015). 
Ultimately, the consequences of this model public consultation may only become clear in 5-
10 years’ time, when there have been sufficient numbers of public consultations on sensitive 
subjects (e.g. endocrine disruptors, tobacco, sugar) or documents brought as evidence in 
litigation pursuits have seen the light of day and have been subjected to scrutiny by 
researchers. There are, for now, concerns that public consultations represent a new arena 
where interest groups can exert a specific kind of influence and engage in power games, for 
example by paying a think-tank to promote an agenda, establishing a front group or hiring a 
law-firm to draft amendments.  
This thesis asks whether these types of influence can be identified using QTA, by means of 
case studies of recent public consultations. As such, it will contribute to the active debate on 
possible mitigation of remaining concerns in consultative pursuits. 
The role of interest groups - A brief review of their scale and nature in Brussels 
There are over 11,366 interest groups operating in Brussels currently, according to the 
Transparency Registry (accessed on 3 August 2017). Their estimated staff levels are in the 
range 15,000-30,000, according to Corporate Europe Observatory, making the EU quarter 
home to one of the highest concentration of lobbyists in the world (CEO, 2011). Formal 
membership of this registry is free of charge, yet not mandatory. Becoming a member of the 
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registry is a precondition for submitting valid consultations via the public consultation 
procedure of the European Commission.  
The Code of Conduct in Annex 3 of the 2014 Inter-institutional Agreement on the 
Transparency Register sets out the rules for all those who register and establishes the 
underlying principles for standards of behaviour in all relations with the EU institutions, inter 
alia not trying to obtain information or decisions dishonestly or by use of undue pressure or 
inappropriate behaviour, providing complete identification whenever needed, not selling to 
third parties copies of EU documents obtained from the institutions and not disseminating 
complete or disseminating outdated or misleading information. 
The EU lobby Transparency Registry is publicly available and is structured in the (sub)sections 
listed in Table 2-1. 
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Table 2-1   Sections of the EU Transparency Register 
Section Name of category Total Breakdown per 
subsections 
I Professional consultancies/law 
firms/self-employed consultants  
 
1,328 -Professional 
consultancies 769  
-Law firms 141  
-Self-employed 
consultants 418 
 
II In-house lobbyists and 
trade/business/professional 
associations  
5,618 -Companies & groups 
2,113  
-Trade and business 
associations 2,326 
-Trade unions and 
professional associations 
852  
-Other organisations 327 
 
III Non-governmental organisations, 
platforms and networks and similar  
 
2,975 No further breakdown 
IV Think tanks, research and academic 
institution 
852 -Think tanks and research 
institutions 542  
-Academic institutions 
310 
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V Organisations representing churches 
and religious communities  
50 No further breakdown 
VI Organisations representing local, 
regional and municipal authorities, 
other public or mixed entities, etc.  
 
543 -Regional structures 120  
-Other sub-national public 
authorities 96 
-Transnational 
associations and networks 
of public regional or other 
sub-national authorities 
81  
-Other public or mixed 
entities, created by law 
whose purpose is to act in 
the public interest 246 
 
  ∑=11 366  
 
 
We will now turn to a public consultation’s individual components, the stakeholder 
contributions in the guise of “formal text submissions” or “policy positions/papers”. 
A brief review of evidence on how interest groups operate – Role of “Formal text submissions” 
and “policy papers” in the political process  
The preceding sections have described how the European institutions have responded to 
pressure for more formalized preparatory processes in the legislative process, including 
explicit frameworks, procedures, and instruments. These developments have also played out 
in many other settings, both in national governments and international organisations. As a 
consequence, formal text submissions have been gaining in importance in a variety of fields 
of policy-making (see appendix C). Authorities responsible for analysing these submissions 
need to undertake a robust analysis to make sense of their content as well as their intent. The 
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UK government’s website features more than 3,100 public consultations. The existence, and 
availability of this wealth of material, including larger volumes dealing with highly technical 
guidelines, has been seen as offering potential for the use of innovative approaches to 
research, and in particular, text mining techniques or machine-based text analytics. This 
approach has been applied to submissions on the topic of standardised packaging on the EU 
Tobacco Products Directive (Costa et al., 2014). Costa et al applied quantitative text analysis 
to evaluate the impact of tobacco industry pressure on EU policy-making and to expose the 
role of vested interests in the process. The analysis demonstrated the presence of textual 
shifts, so that, at the Commission stage, proposals for plain packaging and limitations on point 
of sale displays were removed. At the Parliament and Council stage of the legislative adoption 
process, the size of pictorial health warnings was reduced from 75% to 65% of carton size 
(Costa et al., 2014). By using Word scores estimated using the statistical software package 
STATA, Costa et al. concluded that, compared with traditional hand-coding methods, 
automated content analysis offers an objective quantification of policy positions. The 
underlying assumption is, however, that each actor’s ideology is expressed through word 
choice. 
Incidentally, even though the directive was amended in ways that were desired by the 
tobacco industry, the pressure to weaken it further continues. Very recently, Poland, 
supported by Romania, challenged the prohibition of menthol cigarettes (Case C-358/14) 
before the European Court of Justice in Luxembourg. On 4 May 2016, the Court ruled that it 
confirms the validity of the provisions of the Tobacco Products Directive and, in a linked case 
by a UK company, that the special rules applicable to electronic cigarettes do not infringe the 
principle of subsidiarity. 
As in any public policy debate, health policy-making can only benefit from vigilance by the 
organisations in charge of running the public consultation. However, if massive intrusions and 
misleading, obstructive submissions can be identified (Stuckler et al., 2016), a question that 
lies at the heart of the present thesis, there is a need for improved ways to understand the 
political positioning of stakeholders and where their policy priorities/interest lie, as well as 
offering a means to grasp better their margin of manoeuvre. For these reasons, it is possible 
that automated text analysis could help to understand stakeholder responses. 
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A more fundamental question relates to whether publication or public reporting of 
contributions/ submissions to a public consultation (as required by the European 
Commission) in general improves the quality of the submissions ex-ante, as stakeholders 
dedicate more time and effort to reflect what to focus attention on before submitting their 
contribution. Some studies have indeed suggested that incentives which pursue quality 
improvements through “professional reputation mechanisms” can be stronger than financial 
incentives (Rechel et al., 2016). 
Public opinion polls, surveys and speeches, election campaign manifestos and slogans are all 
vehicles of modern political communication that inherently rely on careful word choices and 
well thought-out semantics. It has already been demonstrated that greater ambiguity can 
help parties as they move to the centre, but it could hurt them as they move to the extremes 
(Lo et al., 2014).  
Given the growing importance of qualitative assessment of policy-related texts in many fields 
of politics, the challenge is how to understand the best argument that wins the case and how 
to examine the architecture of the case – especially, how arguments are stacked, diffused or 
intertwined. This approach could strongly influence health policy-making in ways that polls 
and survey data currently already do.  
 
What is known about how the industry has exerted influence in the fields of health and food 
safety in the European Union? 
 
Tactics employed by corporations: range of methods used to study their 
influence 
Much is known already (beyond Table 1-1) about the numerous and varied political tactics 
employed by corporations and other interest groups to effect influence on health policy and 
democratic processes, tactics that would favour the bottom line over the greater good. The 
larger a corporation’s revenue and the greater the regulatory pressures placed on it,  the 
greater will be the corporation’s political activity (Hansen et al., 2004).  
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Alliances 
A trend among corporations is to partner up with NGOs bestowing staff and programme 
budgets on them, thus avoiding confrontations (Wiist, 2010). Corporations such as tobacco 
companies use philanthropic contributions and public relations strategically to gain political 
influence (Tesler and Malone, 2008). Detailed research to identify charitable causes deemed 
attractive to elected officials helped them to target their philanthropic contributions and thus 
exert leverage to achieve their legislative objectives. Corporations and business alliances 
create or fund industry front groups that pose as consumer or patient groups or think tanks 
and use names that seem bland and supportive of public health, free choice, pluralism and so 
on (e.g. the Center for Media and Democracy) (Wiist, 2010). Without disclosing their 
affiliation or funding, such front groups seek to undermine scientific findings, most notably 
on global climate change and tobacco control (McKee and Diethelm, 2010).  
Corporate Social Responsibility Agendas 
The term “Corporate Social Responsibility” is now recognised as often being highly 
misleading. Frequently, it is used to divert attention away from enforceable standards and 
compliance with laws. To exemplify this, Peeters and Gilmore study the emergence and rise 
to prominence of the concept of “harm reduction” and its connection to CSR agendas of major 
tobacco companies. Simultaneous with the public health community’s emergent interest in 
tobacco harm reduction, transnational tobacco companies’ corporate social responsibility 
(CSR) agenda was increasing in prominence and Peeters and Gilmore’s findings suggest they 
were mutually reinforcing (Peeters and Gilmore, 2015). Their research shows that the CSR 
agenda emerged once evidence from US lawsuits began to damage the tobacco industry’s 
reputation seriously, signalling a pledge by industry to rebuild its lost reputation, improve its 
credibility and re-establish dialogue with public policy officials. 
Misusing research 
Manipulation of scientific research and information is another tactic at hand, which can 
include exerting corporate influence on universities – for example, via partnerships with 
corporations to fund an institute bestowing university-conducted confidential research and 
the rights to license the research results (Wiist, 2010). Much of the evidence on industry 
supported manipulation of research comes from the field of tobacco control, such as the 
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major program by Philip Morris to create uncertainty about the harmful effects of second-
hand smoke (Diethelm et al., 2005) and, more recently, its work to distort the evidence on 
the effectiveness of standardised packaging in Australia to reduce smoking prevalence 
(Laverty et al., 2014, Diethelm and McKee, 2014). Earlier examples include the long-standing 
industry funding for a number of eminent and highly influential epidemiologists and public 
health specialists in Germany (Gruning et al., 2006), an issue that cannot be ignored when 
seeking to understand the persistent opposition by successive German Governments to 
effective tobacco control. However, these tactics are not confined to the tobacco industry, 
with evidence that the alcohol industry has adopted similar approaches (McCambridge and 
Hartwell, 2015b) and, more recently, revelations about the Coca-Cola company and its 
support for researchers seeking to divert attention away from the contribution of soft drink 
consumption to obesity (Kmietowicz, 2015a).   
Safeguards in place: Internal Ethics Guidelines and OLAF 
The European Commission does have a strict internal policy on ethics and reporting and 
foregoing gifts or diplomatic gestures. The internal ethics guidelines have been further 
tightened in 2016 following increased surveillance of irregular incidents – all gifts above a 
modest threshold, including invitations to conferences and events have to be declared and 
returned or donated to selected charities. Circumspection is also widely accepted as a value 
to be nurtured in newcomers to the job and young civil service recruits. 
The same cannot necessarily be said about the other institutions, except perhaps for the 
existence of the watchdog the European Anti-Fraud Office (OLAF). The watchdog can be 
contacted anonymously and works in all of the 24 European languages. OLAF investigates 
fraud against the EU budget, corruption, and serious misconduct within the European 
institutions, and develops anti-fraud policy. It publishes a yearly report available on its 
website, where it investigates a wide range of wrongdoings from embezzlement, fraudulent 
claims and misconduct in public procurement procedures, to customs fraud, although even it 
is not without criticism. For example, the Supervisory Committee (SC), a body of four 
independent experts charged with the task of monitoring the quality of OLAF’s activities, 
issued a relatively critical opinion of a high-profile investigation carried out in 2012: the so-
called Dalli-gate case (McKee et al., 2012).  
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The former Commissioner for Health and Consumer Policy, John Dalli, was forced to resign in 
October 2012 by Commission President, José Manuel Barroso, after an associate was accused 
of asking for €60 million from Swedish Match, the main producer of Swedish snus, in return 
for Dalli’s help in amending European tobacco regulations (Wikipedia, 2017). John Dalli had 
allegedly wanted the OLAF report on his case to be published, with the latter eventually being 
leaked to the press via a Maltese newspaper. On 7 October 2014, a French public television 
station aired a two-hour report entitled “Tobacco Industry: the grand Manipulation”. In this 
feature, the journalists investigated documents they acquired from Philip Morris showing that 
the tobacco lobby had planned a strategy to target Dalli for his drive to push through a 
tobacco products Directive. Corporate Europe Observatory (CEO), a platform aiming to unveil 
corporate lobby influence in Brussels, published online in July 2014 both the Supervisory 
Committee’s analysis of the OLAF investigation of Dalli and the letter to CEO about the release 
of this opinion. The opinion of the Supervisory Committee points to the short timeframe 
which was given to OLAF to check the legality of the allegations and to carry out the 
assessment of the incoming information: “Apart from OLAF verification of the existence of the 
persons/companies whose names figured in the complaint, the SC has not found any trace of 
any other check made or any other additional information gathered by OLAF with regard to 
the allegations and their credibility, as it is foreseen in Article 5(4) of the OLAF Instructions to 
Staff on Investigative Procedures (ISIP) relating to OLAF’s obligation to evaluate the accuracy, 
the reliability and the supporting evidence of the incoming information”(CEO, 2014)1.  
   
What constitutes good or bad lobbying 
Daniel Guéguen, co-founder of the first European school of lobbying (1992) and author of 
several books and guides on the subject, describes “a good lobbyist” as someone who delivers 
                                                   
1 It should be noted, however, that even now, many questions remain unanswered about this case. Indeed, 
the mystery has deepened following the broadcast of a television programme made by two Danish 
journalists who initially were approached by Dalli CAMILLERI, I. 2017. New film claims John Dalli 
unsuccessfully tried to obtain info about alleged conspiracy against him [Online]. Times of Malta. Available: 
https://www.timesofmalta.com/articles/view/20170727/local/new-film-claims-john-dalli-
unsuccessfully-tried-to-obtain-info-about.654229 [Accessed 6th August 2017].  
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solutions, or more precisely, a facilitator. Notably, at first and second reading stages, 
Members of European Parliament often introduce amendments drawing closely on interest 
group data and argumentation. Guéguen offers expertise and explains technical aspects of 
the dossier, looking to forge a European consensus at the heart of the association he 
represents. Where he disputes elements of a proposal, his criticisms are measured, justified 
and his counter-proposals are technically and financially credible. In his role, he pushes for a 
solution, always maintaining his credibility. 
By manner of contrast, a “bad lobbyist” complicates the problem even further, lacking 
technical skill and being of no particular interest to MEPs or officials. He may be seen to act 
systematically in a defensive or negative manner. His case is made up of technically suspect 
building blocks and solutions which are financially untenable. Therefore, he is around, but 
rarely welcome (Guéguen, 2007). 
Major pitfalls in achieving successful lobbying/interest group representation include sloppy, 
dilettante coordination and ignorance of cost-saving opportunities/inefficiencies, lack of 
attention to detail and lack of expertise on decision-making procedures (e.g. comitology or 
co-decision, impact assessment and evaluation, etc).  
The Corporate EU Observatory (CEO), a member of the EU lobby Transparency Register, takes 
on the mission, mandate and motives of lobbyists but is a lobbyist in itself; it is a research and 
campaign group endeavouring to expose the undue influence of corporations and their lobby 
groups in EU decision-making. CEO is registered as a not-for-profit foundation under Dutch 
law at the Amsterdam Chamber of Commerce. In its latest online report “Thinking allowed? 
How think tanks facilitate corporate lobbying”, CEO challenges the guidelines of the 
Transparency Register and the categorisation contained therein and argues how corporate 
interest masquerade as think tanks. As think tanks represent approximately 5% of the 
registered lobbyists in the Transparency Register, it is not surprising that their private agendas 
are not purely academic. 
Conclusions 
This section began by explaining the main institutions in the EU legislative process and then 
argued why the EU is a major target for industry interest, with a focus on how its structures 
and processes offer opportunities for influence to be exerted. The section offered a critical 
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analysis of how public consultation works, existing concerns, and what could be improved for 
the future. A brief review of the scale and nature of interest groups currently operating in 
Brussels provided a quantitative overview of those active in health and food safety. Finally, I 
explain how interest groups operate employing various tactics to strengthen their influence 
in the policy process and what constitutes a good or a bad lobbying agent. 
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Chapter 3. Corporate influence – what do we know?  
Language is central to expressing political opinion. However, this is both an advantage and a 
challenge: mass communication has created powerful platforms that have become the 
vehicle for an impressive volume of text that scholars can no longer analyse individually, 
leading to an interest in automated text analysis, be it qualitative or quantitative.  
The benefits and shortcoming of using text-mining techniques for the analysis of large-scale 
consultations submitted via the Internet have been discussed in various papers (Bicquelet and 
Weale, 2011). Bicquelet and Weale look at automated text analysis in a specific case, i.e. a 
public consultation organised by the National Institutes for Health and Clinical Excellence 
(NICE) in 2008 on “end of life medicines”. They argue that large-scale e-consultations are still 
in their formative years and experience teething issues. Some of the precautions they identify 
to minimise ethical issues are: consultation organisers should inform respondents about the 
presence of analysts/ researchers among those reading responses and obtaining their consent 
for the types of methods used to analyse the opinions expressed. However, by analogy with 
research using social media as a data source, there is a strong argument that these have been 
placed voluntarily in the public domain by their authors. A requirement to obtain permission 
before analysing publicly available text could equally apply to articles in newspapers or 
scientific journals, something that most would view as inappropriate. Second, techniques or 
coding employed should not endanger confidentiality or create potential harm to vulnerable 
groups or individuals. Finally, to enhance the validity and meaningfulness of their findings, 
researchers should usually employ a methodology that blends quantitative and qualitative 
analyses.  
Word-processed text analytics offer new insights and rely both on expedient machine-driven 
poll and survey analysis tools developed chiefly for ethnographers (for interview content 
analysis, such as Nvivo® or Sketch Engine for qualitative text analysis) as well as tools created 
for comparative literature analysis. A number of techniques from comparative linguistics and 
mathematical logic applied to semantics have been stimulating software developments and 
are awaiting further applications to aid our understanding of the evolution of the meaning of 
texts in fast evolving health policy debates. This approach was first used in Grounded Theory 
and sociological research in the 1960s, designed to improve social scientists’ capacity for 
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generating theory that will be relevant for their research. It draws on the constant 
comparative method of qualitative analysis, on clarifying and assessing comparative studies 
and pinpoints the potential of quantitative data handled systematically by theoretical 
ordering of variables in elaboration tables, that the analyst will indeed find rich terrain for 
discovering and generating theory (Glaser and Strauss, 2009). 
Quantitative Text Analysis 
This section will describe QTA in detail. It will note that it comprises a group of methods used 
to make statistical inferences about a population of texts. It complements qualitative 
methods in that it offers metrics and contributes to a theoretical basis. There are different 
methods and algorithms for undertaking QTA. This section will note that there are a number 
of gaps in the literature describing its use in studying corporate power and influence, including 
validation and guidelines for its applicability. 
Principles of automated text analysis 
Grimmer et al (Grimmer and Stewart, 2013) have suggested four principles of automated text 
analysis to guide scholars in their endeavour to faithfully capture political texts in their 
analytical processes: 
1. Quantitative models are of limited use as they fail to capture sufficiently the complex 
nature of the data generation for texts, even for linguists. Evaluations should 
emphasise helping researchers to assign documents to predetermined categories, 
discover new and useful categorization schemes for texts, or measure theoretically 
relevant quantities from large collections of text. 
2. Quantitative methods do not replace but rather augment human capability, as texts 
still need to be read in order to give a fuller understanding of the substance at hand.  
3. There is no single global reference method, i.e. “best method for QTA”. What works 
depends on the nature of the task at hand. 
4. Validation is crucial.  
Roberts, in his seminal paper that addressed the question: “Which quantitative text analysis 
method best affords answers to what research question?”, handles the conundrum of how to 
draw statistical inferences about text-populations, given the data matrix of text-related 
variables as well as a bunch of contextual variables that may also be available (Roberts, 2000). 
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In other words, in encoding text blocks as networks, the coder must appreciate the fact that 
certain types of links are transitive (e.g. if “A triggers B” and “B triggers C”, then “A triggers 
C”), whilst others are not (e.g. if “A loves B” and “B loves C”, it does not necessarily follow 
that “A loves C”). Assumptions that certain nodes in a network are central or conductive will 
be void if the network does not have a causal, equivalent, affective or some other specific 
kind of arc. Roberts warns against the pitfalls of ignoring arc-types, as this may usher in false 
conclusions that nodes are linked in some “unspecified way”. Possible contextual variables 
can then indicate the source, message, channel, and audience associated with each text 
sample being analysed. Among texts with particular types of audience, source, message or 
channel, QTA can genuinely help answer questions such as “what themes occur”, “what 
semantic relations exist among occurring themes”, or “what network positions are occupied 
by such themes or theme relations” (Roberts, 2000). The inferences that can be drawn are 
left to the discretion or the imagination of the analyst. 
Text submissions, policy papers and stakeholder analysis 
Information and communication technologies such as the Internet have enabled a plethora 
of opportunities for the participation of citizens in policy-making (Bicquelet and Weale, 2011). 
Since the 1980s, new public management tools and the public policy reform process have 
created a global interest in stakeholder consultations (Rodrigo and Amo, 2006). The process 
is increasingly formalised and in this context, in support of its health policy-making processes, 
the World Health Organisation (WHO) has produced a number of guidelines and toolboxes. 
The adoption of a systematic approach to consult stakeholders with the aim of drawing up 
major policies such as those on nutrition, diet and health by the WHO, as the UN body 
responsible for health policy, signals an important change imposed by the growing 
importance of civil society organisations in policy-making but also the need to coordinate 
policies among different UN organisations better. The guidelines developed not only provide 
a technical brief to be used within the organisation itself but also inform NGOs and other 
public health actors on the way to make the best use of this instrument. 
In 2015, the European Commission, the executive body of the European Union that also 
doubles as the Guardian of the Treaties and a legislative initiator, published Better Regulation 
Guidelines, with the stated aim of cutting red tape and administrative burdens (European 
Commission, 2015a)  in other words, formal requirements for impact assessments and 
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evaluations that must precede the creation of any new piece of legislation. In these 
guidelines, a major role is given to stakeholder consultation based on a formally agreed prior 
strategy that in turn is based on stakeholder mapping. These requirements will be dealt with 
in extenso in the next chapters. 
Stakeholder mapping and analysis in WHO and its value in health policy 
Based on Schmeer’s methodology (WHO, 1999), stakeholder analysis develops stakeholder 
maps with four quadrants (Schmeer, 1999). Stakeholders are grouped into these quadrants 
based on their position along two axes (Varvasovszky and Brugha, 2000): 
· Position/ Interest, along the x-axis, i.e. whether the specific stakeholder supports, 
opposes or is neutral with regard to a certain policy (e.g. a reform, a standardisation, a 
privatisation of a service) or a mandate or a mission of another actor in the policy field; 
· Power/ Influence, along the y-axis, i.e. the stakeholder’s ability to influence a certain 
policy or a mandate or a mission of another actor in the policy field. 
The key stakeholders are those in the top right quadrant and they are deemed to have both 
a high level of interest in the policy/ mission/ mandate, and some level of influence over the 
implementation or success rate of the latter. These are the “natural” (i.e. relatively easy to 
reach) target audiences for the stakeholders from whose viewpoint the analysis is performed. 
The groups in the bottom right quadrant are potentially interested, but their influence is 
limited, which in effect makes their engagement being strategically less important. 
The stakeholders in the top left quadrant are of note, as their high level of influence coincides 
with relatively low levels of interest.  
Finally, the bottom left quadrant contains the stakeholders that combine low levels of interest 
with a low level of influence. 
Stakeholder Analysis Guidelines in the European Commission 
According to the guidelines, the stakeholders can be assigned to four groups (Figure 3-1). 
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Figure 3-1 Categories of stakeholder 
 
 
 
For each stakeholder type, the European Commission encourages certain steps to be thought 
through (Figure 3-2). 
Figure 3-2  Steps in a stakeholder analysis 
 
High 
influence and 
low stake:
Handle with 
care
High 
influence and 
high stake:
Top priority
Low 
influence and 
low stake: 
Low priority
Low 
influence and 
high stake: 
Need help to 
participate
Relationship is 
paramount
High visibility 
method
Watch out for 
increased 
interest
Use well 
informed 
communicators
High-capacity 
methods
Transparency
Acknowledge 
right to 
participate
Easily accesible 
methods
No 
discrimination
Seek them out 
and understand 
them
Stakeholder 
specific methods
Positive 
discrimination
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It remains to be seen to which extent the above stakeholder engagement strategy is applied 
and how it can influence public consultations. One recent study (Azzopardi-Muscat et al., 
2015) examined the European Semester documents by means of textual analysis, looking at 
the use of words related to “health”. In the European Semester, which is a function of the 
“Europe 2020” strategy on competitiveness, European Union Member States are subject to a 
system of economic monitoring and governance (Földes, 2016). In this process, the European 
Commission produces annual, public Country-Specific Recommendations (CSRs) (European 
Commission, 2017a) as tailored policy guidance to Member States to help address reform 
efforts, including for some countries in the area of health. By examining CSRs as a data source, 
Azzopardi-Muscat et al. analysed the way health systems and their sustainability were 
addressed over the period 2011-2014. The fact that all the CSRs for pensions and health are 
captured under the heading of “sustainability of public finances” and not that of employment 
and social policies reveals the current skewed status of the debate. Whilst the paper calls for 
more active involvement of health stakeholders in the process, Földes et al. recognise the role 
of the crisis in placing health system objectives on the EU agenda to an extent that has not 
previously been observed (Clemens et al., 2014), despite resistance from some Member 
States – i.e. some countries ignore health CSRs and others oppose the very idea of the EU 
making recommendations without a formal legal basis enshrined in the Treaty to do so. This 
raises the question of whether a formal public consultation on CSRs may be a way forward 
for the future, an interesting avenue worth exploring in future research. 
How is QTA undertaken? 
This section will elaborate on the use of QTA, showing how it allows for developing statistics 
and matrices using words as data. Several types of software have been used to undertake 
QTA, each with strengths and limitations (Table 3-1).  
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Table 3-1  Software used to undertake Quantitative Textual Analysis 
Type of 
QTA/Software 
Assumptions Strengths Weaknesses 
Jfreq Word frequency 
matrices built for each 
word in every text. 
Allows the researcher to 
identify extremely 
frequently used words 
and gaps. 
Does not compute 
aggregate statistics. 
Wordscores in 
Stata, R 
Reference texts are 
assigned by the 
researcher. 
Well-suited for analysing 
texts submitted for public 
consultation 
Results may change if 
reference texts 
change.  
Wordfish in R No need to assign 
reference texts. 
Good if words are quite 
different (e.g. Left vs. 
Right) 
Cannot run in Stata 
Plagiarism 
Detection 
Software 
Recognises copy-pasted 
text. 
Good for analysing 
censorship and deviation 
from mainstream 
discourse. 
Is not necessarily 
suited to all purposes. 
ReadMe in R The sample of hand-
coded texts grouped into 
mutually exclusive 
categories provide 
enough info for the 
programme to 
extrapolate the filing 
system to all texts under 
review. 
High reliability. A categorisation tool, 
not an analytical tool. 
 
How has QTA been used previously and how does this thesis add to what is already known? 
As noted above, studies that combined QTA (using Wordscores) with qualitative analysis were 
previously used by Stuckler et al and Costa et al, as well as by Kluever to quantify industry 
influence in environmental issues. This study will apply this method to three case studies, 
selected because their characteristics are thought to pose different challenges to the use of 
QTA. The initial review has identified Wordscores and Jfreq as having the greatest potential 
in selected fields of health. However, while this thesis is focused on quantitative analyses, it 
must be borne in mind that, for a comprehensive analysis, these methods will be 
complemented by qualitative methods.  
Qualitative text analysis takes three main forms: thematic, evaluative and type-building. 
Thematic analysis, being the most common one, is based on pinpointing, examining and 
recording patterns (“or themes”) within data. Themes are patterns across data sets relevant 
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to the research question and describing a particular phenomenon. They test how different 
concepts are related to one another. 
Evaluative text analysis is the process of turning written data such as interview or field notes 
into findings. Its main purpose is evaluative and not descriptive – describing in detail a 
particular phenomenon, usually based on fieldwork results. 
Type-building text analysis is often seen as a goal in qualitative research and it is viewed as 
the method to arrive at representative generalisations, oftentimes applied in quantitative 
research. From case summaries one can extract typologies by reducing the diversity of the 
categories or cases encountered. 
The three methods are independent approaches that build on each other in some respects, 
but this should not be interpreted as a hierarchical ranking (Kuckartz, 2014). They are all 
category-based methods for the systematic analysis of qualitative data (Kuckartz, 2014). 
There are also several software packages that can assist in these analyses, in various ways. 
Selected examples are shown in Table 3-2. 
Table 3-2  Software used to undertake Qualitative Textual Analysis 
Type of 
QTA/Software 
Assumptions Strengths Weaknesses 
Corpus 
linguistics 
The study of language, as 
expressed in “corpora” 
or samples from source 
texts, i.e. real-world text.  
Corpus as a locus of 
linguistic debate via 
annotated samples, 
rather than as an 
exhaustive fount of 
knowledge. 
Corpora need to be 
collected in the field 
with minimal 
experimental 
interference. This may 
result in data being 
scarce. 
 
Nvivo Computer software 
package produced by 
QSR International. It has 
been designed for 
qualitative researchers 
working with very rich 
text-based or with 
multimedia information, 
where deep levels of 
analysis on small or large 
volumes of data are 
required. 
The software allows users 
to classify, sort and 
arrange information; 
examine relationships in 
the data; and combine 
analysis with linking, 
shaping, searching and 
modelling. 
 
The analyst can test 
theories, identify trends 
and cross-examine 
information in a multitude 
Visualisation ranges 
from word clouds to 
charts comparing key 
themes, but there is 
room for 
improvement. 
 
This software needs to 
be downloaded. 
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of ways using its search 
engine and query 
functions. They can make 
observations in the 
software and build a body 
of evidence to support 
their case or project. 
 
Analyses social 
networks to discover 
influencers and opinion 
leaders. 
Sketch Engine Sketch Engine processes 
texts of billions of words 
and retrieves instances 
of a word, a phrase or a 
phenomenon and 
presents the results in 
the form of Word 
Sketches, concordances 
or word lists. 
Sketch Engine is an 
online service delivered 
via standard browsers – 
it does not require 
installation. 
Sketch Engine 
supports corpora in 
over 80 languages. 
Files can be uploaded 
in a language that 
Sketch Engine does not 
currently support and 
one can search the 
corpus and generate 
wordlists or 
collocations but some 
more advanced 
features will not be 
available for languages 
that are not yet 
supported. 
    
 
There are other types of QTA or software available, however for the purposes of this thesis 
the above are the most notable ones at the time of writing: corpus linguistics, Nvivo and 
Sketch Engine software. 
This chapter started by noting the origins of this approach in Grounded Theory and 
sociological research in the 1960s, it discussed the principles of automated text analysis, it 
then moved on to discuss the steps taken in carrying out a stakeholder analysis and finished 
with methods and tools best suited to undertake QTA and qualitative text analysis. The next 
chapter will examine the research question, the conceptual framework used and the methods 
employed in this thesis. 
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Chapter 4. The research question, conceptual framework, and 
methods 
The thesis examines written responses to consultations on European Union policies, using 
QTA to analyse them. It thereby examines processes of public consultation and seeks to 
quantify the potential collective risk of corporate capture of such processes via individual 
written submissions. The research has also allowed me to develop a manual on how to 
calibrate Jfreq and STATA’s scaling algorithm entitled Wordscores to various stakeholder texts 
for rapid identification of their policy positions (Appendix 4).  
Public consultation is the most common regulatory tool used among OECD countries, 
according to research led by OECD (Rodrigo and Amo, 2006). I use QTA for three separate 
health-related case studies in which some variant of public consultation took place, examining 
who stands to benefit from public consultations and how they achieve an advantage in the 
process. I propose that QTA could help foster a dialogue between groups weakly or rarely 
represented in public health consultations and institutional knowledge systems, and focus 
attention on the role of public consultations in challenging power hierarchies between public 
health activists, industry professionals and regulatory affairs practitioners as risk managers 
and knowledge brokers. 
I argue that QTA provides a lens through which value systems underlying contributions to 
public debate can be monitored, tracked, and analysed over time and across policy fields and 
through which anomalous, irregular, or spurious submissions to public consultations can be 
identified and examined. The method unveils written submissions that are partial to certain 
interests but not transparently so and detects contributions that are fake, duplicative, or void. 
The approach has the potential to optimise the mechanisms of public consultation, to render 
them more inclusive and to ultimately facilitate the resolution of protracted policy 
controversies.  
Dialogical Theory, Framing Research and Discourse Analysis 
What follows is a brief account of the theoretical approaches that have informed my 
methodology and my thinking on the nature of public consultations and whether it provides 
a level playing field, while reflecting wider collaborative platforms. By combining dialogical 
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theory with framing research and discourse analysis, I gain a more subtle understanding of 
public consultation processes than would be obtained through the lens of one theory alone. 
Before presenting the research questions, I will succinctly outline the conceptual framework 
and the main constructs that underpin it.  
 
Dialogism  
Dialogism recognises that the world as perceived is grounded in dialogic relations between 
groups and individuals, and the mutual effects that they have on each other (Bakhtin, 2010). 
Perspective taking and recognition allow for diversity to be discovered and are a precondition 
for dialogue which consists of mutual recognition (Jovchelovitch, 2007). Sandra Jovchelovitch 
(Jovchelovitch, 2007) mixes dialogical theory, social psychology and philosophy with a critique 
of self-other relations to examine encounters between different social groups. Observing and 
analysing variants of open public consultation as knowledge encounters between stakeholders 
(and the wider public) through a dialogical lens will help to critically analyse whose voices are 
heard, which positions are subsumed and whose interests are ultimately served in public 
consultations. Embracing the existence of a plurality of knowledge (or recognising different 
forms of knowledge) can shed light on how different forms of knowledge are inter-related 
and how communication between these forms can lead to new forms of knowing 
(Jovchelovitch, 2007). “Knowledge” here, constructed in communication, refers not just to 
the technical knowledge of biomedicine, biochemistry, economics, law, or sociology but also 
to social, cultural and political functions, which apply equally, leading to a plurality of 
knowledge, and thus informing policy. 
 
Discourse Analysis: Interpretive Policy Analysis (IPA) and Framing Research 
Along with theorists like Frank Fischer and Maarten Hajer, proponents of IPA (myself 
included) emphasise the importance of non-technocratic forms of policy-making that 
encourage greater citizen participation and deliberation (Fischer, 2000). Innovative methods 
to analyse the production and contestation of meaning in policy can render practices of policy 
formation and implementation more accountable and democratic (Glynos et al., 2009). 
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Such methods have been developed in parallel to framing research or framing analysis. The 
theoretical origin of frame analysis is widely regarded to lie with the work of Erving Goffman, 
a sociologist who in his pioneering work “Frame Analysis” defined interpretive frames as a 
principle of organisation “which govern the subjective meaning we assign to social events” 
(Goffman, 1974). In Goffman’s conception, frames balance structure and agency. Overtly and 
covertly, they highlight the problem and the problem holder while obscuring the analyst and 
other aspects in order to define problems and suggest a remedial course of action. Frames 
are a variety of ideas, packaged as values, social problems, metaphors or arguments – their 
“strength” and “resonance” play a more defining role in determining the size of the effect in 
competitive environments than a frame’s repeated usage (Koon et al., 2016). Studies of voter 
behaviour and public opinion formation have benefitted from the framing concept in material 
and meaningful ways across different academic disciplines: political psychology, behavioural 
economics, communication and media studies, social movements research and socio-
linguistics. Moreover, recent management theory focusing on NLP (neuro-linguistic 
programming) has also highlighted the shared understanding that “frames in communication” 
influence “frames in thought” (Druckman, 2011), stressing the transformative nature of 
discourse. Framing therefore offers key insights into understanding the nature of political 
debate by providing an explanation of both structure and agency in the policy process. Some 
accounts even go as far as to argue that rhetoric and argumentation are the “mobilisation of 
bias” (Howarth, 2010). 
 
I take the view that frames and discourse, alongside beliefs and narrative, can be labelled as 
“ordering devices”, which explain how policy makers and stakeholders structure reality to 
gain a handle on practical questions, in a complex world where politicians look to their 
advisers for clarity, to help them overcome ambivalence (Hajer and Laws, 2006). Ambivalence 
(equivalent to ambiguity) is defined by Hajer and Laws as the possibility of assigning an object 
or an event to more than one category and is not always a problem but can also be a tool to 
engage with good policy work – "what we want is not terms that avoid ambiguity, but terms 
that clearly reveal the strategic spots at which ambiguities necessarily arise" (Burke, 1969). 
Whilst concerns with framing and reframing, dominance and intractability abound when 
dealing with ambiguity in situ, seeking stability and acting in a social world that is a 
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kaleidoscope of potential realities and meanings is only a natural reaction. Acknowledging 
and handling ambivalence is therefore essential for prudent action (Hajer and Laws, 2006). 
 
Further conceptual frameworks for analysing political discourse  
As more and more stakeholders (including industry front groups and trade organisations) seek 
and obtain public consultation credentials (inter alia, public consultation experience, 
feedback and results), the increased analytical and administrative burden placed on the 
shoulders of public consultation managers can be expected to erode the efficiency of public 
consultations. This has stimulated interest in new approaches (quantitative and qualitative), 
including text mining, to facilitate this process. However, this requires a nuanced approach: 
for example, alcohol pricing policy should not be seen as a simple dichotomy between public 
health activists on the one hand and a uniform, monolithic alcohol industry on the other 
(Hawkins and Holden, 2013), but between subsets within each group. This is the approach the 
present research adopts, for a more informed and nuanced view. 
 
Democratising choice and policy literacy  
In many OECD countries, better educated and informed citizens are taking on new roles in the 
development, implementation and revision of regulations and demanding more information 
from governments, thereby pushing for more open consultative mechanisms, with better 
information and more effective opportunities for participation and dialogue (Rodrigo and 
Amo, 2006).  
It is my contention that public consultations can help to level the playing field for citizens and 
advocacy groups entering public debates alongside representatives of industry. However, this 
depends on consultations being designed and analysed in ways that offer the former equal 
opportunities for input into the policy-making process. Well run consultations may also 
improve the level of voluntary compliance, including a smoother implementation of new 
legislation, once agreed. Advances in information technology are enhancing the abilities of 
civil society groups to organise in pursuit of their goals (Rodrigo and Amo, 2006). Policy 
outcomes may still vary, but do so increasingly according to merit and the strength of the 
evidence base underlying the policy arguments put forward, rather than owing to stakeholder 
group background. By endowing open consultation with greater visibility, public consultation 
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managers (organisations, governments, or knowledge brokers) strengthen the level of policy 
literacy (civic educational attainment) and of policy performance in a jurisdiction. 
Furthermore, they may reduce both the risk of regulatory capture by well financed groups of 
interest or with a deep legislative knowledge (Rodrigo and Amo, 2006) and the risk of spurious 
or anomalous texts under the guise of credible, legitimate submissions, which have in the past 
been criticised for unsettling or disrupting the public consultation process (e.g. the 
consultation on the Natura 2000 network recognising the importance of nature conservation 
in a living and changing landscape where crowd-surfing was used to intercede in the 
consultation process and burden it with duplicated contributions). By anomalous texts I refer 
to submissions that are irregular, present abnormalities or deviate significantly from their 
immediate context, deliberately or otherwise. 
Approaching this contention from the perspective of framing research, inclusiveness of 
consultation (not least via use of plain, accessible language and ability to dissect issues of 
technical complexity) alongside capacity to disseminate detailed and timely information on 
regulations can both provide a rationale for the emergence of open public consultations as a 
normative prescription and act as a plausible framing mechanism going forward. There is a 
further reason why anomalous submissions erode the quality of public consultations. Since 
public consultation credentials (dictated by previously published submissions, not by 
stakeholder background) send a signal to the public about stakeholder abilities, equality of 
opportunity becomes deeper and more meaningful, increasing the information value of the 
credential. In a scenario where there is a level playing field, credentials tell citizens and the 
public more about a stakeholder’s ability to represent their interests competently and fairly 
than in a context where opportunities for exercising one’s consultation abilities are a privilege 
rather than a meritocratic exercise. 
 
Research questions 
This thesis seeks to answer two questions:  
· Can innovative methods of text analysis reveal patterns of interest representation in the 
European policy process? 
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· Can the various public consultation norms, constellations and mechanisms that 
characterise knowledge brokering help to decrease the relative disadvantage of public 
health advocacy groups in the policy arena? 
This thesis is an effort to investigate, explain and contextualise anchors, mechanisms, and 
outcomes of public consultation processes. Firstly, the present research will support public 
consultation managers as “explorers”, inviting views and expertise on a particular public 
policy, mapping policy positions onto written submissions. Secondly, and perhaps more in 
hope than expectation, a more reflective approach in submitting input to public consultations 
could engender broader and deeper analysis prior to submission by the actors involved and 
contribute to raising the standard of responses across the board, thus enhancing the quality 
of the evidence-base for reinforcing, negating or qualifying the terms, the elements and the 
overall policy action subject to consultation.  
This thesis begins with the premise that industry, and especially multinational corporations, 
and possibly other stakeholder groupings (e.g. trade organizations, industry front groups) use 
a particular vocabulary, evidence, position-taking and semantic shifts to influence the policy 
process. Such groups begin with many advantages. Thus, they are often forewarned that an 
issue will reach the policy agenda. Guéguen (Guéguen, 2007) argues that those who engage 
earliest in the process are best able to exert influence. Recent research from Copenhagen 
Business School corroborates this hypothesis – i.e. that keeping tabs on the Commission 
services’ Working Groups and acting before the first draft is written pays off from the 
perspective of the lobbyist in the long run (Jensen, 2015). The aim of the present research is 
to test this hypothesis further and to analyse and explain the findings obtained via QTA.  
The thesis then explores the scope to use QTA as a tool to “interrogate” the subject (the text 
submitted to a public consultation), to examine and assess the content of public consultation 
documents and to evaluate the policy position of stakeholders as well as their evolution. 
The primary research question aims to ascertain whether text analysis using Wordscores can 
reveal patterns of interest representation in the European policy process. The research aims 
are three-fold: first, to review research on the ways in which the food, alcohol, tobacco and 
pharmaceutical industries have sought to influence EU policies, including a description of their 
actions and its impact but, especially, the methods used to study it. Second, having identified 
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a gap in the available methodologies and the potential for QTA to fill it, to review its use, 
including its strengths and weaknesses. Third, to gain experience by applying it to three case 
studies purposively selected to exhibit characteristics that may influence the use and 
interpretation of QTA.  
A series of subsequent questions arise and are developed further in the next chapter, under 
aims and objectives of present research. 
 
Aims and objectives  
As set out in the previous section, this thesis reviews the predominant methods for QTA in 
political science (including examining their strengths and limitations), to set out the rationale 
for selecting one method and applying it to three case studies of interest and to make 
practical recommendations on how QTA methods could be deployed and mainstreamed into 
the EU political process in the future. Public consultations becoming more and more the norm 
before important legislative proposals are put forward for co-decision to the European 
Parliament and to the Council, QTA solutions could improve efficiency and drive down costs. 
The objectives are therefore two-fold: 
· Landscape analysis of political/scientific texts submitted for public consultation: to 
assess the feasibility of applying different methods of textual analysis to written responses 
to EU consultations and determine whether they can differentiate material from different 
sources; 
· Detecting patterns (constellations of stakeholder mapping): to determine whether the 
positions of individual texts and constellations of texts relate to the positions of the parties 
to a negotiation (interest representation in the policy process) and whether it is possible, 
quantitatively, to identify significant shifts in the content (and thus the underlying 
expression of interests) during the course of a consultation?  
A third objective, visual analytics, i.e. developing a type of visual analytics that can help 
capture best the results of such a QTA was dropped at the Upgrade stage following the advice 
of the Examination Panel. 
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These objectives are further reiterated in Appendix A. The methodology for each objective is 
detailed below. 
Choice of methods 
In choosing the methods to use in this thesis, it is first necessary to review the methods that 
have been developed so far for text analysis in sociological and political science – what are 
their limitations and how could they be improved and mainstreamed?  
Wordscores is an algorithm that infers policy positions, or scores, for new documents, i.e. 
“virgin texts” on the basis of documents with known scores, i.e. “reference texts”. It measures 
positions along an axis, for example right or left wing party manifestos or press releases for 
or against health regulation. Based on the underlying assumption that agents with different 
policy positions use different wording that reflects their stance, it uses the frequency of words 
in each document, relative to the total number of words in a text, to generate scores for each 
document. Wordfish is another software tool that uses frequency distributions of words 
(Slapin and Proksch, 2008). However, no assumptions concerning reference texts are needed. 
This is rather more appropriate for examining left/ right party manifestos (Proksch and Slapin, 
2009), where texts are quite different and use different words, rather than for public 
consultation processes that are the focus of our present investigation (Proksch and Slapin, 
2010). 
Cost is not a criterion in the selection – Wordfish is available free of charge and Wordscores 
is a package within the statistical analysis software STATA v14.0 or within R (the latter is also 
free). A further freely available method is Jfreq, which simply lists all the words in a number 
of uploaded texts and compiles a matrix of their frequencies. Wordfish software has been 
used extensively in publications by Heike Kluever (Klüver, 2011) and Sven-Oliver Proksch. 
However, Wordscores has been evaluated as a valuable word scoring technique, arriving at 
largely similar estimates to independently derived position measures and producing time 
series of government positions with high validity (Klemmensen et al., 2007). I shall therefore 
use Wordscores rather than Wordfish in the three case studies at hand. 
Extracting policy positions from political texts using words as data has already been employed 
with the Better Regulation agenda e.g. on environmental policy public consultations at EU 
level (Bunea, 2014) and at national level by reviewing tobacco industry submissions to the UK 
66 
 
government consultation on standardised packaging of tobacco products (Ulucanlar et al., 
2014). Uluncalar et al argue that stakeholder consultation provides an opportunity for highly 
resourced corporations to slow down, weaken or to prevent altogether public health policies. 
Theirs is an examination of how the industry critiqued evidence supporting Standardised 
Packaging, via examination of the curriculum vitae of “experts”, a cross-documentary analysis 
comparing references made to published sources with the original sources to confirm their 
veracity, an interpretative analysis to identify conceptual themes and a thematic analysis 
based on systematic conceptual coding (e.g. the micro-themes “misleading quoting”, 
“misleading interpretation” and “selective quoting” were grouped under “misleading quoting 
of evidence”). This paper will inform the pattern-recognition objective of the present 
research. 
Stuckler et al. (Stuckler et al., 2016) continue this examination, by unveiling various tactics 
that industry employs in order to thwart effective public health intervention, to the detriment 
of global nutritional goals. They demonstrate how alcohol and sugar-related/ affiliated 
industries employ denialism (promoting doubt and undermining the case for action) as well 
as a complex array of tactics: a) obfuscating the relationship of sugar with health outcomes 
by disputing what is being measured – i.e. total or added sugar, b) setting unrealistic 
expectations of science, c) displacing attention to other risk factors such as physical activity 
and d) shifting focus on avoiding the harms associated with their product rather than 
measures to reduce consumption. 
The approach to methodology outlined in Stuckler et al will be replicated here. I will first run 
a prima facie analysis of the texts using the program JFREQ to identify the most commonly 
used words and then I will select the reference texts for each case study and run them through 
Wordscores in Stata v14.0. 
I endeavour to present a framework for the visual integration, comparison, and exploration 
of correlations in non-spatial text-mining research data (for details, see summary measures 
graphs in Chapter 5, 6 and 7). 
Such visual representations have received considerable attention of late, not least since a 
nascent category of computational tools integrate data analytics with interactive 
visualisations, to facilitate the performance of cognitive activities involving big data, especially 
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textual analysis techniques. To illustrate this point, to investigate causation of a mosquito-
borne outbreak, an epidemiologist can examine relationships between most frequent words 
in tweets (e.g. referencing parties in specific locations prior to an epidemic) and local bodies 
of water in a specific region (Sedig and Ola, 2014). Visual analytics thus offer an advantage by 
illustrating geographical, age-related or historical data trends in a way that a human mind can 
capture them quickly. 
Alternative methods not selected for use 
An alternative choice of methods for my research could have followed the path of press 
releases compared via plagiarism detection software, along the lines of studies indicating 
that NGOs create cultural change by relying on mainstream messages that resonate with 
prevailing discursive themes (Bail, 2012). I have chosen not to use this software since 
plagiarism detection software tends to work best for censorship/ deviation of press releases 
from mainstream discourse where reliance on validated text is more illustrative than in public 
consultations where copy-pasting is not likely to influence the end result, i.e. the consolidated 
document. 
Secondly, the ReadMe software package for R2 examines a set of text documents (such as 
speeches, blog posts, newspaper articles, judicial opinions, movie reviews, etc.), a 
categorization scheme chosen by the user (e.g. ordered positive to negative sentiment 
ratings, unordered policy topics, or any other mutually exclusive and exhaustive set of 
categories), and a small subset of text documents hand classified into the given categories. 
ReadMe software can thus report, normally within sampling error of the truth, the proportion 
of documents within each of the given categories among those not hand coded. ReadMe 
computes quantities of interest to the scientific community based on the distribution within 
categories but does so by skipping the more error prone intermediate step of classifying 
individual documents. I have chosen not to use this software since neither of the three case 
studies lends itself well to categorisation based on hand-coding. 
                                                   
2 http://gking.harvard.edu/readme 
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It is however expected that the methods outlined in detail above will be sufficient and fitting 
to the objectives of the present research. 
 
Transformation applied 
The logic of Wordscores is to ‘‘score’’ texts mechanically (and the policy position contained in 
documents) based on the frequency of words, using the dictionary created from the reference 
texts. It is precisely the simplicity of this approach, which eliminates the need for close 
analysis of meaning that characterises Laver Benoit Garry’s insight in creating Wordscores. To 
compare texts, what a researcher wants to know is how the frequency of word usage in one 
text compares to that in another, as judged by the dictionary of words contained in the 
reference texts. 
In analysing scores, the central issue concerns comparing virgin and reference texts. The core 
assumption at the heart of the LBG (Laver Benoit Garry) transformation is that the dispersion 
of reference and virgin texts is the same (Martin and Vanberg, 2008). Since reference texts 
tend to have overlapping, non-discriminating words, their word scores tend to be pulled 
towards the middle of the scale (Lowe, 2008). Bias will be removed to capture the correct 
baseline and to address the tendency for non-discriminating words to pull scores towards the 
middle of the distribution. Wordscores are then re-scaled using the Martin-Vanberg 
transformation3 (Martin and Vanberg, 2008), rather than Laver Benoit Garry’s transformation 
(Laver et al., 2003). Laver et al offer a far more complex algorithm that also rests on the 
unjustified assumption that the dispersion of reference and virgin texts is the same – the LBG 
transformation adjusts the variance of virgin text scores to equal the variance of reference 
scores (Martin and Vanberg, 2008). Centrist parties may become more polarised from one 
election to another and, in any case, the constant variance assumption is problematic. 
Therefore, I will use the more straightforward Martin-Vanberg transformation for my 
purposes. 
                                                   
3 Scores for each virgin text are rescaled using equation (sv-s1)/(s1-s2), where sv stands for the raw score 
of each virgin text and s1 and s2 for the estimated scores of those virgin texts with the most extreme values. 
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Rationale for selection of case studies? 
The rationale for the selection of case studies is outlined below. During the upgrading process 
it was agreed that, at most, three case studies could be undertaken in sufficient detail within 
the scope of a DrPH thesis. Following from this, two criteria were used to select appropriate 
examples. The first was the nature of the evidence that was available. This ranged from issues 
where the evidence was highly technical, such as that relating to product safety, even if there 
was debate about how the evidence should be interpreted and the weighting placed on 
different findings, to those where there was genuine scope for debate about the goals to be 
pursued, where the interests of different stakeholders in pursuit of legitimate, but differing 
goals might vary. A second consideration was the extent to which the decision to be reached 
impinged on commercial interests.  
Pragmatically, the choice was limited to recent consultations for which details of responses 
were available. Several were considered, such as one on mHealth. However, consistent with 
the considerations outlined above, the final choice was narrowed down to: 
a) An examination of a narrow technical issue where the evidence was reasonably clear. 
This was the public consultation on the European Food Safety Authority’s scientific 
opinion on acrylamide. It is worth pointing out that technical consultations, or public 
consultations on very technical texts such as on acrylamide (and many others run inter 
alia by the UK government) will have limited spectra of semantic shifts. 
b) Examination of a complex issue involving multiple stakeholders, with their own 
legitimate, but differing, perspectives and interests. For this, a consultation with 
selected stakeholders during a technical study concerning pharmaceutical product 
pricing was selected. The relevant study involved a complex process of negotiation 
with multiple and often competing agendas of key actors (institutional and non-
institutional). 
c) The third is an example where there are few vested commercial interests, the EU 
Directive on the application of patients’ rights in cross-border healthcare, where the 
parties are primarily governments and non-governmental organisations.  
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The case studies 
Pharmaceutical pricing  
Pharmaceutical expenditure represents an increasing share of health expenditure and has 
been the fastest growing cost pressure on health systems for many decades. There is a 
consensus that there are unintended effects from current pharmaceutical product pricing 
systems in the European Member States, even if views differ as to their importance. The high 
prices of innovative medicines have also attracted much attention lately. The European 
Commission, in response to Council Conclusions agreed under the Italian presidency, 
launched a study on enhanced cross-country coordination in the area of pharmaceutical 
product pricing in 2014. The interim report was shared with selected stakeholders for written 
consultation on August 10th 2015, in accordance with the Terms of Reference for the study. 
The participants belonged to one of the following three groups: representatives of the 
interests of consumers and patients, of public payers, and of the pharmaceutical industry. The 
stakeholder representatives were European associations of manufacturers, patient/ 
consumer/ professional organisations, plus some Member State representatives/ public 
payers. The rationale for selecting the stakeholder group of participants followed the same 
approach as applied for the Working Group of the Platform “Access to Medicines in Europe” 
under the process on Corporate Social Responsibility in the field of pharmaceuticals. The aim 
of the stakeholder meeting on 17 September 2015 was to garner the views of stakeholders 
on the report. The case has been chosen since the issue of pharmaceutical pricing is likely to 
be controversial in the years to come, in particular given its inclusion in the agenda of the 
2018 Austrian presidency. 
Acrylamide  
I ask whether and how the scientific opinion of the European Food Safety Authority (EFSA)4 
shifted towards positions that favour the biscuit, coffee, and baking industries5(starch users) 
which are against acrylamide regulation. 
                                                   
4http://www.efsa.europa.eu/en/consultationsclosed/call/140701 
5http://www.efsa.europa.eu/en/efsajournal/pub/4104 
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Acrylamide is a chemical compound/ contaminant of interest since its significance as a 
potentially toxic food ingredient was not understood until some 15 years ago whereas it was 
well known as an occupational hazard in the chemical industry. According to Jorgen Schlundt, 
World Health Organization (WHO) coordinator of food safety research, acrylamide probably 
has similar effects to heterocyclic amines which caused cancer in animal tests. However, only 
little was known about potential health risks in humans. Acrylamide is an obligatory by-
product of heating starch and other complex polysaccharides present in many foodstuffs such 
as fries, potato chips, biscuits, but also soluble coffee. Its increasing occurrence is directly 
linked to industrial food processing. The discovery is likely to have a significant impact on the 
food industry as a whole: the determination of threshold levels that, under EU legislation, will 
need to be advertised on the food labels and even as warnings, might have a large impact on 
sales as well entail obligations to change the food processing technologies employed. The 
consultation on the scientific opinion ran between 1 July 2014 and 15 September 2014. 
Cross-border Healthcare Directive (Directive 2011/24/EU) 
Directive 2011/24/EU sets out the conditions under which a patient may travel to another EU 
country to receive safe and high quality medical care and have the cost reimbursed by their 
own health insurance scheme. It also encourages cooperation between national healthcare 
systems. 
The European Treaties have given the EU a limited and clearly defined role in health policy. 
Article 168 of the Treaty on the Functioning of the European Union notes that Member States 
have responsibility for “the definition of their health policy and for the organisation and 
delivery of health services and medical care.” The same article also states that: “The 
responsibilities of the Member States shall include the management of health services and 
medical care and the allocation of the resources assigned to them.” Historically, therefore, 
there was considered to be virtually no EU dimension to policy on the management and 
provision of health services. In recent years that view has changed, for a number of reasons.  
Firstly, EU legislation originating from other policy areas – for example the Directive 
2003/88/EC concerning certain aspects of the organisation of working time and Directive 
2005/36/EC on the recognition of professional qualifications – has had significant impacts on 
health services. 
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Secondly, over a number of years, the European Court of Justice has developed the principle 
that healthcare was a service within the meaning of the Treaty on the Functioning of the 
European Union, and that the principles of the free movement of services therefore apply to 
health services, albeit with important safeguards. 
The EU institutions and the Member States are therefore faced with a series of questions 
about how these principles apply to health services, and what this means in practice for health 
systems. 
The Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare 
was the first step towards answering some of these questions. This Directive codified and 
clarified the jurisprudence of the Court with regard to the rights of patients to obtain and be 
reimbursed for healthcare received in another Member State. The Directive did not just deal 
with the rights to reimbursement, but also introduced a number of significant flanking 
measures to ensure that patients could use these rights in practice. As part of this there is 
now, for the first time, a minimum set of requirements which apply to all health providers 
and all healthcare provided within the EU. These requirements relate to transparency, 
information to patients, and safety and quality of care. 
My intention is to examine whether and how the initial text proposed by the European 
Commission has been altered following the opinion of the European Parliament and the 
General Approach of the Council in the two readings of the co-decision procedure. 
Case studies considered but rejected 
The inter-related topics of eHealth and mHealth were considered but dropped from the list 
of case studies in this research because aligning positions for and against regulation of 
eHealth and mHealth at this stage appears premature and intractable as a problem (European 
Commission, 2011). Telemedicine is the provision of healthcare services through deployment 
of ICT (Bashshur et al., 2000) in situations where the health provider and the patient (or two 
health professionals) are not in the same location (Sood et al., 2007). Telemedicine requires 
the secure transmission of medical data and information through sound, text, images, video 
and so on needed for the prevention, diagnosis, treatment, monitoring and follow-up of a 
patient’s illness or state of health. Data transmission can be synchronous (real-time), as in 
video-conferencing or telephone, or asynchronous (store-and-forward) as with imaging in 
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Telepathology or Teleradiology (McLean et al., 2013). Therefore, eHealth and mHealth were 
dropped as fields of investigation precisely because aligning positions for and against 
regulation of eHealth is premature at this stage of proceedings. 
What are the expected outcomes of the research? 
The expected outcomes are both generic and specific. The generic outputs include an 
expansion of the so far sparse literature on the use of QTA to study influences on policy 
processes, insights into the type of policy proposal where it can be most effective, and 
guidance for others in its use. The specific output is the generation of evidence on the nature 
and impact of industry or advocacy influence on public consultations on EU policies.  
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Chapter 5. Pharmaceutical Policy and Healthcare Systems 
The issue 
Pharmaceutical spending (including pharmaceutical consumption in hospital and purchase of 
drugs in the retail sector) in OECD countries reached US$ 800 billion in 2013, accounting for 
an estimated 20% of total health spending (Belloni et al., 2016). Yet while the volume of 
medicines consumed and prices of innovative products continue to rise, pushing 
pharmaceutical spending up, cost-containment measures by funders and governments, 
coupled with the expiration of patents on a number of top-selling products have exerted 
downward pressure on pharmaceutical expenditures, slowing the pace of growth in spending 
over the past decade (Belloni et al., 2016). There are, however, many concerns about what is 
seen as market failure in the pharmaceutical sector. 
These concerns are wide-ranging. The pharmaceutical industry is concerned about its 
profitability and what it sees as the regulatory burden placed on it when bringing products to 
market. Governments and payers are concerned about high prices of new medicines and how, 
as noted by the European Court of Justice (European Court of Justice, 2009), intellectual 
property rights have been used by manufacturers to delay generic competition (Hancher and 
Sauter, 2016). Health professionals and patients are concerned about a failure to invest in 
products that are truly innovative, rather than so-called “me too” medicines, adding little 
therapeutic benefit to what already exists.  
There have been many responses to these concerns. Thus, a growing number of countries 
have implemented innovative mechanisms for assessing the costs and therapeutic benefits of 
new products, beginning with Australia and Canada in the early 1990s (Annemans et al., 
2011). Similar mechanisms have been implemented in a number of EU Member States, where 
various organisations systematically appraise the cost-effectiveness, budget impact, medical/ 
therapeutic needs of certain target groups, and any social and ethical considerations of such 
decisions (Annemans et al., 2011). Health-technology assessment (HTA) plays an important 
role in these decisions, which should not represent solely the perspective of the payers, but 
also incorporate the views of a wide range of stakeholders, as a means to promote better 
value through informed choice (Rotter et al., 2012). However, there is presently a patchwork 
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of national approaches to these issues, with various pricing arrangements in place. At the 
same time, third party payers (social health insurance institutions or national health services 
or bodies representing them) recognise that the pharmaceutical company is entitled to a 
sufficient return on investment to encourage them to seek new innovative medicines.  
In addition, European governments have identified the pharmaceutical industry as a major 
contributor to economic growth and, recognising the power of the industry to relocate 
research, development, and manufacture to cheaper or more supportive environments, in 
the US, China, India, and Singapore, they have sought to provide manufacturers with a range 
of incentives to retain their activities in the EU. This raises complex issues that go beyond the 
scope of this thesis but recognition of this reality provides background to what follows in this 
chapter  (Scullin et al., 2012).   
The regulatory environment  
The regulation of pharmaceuticals within the EU is complicated because certain aspects, such 
as manufacture and trade, fall within the remit of the single market and thus squarely within 
the competence of the European institutions. On the other hand, decisions about the use of 
medicines within health systems lie within the competence of Member States. With regard 
to the internal market aspects of pharmaceuticals, relevant decisions are made by 
representatives of governments of Member States meeting in the Employment, Social Policy, 
Health and Consumer Affairs Council (EPSCO). Preparatory work for EPSCO meetings takes 
place in five working parties/ groups, one of which is the Pharmaceuticals and Medical Devices 
Council Working Group. The other four are: the Working Party on Social Questions, the 
Working Party on Public Health, the Senior Working Party on Public Health, and the Working 
Party on Foodstuffs (Council of Ministers, 2017). Other relevant structures related to 
pharmaceutical policy (Council of Ministers, 2015) are shown in Box 5-1. 
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Box 5-1    Institutional structures in the field of pharmaceutical policy in the EU 
• The Commission expert group on “Safe and Timely Access of Medicines to Patients” 
(STAMP), comprised of experts from the European Medicines Agency and the Member States, 
discusses regulatory issues related to pre-market approval of medicines, including conditional 
marketing authorisations and accelerated assessment; 
• The network of competent authorities on pricing and reimbursement (CAPR) is a 
voluntary network of competent authorities set up to deal with pricing and reimbursement 
policies, depending on the priorities of each 6-month rotating Presidency of the EU Council; 
• The Process on Corporate Responsibility in the Field of Pharmaceuticals (2010-2013) 
convenes Member State representatives and stakeholders from industry, insurers, health 
professionals and patients to achieve a number of concrete consensus reports on facilitating 
supply in smaller markets, a mechanism for access to orphan drugs, capacity building for 
managed entry agreements for innovative medicines, good governance for non-prescription 
medicines and market access for biosimilars. 
 
 
When it comes to healthcare however, as noted above, policies fall within the competence of 
Member States. Article 168 (7) of the Treaty on the Functioning of the EU clearly states that 
Union action shall respect the responsibilities of the Member States for the definition of their 
health policy and for the organisation and delivery of health services and medical care: 
“The responsibilities of the Member States shall include the management of health 
services and medical care and the allocation of the resources assigned to them.” 
All EU member states, and health payers within them, are thus entitled to decide what 
medicines they will pay for, based on criteria such as budgetary impact and cost-effectiveness, 
although they are not required to do so. However, if they do, their decisions are subject to 
Directive 89/105/EEC, also known as the Transparency Directive (Council of Ministers, 1988). 
Specifically, the Directive lays down three major requirements with respect to individual 
pricing and reimbursement decisions: 
· decisions must be made within a specific timeframe (90/180 days); 
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· decisions must be communicated to the applicant and contain a statement of reasons 
based on objective and verifiable criteria; 
· decisions must be open to judicial appeal at national level. 
The Transparency Directive covers decisions about whether or not to purchase a drug for 
inclusion on the positive list of reimbursed medicinal products, the price to pay the 
manufacturer for that drug, and the amount the patient is to be reimbursed.  
Current developments 
In 2012, a review of the Transparency Directive concluded that it no longer reflected the 
complexity of the pharmaceutical market in Europe and the Commission proposed a new 
Directive to replace it. This was intended to streamline and reduce the duration of national 
decisions on pricing and the reimbursement of medicines. The proposed new directive was 
portrayed as an important simplification of existing procedures. However, pharmaceutical 
policy is an issue that is fraught with endemic scepticism about the appropriateness of any 
EU-level action that would go beyond the existing acquis (accumulated body of EU law) and 
the present level of interstate cooperation. The scale of differences between the Member 
States’ health systems is seen by many as precluding any silver bullet, or single solution that 
could suit all Member States when it comes to enhanced coordination on pharmaceutical 
pricing policies. These differences meant that it was impossible to reach any meaningful 
agreement, even after 16 meetings of the Pharmaceuticals and Medical Devices Council 
Working Group (see below). The objections raised by some Member States were seen as 
irreconcilable and the Commission concluded that there was no realistic possibility of 
producing proposals that would be acceptable to all Member States. This decision was 
announced on 7 March 2015. This also meant that a significant number of pending legislative 
initiatives were withdrawn. 
Despite this setback, there was widespread recognition that some action was needed. 
Consequently, the 2016 Dutch Presidency of the European Council promulgated Council 
Conclusions on sustainability and affordability of pricing and reimbursement strategies 
related to purchasing medicines in the Member States (Council of Ministers, 2016). These 
Conclusions identified scope for greater co-operation among Member States to tackle high 
prices, supply shortages, and for some countries, deferred launches and problems associated 
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with small markets. One important proposal was to assess the scope for combining the 
purchasing power of several Member States to drive down prices.  
Policy options 
It is beyond the scope of this thesis to review in detail the many options that are being 
discussed to address the problems of the pharmaceutical market. Some relate to the approval 
of new products. These include ideas such as adaptive pathways, involving accelerated 
introduction of new products to the market, linked to enhanced post-marketing 
pharmacovigilance and monitoring, as well as moves towards a pan-European assessment of 
relative effectiveness of drugs, seen as a way to make sure that the most effective medicines 
make it to market while avoiding duplicating the same work 28 times. Other ideas involve 
challenging the existing system of patent protection, seen as a means of postponing the entry 
to the market by generics and biosimilar drugs, and in recognition of the fact that many 
patients with chronic, complex diseases require multiple medications, incentives to promote 
the development of fixed-dose combinations (FDCs). These may be advantageous in 
increasing patient adherence (Sawicki-Wrzask et al., 2015) but the existing intellectual 
property regime provides few incentives to develop them.  
Others relate to payment and reimbursement, such as value-based pricing, seen as a means 
to link payment to manufacturers to the effectiveness of the product, but also other 
approaches to price setting, discussed in the next section. 
Other approaches are less controversial, such as those that focus on providing more 
information to patients to help them make informed choices about their own treatment, as 
part of a wider patient engagement and empowerment/ health literacy agenda  (Stacey et al., 
2014). From this perspective, patient empowerment may inter alia be able to reduce over-
prescription and overconsumption of medicinal products. 
The decision being discussed 
The focus of this chapter is on one particular aspect of pharmaceutical policy, the pricing of 
medicines. Drawing on an earlier study by Toumi et al (Toumi et al., 2014), the European 
Commission asked Gesundheit Oesterreich Forschungs- und Planungsgesellschaft GmbH, 
together with SOGETI (Luxembourg) and UMIT (Private University for Health Sciences, 
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Medical Informatics and Technology, Austria) to carry out a study on enhanced cross-country 
coordination in the area of pharmaceutical product pricing 
(Gesundheit_Österreich_Forschung-_und_Planungs_GmbH, 2016).  
The study analysed the potential for use of two options, “external price referencing” (EPR) 
and “differential pricing” (DP) in terms of technical, economic and legal considerations, in 
order to investigate possible benefits from improved cross-country policy coordination in the 
area of pharmaceutical pricing. EPR is applied widely in Europe – according to the report, in 
2015, apart from Germany, Sweden and the UK, all EU Member States and Iceland, Norway, 
Switzerland and Turkey set the prices of some medicines based on comparisons with other 
markets.  
“Differential pricing” (DP), on the other hand, involves charging different customers different 
prices for the same product, i.e. setting the price of medicines according to ability to pay or 
the economic situation of the countries concerned. This is widely used at the global level, to 
enable access to drugs such as those for HIV/AIDS, malaria, and TB, as well as vaccines in low-
income countries.  There is however no experience of implementing such a policy in relatively 
high-income countries, while in the EU, with its single market, there are particular challenges 
related to parallel trade whereby a product placed on the market at a low price in one country 
can easily be exported to another.  
The study entailed simulations of approaches to EPR using econometric modelling, illustrating 
the savings that could be generated for payers if EPR was applied in an appropriate manner. 
By publishing the details of the models and the assumptions underpinning them, interested 
parties could engage in detail with the process. The contractor was asked to engage with 
these interested parties, with the approach specified including interaction with a minimum of 
20 stakeholders, one face to face stakeholder meeting, and collection of comments from 
stakeholders in writing (a written review). In line with the Tender Specifications of the study 
on ‘Enhanced cross-country coordination in the area of pharmaceutical product pricing’, the 
stakeholder review had to be “open to participation of EU-level representatives from patients, 
public payers and medical industry” (Gesundheit_Österreich_Forschung-
_und_Planungs_GmbH, 2016). 
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The consultation 
Based on experience with a previous, similar study (Vogler et al., 2014), the consultants 
proposed to extend the stakeholder groups invited to participate to include consumers, 
competent authorities for pricing and reimbursement, and healthcare professionals, 
especially doctors and pharmacists. On the manufacturing side, industry was represented by 
a variety of groups including the research-based pharmaceutical industry (also including the 
biotech industry), generics and biosimilar manufacturers, and producers of medicines for self-
medication. Medical devices were beyond the scope of the consultation since the study 
targeted only pricing policies for medicines, not health technology. 
The consultants were required to engage with up to 60 stakeholders for the written review 
(as set out in the Tender Specifications), so it would not be sufficient to engage with only the 
pan-European organisations. Consequently, some other stakeholders from Member States 
were also invited. However, the European associations were able to nominate these other 
stakeholders. The consultant’s rationale for proposing this approach was that this had been 
done with the Working Groups for the Platform “Access to Medicines in Europe” under the 
Process on Corporate Social Responsibility in the Field of Pharmaceuticals. 
The consultant applied a differentiated approach for the written review and the stakeholder 
review meeting: to allow for a constructive and comprehensive dialogue during the meeting, 
the number of participants in the meeting was limited to around 25 stakeholders, whereas 
the remaining stakeholders would have the possibility to comment in writing. For the written 
review, participants were invited to provide their feedback in a “feedback template”, divided 
into “general comments” and “specific comments” relating to specific paragraphs of the draft 
report.  
The principle of “one institution - one voice/representative” was applied. As a result, only one 
coordinated response per institution was accepted in the written stakeholder review, either 
a European association or national stakeholder organisation. 
In line with these principles, the consultant proposed a list of stakeholders to be invited for 
the stakeholder review meeting. The consultant discussed this list of stakeholders with the 
European Commission at the kick-off meeting in Brussels in December 2014. In principle, the 
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list was accepted, and it was expanded with further suggestions from the European 
Commission.  
In the stakeholder meeting, the presentation of the key findings and results was accompanied 
by a summary of the written comments submitted thus far, which were often contradictory. 
Following the presentation, some specific questions were discussed. How can EPR be 
improved in order to increase access to medicines and improve cost containment? Should a 
differential pricing scheme be developed in the European Union, and if yes, how to 
differentiate prices, what limitations should be imposed, and how would it be co-ordinated 
among Member States? 
The meeting was held under Chatham House Rules. Possible ways forward, what was missing 
from the debate, and proposals for further research were also touched upon in the 
discussions. 
Figure 5-1 Stakeholder consultation in the pharmaceutical pricing case study 
 
Documents submitted to the consultation 
The consultants emailed the draft interim report on 10 August 2015 to a total of 51 groups, 
encompassing 13 stakeholders (associations / interest groups), 32 Member State institutions 
(pricing authorities), and 6 differential pricing experts (that had been available for interviews). 
Written 
consultation
51 stakeholders
amounting to 23 
group submissions
Launched August 
2015
Stakeholder 
review meeting
34 stakeholders 
attending
17 September 
2015
Written comments 
further to the 
stakeholder 
review meeting
24 non-identical 
submissions 
included in the 
case study 
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Prior to the stakeholder meeting, written feedback was received from a total of 23 groups, of 
which 7 were stakeholders, 16 were institutions from 15 countries, and 2 were differential 
pricing experts. Written feedback was received between 14 August and 7 September 2015, 
with formats ranging from 50 page submissions to single paragraphs. Stakeholders providing 
shorter comments did not use the feedback template. I translated submissions in another 
language than English (i.e. German) into English and analysed them alongside the others. 
Participation in the stakeholder consultation 
According to Annex 15 of the published final report, a total of 34 participants attended the 
stakeholder review meeting held in Brussels on 17 September 2015. In addition to 
representatives of the European Commission and of the upcoming EU Presidencies 
(Netherlands, Malta and Slovakia), 11 stakeholder representatives and 11 country 
representatives (two of them also represented a stakeholder perspective) attended the 
meeting.  
Table 5-1 provides detailed information on the participation in the stakeholder review 
meeting (Gesundheit_Österreich_Forschung-_und_Planungs_GmbH, 2016). However, I was 
not able to obtain all written comments (notably, those from the UK, CPME and differential 
pricing experts were not available). Only those that were accessible were included in the 
algorithm. These texts are described in Table 5-2. Appendix 3 contains a description of the 
type of organisations having participated in the stakeholder review process.  
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Table 5-1   Stakeholder review process – overview of participation and submissions 
Stakeholder/Member State  Written comments 
(between 14 August and 7 
September) 
 Participation in the 
workshop (17 September 
2015) 
   
Association Internationale de la Mutualité 
(AIM) 
✓ ✓ 
Bureau Européen des Unions de 
Consommateurs (BEUC) and national 
associations 
✓ ✓ 
Health Action International (HAI) ✓ ✓ 
European Patient Forum (EPF) and national 
associations 
 ✓ 
European Public Health Alliance (EPHA) ✓ ✓ 
European Federation of Pharmaceutical 
Industries and Associations (EFPIA) and 
national associations 
✓ ✓ 
European generic and biosimilar medicines 
Association (EGA) and national associations 
✓ ✓ 
European Association for Bioindustries 
(EUROPABIO) 
  
Association Européenne des Spécialités 
Pharmaceutiques Grand Public (AESGP) 
 ✓ 
AmGen ✓  
GAVI ✓  
WHO ✓  
European Social Insurance Platform (ESIP)  ✓ 
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Table 5-1 Stakeholder review process – overview of participation and submissions 
(continued) 
Stakeholder/Member State Written comments (between 
14 August and 7 September) 
Participation in the work-
shop (17 September 2015) 
European Association of Hospital 
Pharmacists (EAHP) 
 
✓ 
Comité permanent des médicins 
européens (CPME) & n. assoc. 
✓ ✓ 
Euripid  ✓ 
Austria   
Belgium  ✓ 
Bulgaria   
Croatia ✓  
Cyprus   
Czech Republic  ✓ 
Denmark   
Estonia   
Finland ✓  
France  ✓ 
Germany ✓ ✓ 
Greece  ✓ 
Hungary ✓ ✓ 
Iceland   
Ireland ✓  
Italy   
Latvia  ✓ 
Lithuania ✓  
Luxemburg   
Malta ✓ ✓ 
The Netherlands  ✓ 
Norway ✓  
Poland   
Portugal   
Romania   
Slovakia ✓ ✓ 
Slovenia ✓  
Spain ✓ ✓ 
Sweden ✓  
Switzerland ✓  
Turkey ✓  
United Kingdom ✓  
DP experts ✓  
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The Dutch representative also represented ESIP and the Hungarian representative also 
represented EURIPID (international database of pharmaceutical pricing hosted by the 
National Health Insurance Fund OEP Hungary). 
The consultation  
The consultation on the technical study ran from August to October 2015 and there were 24 
non-identical submissions, with the exception of the differential pricing contributions from 
experts. Some submissions took the form of text in emails and some were submissions using 
the template. I combined them for each stakeholder when both forms were used, collated 
the contributions, and assigned the aggregated text to the same stakeholder group. For 
example, GAVI (Global Alliance for Vaccines and Immunization) submitted an email and a 
review template, which I combined into one text submission. To these 24 texts I added the 
stakeholder review report as published (Gesundheit_Österreich_Forschung-
_und_Planungs_GmbH, 2016) bringing the total to 25 texts. I also added the executive 
summary of the study before the consultation and after the consultation, bringing the total 
to 27 texts.  
Submissions were clustered according to industry, government, or public health sources 
(Table 5-2). This yielded 5 from industry (including contributions from the social health 
insurance payers), 5 public health submissions and 14 government agency contributions, with 
the two executive summaries and the stakeholder review report being labelled as neutral and 
independent. The submissions from EFPIA (European Federation of Pharmaceutical Industries 
and Associations) and EGA (European Generic and Biosimilar Medicines Association) were 
used to represent the corporate/ industry end of the scale, whilst BEUC (Bureau Européen 
des Unions de Consommateurs, an umbrella consumers organisation) and HAI (Health Action 
International, a NGO campaigning for access to essential medicines) submissions were used 
as the public health end of the continuum. All four of these stakeholder groups submitted 
review templates, ensuring good coverage of concepts and a detailed text submission, 
meeting the basic pre-requisites for being selected as a reference text under the STATA 
algorithm Wordscores. 
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Table 5-2  Format of submission by stakeholder group and cluster  
Stakeholder group Stakeholder cluster Format of submission 
   
AIM Industry Email 
AmGen Industry Review Template 
EFPIA Industry Review Template 
EGA Industry Review Template 
DE AOK Industry Email (in German) 
HAI Public health/ Advocacy Review Template 
BEUC Public health/ Advocacy Review Template 
EPHA Public health/ Advocacy Email 
GAVI Public health/ Advocacy Email combined with review 
template 
WHO Public health/ Advocacy Review Template 
DE BMG (Ministry of Health) Government Agency Email (in German) 
BE Government Agency Email 
CH Government Agency Review Template 
IE Government Agency Review Template 
FI Government Agency Email 
HR Government Agency Email 
ES Government Agency Review Template 
LT Government Agency Email 
HU Government Agency Review template 
SK Government Agency Review template 
MT Government Agency Review template 
SE Government Agency Review template 
NO Government Agency Email 
TK Government Agency Review template 
 
I ran Jfreq and the Wordscores algorithm in STATA for the 27 text files in the written 
consultation. In parallel, I worked on a logbook, as presented in the Manual in Appendix 4. 
This Manual was pilot-tested and validated, and represents a stand-alone deliverable from 
this thesis. 
As described previously, the scaling algorithm Wordscores has been used before in automatic 
content analysis research on health policy (Costa et al, Stuckler et al, Laver, Benoit and Gary, 
etc). Wordscores infers policy positions in new documents – so-called virgin texts – by 
calculating scores for these documents based on the scores of reference texts. Scores are 
derived from the frequency of words in a document relative to the total number of words. 
First, I converted documents from portable document format to more manageable text files. 
Then I manually removed superfluous information i.e. names of interest groups, headers and 
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footers, contact details and citations. I then created a frequency matrix using the programme 
Jfreq in R, which estimated the frequency distribution of words across documents, reduced 
words to their roots and removed stop words, numbers and symbols.  
The Martin-Vanberg Transformation 
MV (the Martin-Vanberg) transformation compensates for the tendency of non-
discriminating words to pull scores towards the middle of the scale, making the alignment 
less visible and clear. 95% confidence intervals based on standard deviations in score 
frequencies across documents are calculated. Then, I compare the score of the document 
before and after the consultation: for this I use the Executive Summary of the study as using 
the entire report would be too cumbersome and would not provide any meaningful results.  
For the MV transformation, I selected the BEUC paper as the anchor to calculate the standard 
unit, as it had the lowest raw STATA-calculated score. Then I chose the EGA paper as the upper 
MV transformation anchor, as it had the highest STATA-calculated score.  
The production of the Guide 
The step-by-step guide in the Manual (Appendix 4) traces the different steps undertaken 
during the data sanitation and analysis stage. The following paragraphs describe the steps 
taken to carry out the data sanitation for this particular case study. 
First, I converted the PDF/ Word text files into simpler text format (extension “.txt”), 
translated the texts from other languages into English6 and classified each text according to 
email or template submission. For the GAVI text (where there was email text as well as a 
template submission), I combined the two into one single .txt document. 
Next, I removed all text pertaining to the template i.e. the template headings (“Chapter”, 
“Comment”, “Suggested Change”), the title of the study, interest group names, headers and 
footers, contact details, address formulae (“Dear”) and citations; I further removed the email 
subject phrase “draft report for written review”. Individual page numbers and chapters 
quoted in the templates are furthermore removed. Bibliographic references are kept in, as 
the bibliography that stakeholders choose to quote reveals their interests. Links in references 
                                                   
6 The translation process is important. In an ideal case, the translation would be conducted “blind” by 
someone who does not know the main distinctions driving the research. 
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(e.g. for BEUC) are kept. I corrected any typos. I treated the words “pharma”/ 
“pharmaceutical” as synonymous. 
At first, I ran Jfreq with no pre-processing. After inspection and initial analysis, I established 
that it was more beneficial to tick all pre-processing options (no numbers or no currency, no 
stop-words in all files, no capitals). This proved more useful as there are fewer columns with 
unique word roots in the final results. Jfreq is extremely useful to detect errors in the 
sanitation of the data (spacing problems, words lumped together, etc). Then I ran the 
Wordscores algorithm in STATA.  
To ascertain whether there was any change between the draft and final reports, I included 
the executive summaries of the documents pre- and post- consultation, re-running both Jfreq 
and STATA Wordscores. I considered including the entire report pre- and post-consultation 
but this was too complex for this case study. 
Lastly, once the STATA Wordscores results were obtained, I proceeded to validate the findings 
by calculating the MV score using Excel to calculate the MV standard error and the 95% 
confidence interval. I undertook a sensitivity analysis, performed robustness checks, and 
plotted the results, including confidence intervals, in a graph. Finally, I proceeded to interpret 
the results. 
Results 
Main Issues and Limitations Identified with EPR and Differential Pricing 
EPR is widely used in Europe – all EU Member States except for Germany, Sweden and the 
UK, and other countries such as Switzerland, Iceland, Norway and Turkey use comparisons 
with other markets to set the prices of the drugs prescribed, administered in hospital or 
available over-the-counter in their individual jurisdictions. The report notes that although 
German law allows EPR to play a role in the pricing of new medicines, “it is claimed that EPR 
is not applied in the follow-up procedure” (Gesundheit_Österreich_Forschung-
_und_Planungs_GmbH, 2016). Similarly, EPR is only used in Denmark in support of pricing in 
the hospital sector. A literature review undertaken as part of the study concluded that EPR 
could generate significant savings for public payers – however the extent of savings largely 
depended on the type of EPR applied. Surveys conducted as part of the study found that 20 
of the 29 countries using EPR employ it as the sole or main pricing policy, with the number of 
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reference countries included in the basket varying from one (in Luxembourg) to 30 (in Poland 
and Hungary). Also, several Member States do not seem to perform regular (i.e. bi-annually, 
annually or at other defined time intervals) price re-evaluations, even if provided for in their 
legislation. Re-evaluations carried out more frequently could generate more savings for 
payers. 
Some of the limitations of EPR include hidden discounts (whereby the manufacturers offer 
large discounts on the published prices to governments and other payers, so as to obscure 
the data on which EPR is based), delays in re-evaluations, and problems arising from parallel 
trade. There are two kinds of discounts: statutory manufacturer discounts and confidential 
discounts (e.g. rebates or other similar financial arrangements). Currently, the data that are 
exchanged are the undiscounted prices and the true prices paid are treated as commercially 
confidential. Delayed re-evaluations of comparative prices (even if provided for in legislation) 
create inertia with respect to real prices. Parallel trade, on the other hand, consists of the 
illegal import of indications of drugs from low-priced countries to high-priced countries. 
Importantly, EPR has been fiercely criticised for incentivising the pharmaceutical industry to 
first launch in higher-priced countries and delay or even to forego entering the market in 
lower-priced countries.  
These factors have led to endemic high prices and drug shortages (particularly in the Visegrad 
countries of Central and Eastern Europe) and in small markets (e.g. Luxembourg). 
Some of the limitations of Differential Pricing include the appropriate starting price, as well 
as the identification of a maximum and minimum entry price threshold for each drug under 
consideration. Whilst Differential Pricing schemes have not been applied in high-income 
countries, such mechanisms would require economic indicators such as purchasing power 
parities and gross domestic product to be taken into account. The introduction of such a 
scheme would need significant political will. 
Nature of Comments Received 
As discussed in Annex 15 of the published study report (Gesundheit_Österreich_Forschung-
_und_Planungs_GmbH, 2016), responses to the draft report differed greatly among the 
various categories of stakeholders. Since Member States’ representatives had already been 
involved in the survey of existing EPR systems, they saw the sharing of the interim study 
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report as a chance to validate the information about their country. Comments submitted by 
stakeholder associations not representing Member States, by contrast, were not country 
specific but more general in nature. The extreme manifestation of this phenomenon entailed 
comments so general and vague that they did not even refer to the draft report, but were 
general statements related to EPR, differential pricing and/or pharmaceutical policies, 
reflecting their organisation’s positions on the matter.  
The study had aimed, primarily, to initiate a reflection about improvements to EPR and 
exploring alternative pricing possibilities, including differential pricing in a “pedagogic 
exercise” to raise awareness and understanding of the latter concept. Stakeholders and 
Member States alike welcomed the critical discussion about the limitations of EPR that had 
resulted from the production of this report. Several comments thus concerned the limitations 
of EPR that were generally acknowledged by both stakeholders and Member States.  
The different parts of the report were addressed in varying degrees. Most comments related 
to the validation of the country-specific information about EPR. For the remaining non-
country specific information, considerably more comments referred to the EPR section than 
to the differential pricing section. One stakeholder critically addressed the methodology of 
the simulations, proposing to run a dynamic instead of a static model. The legal analysis part 
of the report (annex 13 of the published report) elicited no comments. 
Several comments referred to the role of EPR within the spectrum of available policy options 
for cost-containment using price setting. Stakeholders’, but also, to a lesser extent, Member 
States’ comments stressed that EPR should not be employed in isolation, as a single tool, but 
only with other pricing policies. Furthermore, pricing is only one lever to ensure equitable 
access to medicines while containing costs. One stakeholder addressed the scope of this 
policy, stating that EPR should not be used for generics. It was suggested that the non-
availability of medicines should be further highlighted. One stakeholder recommended 
considering it in the simulations, in connection with the disclosure of discounts. 
Transparency  
The most contested issue was transparency. One stakeholder stated that price information, 
in particular discounts, rebates, and managed-entry agreements, should remain confidential, 
as this was understood as part of the business. Other stakeholders and, especially, Member 
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States, expressed a preference for (full) disclosure of these price reductions. While there were 
polarised views between commenters about confidentiality, the proposal of the study authors 
to consider at least published mandatory discounts in EPR was addressed by only one 
stakeholder. This proposal was challenged since mandatory discounts were seen as a 
temporary measure only. 
Possible Improvements 
Proposals for improvements also attracted a host of comments. The first proposal was to 
establish an extended price database. This was the part of the report that attracted most 
comments. Member States confirmed the value of the existing pricing database, Euripid, as a 
resource for undertaking EPR (Council of Ministers, 2015). Stakeholders who did not have 
access to the Euripid database expressed reservations about its methodological limitations.  
Some commentators objected to the database containing price data calculated on average 
margins (e.g. ex-factory prices based on average wholesale margins). Furthermore, Member 
States and several other commentators again broached the issue of confidential discounted 
prices, and advocated the inclusion of statutory discounts in a price database. Stakeholders 
without access to the Euripid database called for a price database that was open either to all 
stakeholders or at least to industry, allowing cross-checking if prices listed in Euripid. 
Only a few comments discussed a coordinated EPR formula and no explicit written comments 
were made with regard to regular price monitoring. Generally speaking, the proposal of 
weighting prices by the income / wealth of the countries was welcomed by several com-
menters, both stakeholders and Member States representatives. 
Parallel Trade and Differential Pricing 
An industry representative felt that the issue of parallel trade was not sufficiently explicitly 
addressed by the study. Similarly, one industry stakeholder challenged the definition of 
“differential pricing” that was deployed in the study. In line with the Tender Specifications, 
the study elaborated on differential pricing as a coordination measure applied by 
governments, and did not consider “Ramsey pricing” or in other words, price differentiation 
applied by the seller with respect to line of business (upmarket versus downmarket), as a 
function of price elasticity of demand. The more inelastic the demand for a particular product, 
the more a seller may price the product upmarket as opposed to downmarket. Put more 
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simply, Ramsey pricing is where a seller who has a monopoly adds the greatest price mark up 
to products where demand is price inelastic as people will buy the product anyway. The 
stakeholder who insisted on “Ramsey pricing” would have preferred further assessment of 
the scale and nature of contemporary price differentiation deployed by industry in confiden-
tial discounts to different public payers. Another stakeholder expressed concern that 
differential pricing could run the risk of being employed as a commercial strategy, allowing 
the pharmaceutical industry to maximise the bottom line rather than to pursue the greater 
good. 
Some commenters (both stakeholders and Member States) expressed concern about the 
feasibility of a differential pricing scheme in Europe and severe doubt as to sufficient political 
will favouring such a scheme.  
Voices from the consumers/ patient advocacy side confirmed findings of the literature 
reported in the study that other instruments, in particular generic competition, might be 
more effective to secure cost-containment and long-term access to medicines. 
Consideration was given to the appropriate price to start with in a differential pricing scheme. 
One stakeholder challenged the proposal made in the interim report to design the differential 
pricing model in such a way that higher-income countries would not pay more with such a 
scheme than without it. One stakeholder expressed concern that the Member States might 
be under pressure to reimburse a differentially priced product. It was ultimately suggested to 
draw conclusions from literature related to risks and benefits of donations. 
The above discussion and preliminary observations reflected the different power dynamics 
between stakeholders and Member States. One participant from an international 
organisation considered Member States in their current role as “price takers”, whilst industry 
referred to the authorities as “price setters”. Certain voices raised legitimate questions about 
how to establish a “fair” EPR and differential pricing scheme, i.e. what is a “fair price” for all 
and last but not least, about the cost of research and specifically who should shoulder the 
latter, i.e. manufacturers or public payers.  
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Summary of the positions of industry, governments and the public health 
community 
All in all, the study only zoomed in on two of the three objectives as defined in European 
processes such as the Pharmaceutical Forum, i.e. access to equitable medicines and cost-
containment/financial sustainability. The industry representatives were very much of the 
view that the objective of reward for innovation should also be taken into consideration. The 
government representatives had much more neutral views and corrected factual statements 
in particular, whereas the public health community took up the patient perspective and 
advocated for generic competition, a broader access and a more equitable price structure 
without launch delays for high-cost medicines and orphan drugs. Before discussing the main 
results, trends and key figures, it is worth pointing out that a more refined analysis could be 
done by operationalising market size, as this is a crucial factor to consider, driving the 
pharmaceutical industry’s structure. This is however beyond the scope of this present 
analysis. 
STATA and Jfreq analyses 
In this section, we examine in-depth the word scores of the texts submitted by the different 
clusters of stakeholders: the industry versus the government versus the public health 
advocacy groups. Later on, we examine the movement of the neutral text (in this case, the 
executive summary of the report submitted for consultation) and its original starting point, 
as measured by the Wordscores algorithm. 
Table 5-3 shows the word count and word scores (raw score, LBG score, MV score) of a 
selection of texts from the industry and advocacy camps. To recall, AIM is the International 
Association of Mutual Insurers, whilst AOK is one of the largest statutory health insurers in 
Germany. EGA is the European Generic and Biosimilar Medicines Association, EFPIA is the 
European Federation of Pharmaceutical Industries and Associations and Amgen is one of the 
world’s leading biotechnology companies. BEUC is the European Office of Consumer 
Organisations, HAI is Health Action International and EPHA is the European Public Health 
Alliance. 
Positions of stakeholders having similar interests (e.g. EGA, EFPIA, Amgen, AIM and AOK on 
the one hand and HAI, BEUC, EPHA and WHO on the other) translate into scores with very 
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similar values. As illustrated in the table, the industry cluster has adjacent raw scores based 
on the Wordscores algorithm in STATA with values converging around 0.66 values whereas 
the advocacy cluster has visibly lower raw score values converging around 0.35.  
Table 5-3  Comparative Analysis of Scores of Stakeholder clusters 
Stakeholder Word count Unique 
words 
scored 
Raw score LBG score MV score 
Industry 
EGA 1275 499 0.6987 1.7807 1 
EFPIA 12,855 2482 0.6576 1.4885 0.8999 
Amgen 5367 1223 0.63736 1.1678 0.7902 
AIM 162 93 0.66934 0.7245 0.6385 
AOK 588 225 0.66332 0.4256 0.5361 
Advocacy 
BEUC 479 264 0.2878 -1.1416 0 
HAI 2088 737 0.356 -0.6564 0.1659 
EPHA 286 141 0.54547 0.0198 0.3974 
WHO 238 125 0.62397 0.4775 0.5539 
 
When Laver-Benoit-Garry (LBG) scores are considered (also calculated via the Wordscores 
algorithm in STATA), the order and positioning is conserved, except for the value of the WHO 
submission, which is slightly higher under this method than the AOK value. The same can be 
observed if MV scores are compared, with the WHO value jumping into the “industry” cluster 
and surpassing by a few hundredths decimal points the AOK MV transformed value. Overall, 
however, it is clear that the industry cluster has higher average scores under any of the three 
methods than the average score of the public health advocacy cluster. 
The results obtained via Jfreq show the following key trends for truncated words: 
· The longest submissions featured the highest use of the stop word/article “the” (Amgen, 
EFPIA, the summary report, HAI, etc); 
· “Pharmaceutical” was used mostly by the longest submissions (EFPIA, Amgen, HAI, etc); 
· “equitable” was used most frequently by the report of the stakeholder review, by HAI and 
once by EFPIA and by Amgen (indicating that the industry mimics and also adopts the 
language of the opponents); 
· “discounts” the same as above, plus by IE and BE; 
· “spend” used by EFPIA and Amgen and once by HAI;  
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· “negoti” used notably by Amgen, EFPIA and to a lesser extent by HAI and by the report; 
· “agreement” used mostly by EFPIA and Amgen. 
In the post-consultation summary, DE is reported as not applying EPR, with the added 
sentence: “In Germany, though the law provides for prices in other countries to be considered 
as an additional piece of information in pricing of new medicines, it is claimed that EPR is not 
applied in the follow-up procedure”. 
Similarly, at the top of page 2, the following sentence was added in the post-consultation 
version: “Germany, though not applying EPR, specified in its law that discounted prices are to 
be reported by the manufacturers”. 
One further sentence was added post-consultation: “There are lost opportunities due to 
discounts, rebates and similar arrangements in the reference countries that are not considered 
in EPR”. 
Legal restraints to join a centralised database of Member State price data were also added 
e.g. “no possibility to share the price data of the own country due to a lack of ownership”;  
· “it is recommended adding an indication in the price database of whether, or not, 
discounts are applicable to that product” changed into “have been granted to that 
product”; 
· “EPR could generate higher savings for public payers if the price comparisons were 
done at the level of real prices paid by payers (discounted prices) instead of list prices” 
was turned into “EPR could provide lower prices if…”; 
· Sentence added: “to impact the differentiation of prices between countries along the 
lines of ability-to-pay” (and thus improve access to medicines); 
· “medicines as such are no exception to the free mobility of goods in the internal 
market” was added to the parallel trade paragraph; no ECJ ruling  exists to date 
“although the effects of parallel trade on health and safe access to medicines remain 
a matter of strong controversy” added; 
· Sentence added: “The exact impacts of a possible differential pricing scheme within 
the European market are still unclear”; 
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· Sentence added: “It is recommended using fora, such as the stakeholder review 
meeting of this project, to openly discuss strategies among stakeholders on how to 
deal with new high-cost medicines.” 
In conclusion, the industry cluster tended to use words such as “agreement”, “negotiation” 
and “spend” more often than the public health advocacy and government clusters based on 
a certain framing of the discourse around reward for innovation. The rhetoric therefore 
focused on negotiation strategies and maintaining profit margins. By way of contrast, value-
based concepts such as “equitable” tended to be used rather more by the public health 
advocacy groups. 
Changes between the draft and final report 
In this section, I examine whether there was a shift in the neutral text (the executive summary 
of the report submitted for consultation) from its starting point, as measured by the 
Wordscores algorithm. 
As illustrated in Table 5-4, following the consultation, the score of the executive summary is 
marginally closer to the industry cluster than to the scores of the advocacy cluster (moving 
upwards from a value of 0.58277 to 0.58796) and its word count, as well as unique word count 
increases (the word count augments from 2260 to 2432 words and the unique word count 
from 599 to 627). This observation is valid under each of the three methods: the raw score, 
the LBG score and the MV score. Post-consultation, scores marginally increase in the direction 
of the industry scores. The report of the stakeholder review has word counts and scores 
similar or comparable to the executive summaries. 
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Table 5-4    Comparative Analysis of the Review Report and its Executive Summaries 
Stakeholder or 
version of report 
Word 
count 
Unique 
words 
scored 
Raw score LBG score MV score 
Industry 
EGA 1275 499 0.6987 1.7807 1 
EFPIA 12,855 2482 0.6576 1.4885 0.8999 
Neutral 
Pre-consult (Exec 
Summary) 
2260 599 0.58277 0.6371 0.60866 
Post-consult 
publication (Exec 
Summary) 
2432 627 0.58796 0.6669 0.61888 
Report of the 
stakeholder review 
2717 579 0.59511 0.4472 0.54368 
Advocacy 
BEUC 479 264 0.2878 -1.1416 0 
HAI 2088 737 0.356 -0.6564 0.1659 
 
Based on Annex 15 of the published report, the main issues raised during the written 
stakeholder review by various actors were also mentioned during the meeting: 
· Limitations of EPR were stressed. 
· It was repeated that prices are not the only component of pharmaceutical policies. 
· The issue of “layered transparency” emerged: the idea that different levels of 
transparency with regard to different target groups might be in place. 
· The definition of “differential pricing” (the definition of a government-fledged differential 
pricing system) was challenged. The difficulties related to defining a starting price or a 
minimum/ maximum threshold were discussed. 
· The scope of EPR policies was touched upon (one stakeholder repeated that EPR should 
not be used for generics, but rather for other types of pharmaceuticals). 
· The crucial role of political will as a prerequisite for starting a new pricing policy such as 
differential pricing was highlighted. 
· Stakeholders asked the consultant to elaborate on the industry perspective in general and 
the objective of reward for innovation. 
· The importance of other tools and policies was stressed, especially compulsory licensing 
as well as policies regarding generics. The importance of horizon scanning and health 
technology assessment was also highlighted. 
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Continuing in this vein, the following suggestions were made by different stakeholders during 
the stakeholder review meeting: 
· Citizens and consumers should be increasingly involved in the pharmaceutical pricing 
debate; 
· Improving the capacity of procurers to negotiate and to become price setters (capacity 
building); 
· Policy-makers should define what the health care system is willing, and can afford, to pay, 
and should then communicate this to industry (thus moving from an offer-based to a 
demand-based system); 
· New ways of financing; 
· Moving the focus away from medicine prices to a more comprehensive consideration of 
the treatments at hand; 
· Investigating parallel trade related to medicines; 
· Considering also the impact of pricing policies on the distribution part of the chain 
(wholesale and pharmacies); 
· Collaboration between countries beyond pricing issues; 
· It was suggested to launch research projects and practical pilots on the methodology for 
defining a “fair” price; 
· An independent review on the cost of research was requested, to foster better 
understanding of the topic. 
 
Reaching beyond the scope of the study, the following topics emerged during the stakeholder 
meeting: 
· The importance of managed-entry agreements for certain pharmaceuticals (especially for 
orphan drugs), as an appropriate policy option to address current challenges, however 
limited capacity in many countries in this respect was identified; 
· Increased pressure from the public about novel treatments could have an impact on tech-
nical assessments; 
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· Although limitations of EPR and differential pricing were revealed and discussed during 
the debate, these policies should not be stopped but adapted in a way that the ideas and 
elements could evolve in the future. 
In conclusion, this section served to illustrate that following the written review and the 
stakeholder consultation meeting, there was indeed a shift in the neutral text (the executive 
summary of the report submitted for consultation) from its starting point, as measured by the 
Wordscores algorithm. The qualitative corpus analysis above also showed that the executive 
summary changed and very marginally reflected more of the concepts brought forward by 
stakeholders representing the industry. The next section in this chapter will plot the Martin-
Vanberg scores and develop summary measures per cluster of stakeholders to crystallise 
results. 
Plotting stakeholder positions based on MV scores to improve stakeholder analysis 
Figure 5-2 shows a plot of Martin-Vanberg scores and their corresponding 95% confidence 
intervals for all the texts in the consultation and demonstrates that, when looked at in 
aggregate, the advocacy scores (namely, advocacy 1 to advocacy 5) are all aligned to the left 
of the industry scores (industry 1 to industry 5), with the governmental agencies’ scores (gvt1 
to gvt14) anchored in the middle of the spectrum. The published version of the study’s 
executive summary (plotted as “published version” in Figure 5-2) is only marginally to the 
right of the pre-consultation version, with the consultation summary anchored in the middle 
ground, equally distant from the scores of the reference texts, namely 0 and respectively 1. 
While the change is extremely small, the executive summary does shift marginally to the right. 
This is further explored in the Discussion chapter at the end of this thesis. 
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Figure 5-2  Plotting stakeholder positions based on MV scores 
 
 
 
 
As is visible in the colour-coded Figure 5-2 above, each stakeholder group translates into 
scores that are close to each other – the advocacy texts have scores plotted in green with 
corresponding confidence intervals, the governmental agencies have scores plotted in 
purple with corresponding whiskers for 95% confidence intervals and industry texts feature 
scores depicted in yellow. The neutral texts (the executive summary pre- and post-
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consultation and the consultation summary) are plotted in blue. Figure 5-3 below renders 
the stakeholder clustering analysis easier to interpret by calculating summary measures 
across the 5 advocacy texts (“Advocacy Summary Measure”), across the 14 governmental 
agency texts (“Government Summary Measure”) and across the 5 industry texts (“Industry 
Summary Measure”). 
 
Figure 5-3 Plotting stakeholder positions based on MV scores (summary 
measures) 
 
In figure 5-3 above, the green triangle represents the summary measure of MV scores for that 
stakeholder category or neutral text, the red square represents the lower limit of the 95% 
confidence interval and the blue diamond the upper limit of the same confidence interval. 
Hence, the green triangle is always at the half-way point between the red square and the blue 
diamond. The figure illustrates that the advocacy summary measure just undercuts the 0.4 
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score, the government summary measure the 0.6 value and the industry the 0.8 score. 
Moreover, the consultation report giving an overview is anchored around the 0.5 mark, 
whereas the pre-consultation version of the executive summary is slightly above 0.6 with the 
post-consultation version marginally, yet visibly towards the 0.7 value. This effectively means 
that the post-consultation version moved in the direction of the industry scores, rather than 
being pulled into the direction of the much lower advocacy scores. The implications of the 
results above will be teased out in the Discussion chapter later in the thesis. 
Last but not least, stakeholders from different categories expressed an interest to continue 
the multi-stakeholder dialogue as done in the stakeholder review meeting – the meeting on 
17 September 2015 was seen as a step in the right direction for enhancing dialogue and 
coordination. Indeed, in line with these requests, a further multi-stakeholder dialogue 
meeting took place on 26 February 2016 to disseminate the results of the pharmaceutical 
pricing study to the consulted parties. 
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Chapter 6.  Acrylamide  
The issue  
Acrylamide is a carcinogenic contaminant found in food items such as potato chips, crisps and 
soluble coffee. It is produced when ingredients containing starch and other complex 
polysaccharides are cooked at above 120ᵒ. It has attracted considerable attention in recent 
years as, although it was well known as an occupational hazard in the chemical industry, its 
significance as a potentially toxic food ingredient was not understood until some 15 years 
ago. It has assumed importance now because of the growth in industrial food processing.  
Jorgen Schlundt, World Health Organization (WHO) coordinator of food safety research, 
suggests that it could have similar effects to heterocyclic amines which have been shown to 
cause cancer in animal studies. However, little is known about potential health risks in 
humans but, if found to be harmful at levels currently found in food, this is likely to have a 
significant impact on the food industry as a whole: if safety thresholds for food are defined 
then, under EU legislation, they would have to be noted on food labels and warnings may also 
be necessary. This could have a large impact on sales and require changes in food processing 
technologies. 
The regulatory process  
Over a decade ago, the European Commission issued a Recommendation that acrylamide 
levels in food should be monitored (European Commission, 2007). The European Food Safety 
Authority (EFSA) in Parma was given responsibility for compiling the results of the monitoring. 
A second Commission Recommendation (European Commission, 2010), adopted in January 
2011, requested Member States to carry out checks at the premises of any food operator 
when monitoring reveals high acrylamide levels in their products. This latter recommendation 
established indicative values – in other words, if an indicative value is exceeded, an 
investigation should be carried out. However, indicative values are not legal limits and hence 
there is no requirement for enforcement measures if they are exceeded. Member States were 
encouraged to report the results to the Commission. On the basis of the information 
gathered, the Commission determined that there was a need for a new assessment as to 
whether further measures were required to reduce the presence of acrylamide in food. As a 
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result, the Commission asked the EFSA to undertake a comprehensive assessment of the risks 
associated with acrylamide in food products. 
The draft Scientific Opinion issued by the EFSA on 15 May 2014 was subject to a public 
consultation prior to its final adoption by the EFSA Panel on Contaminants on the Food Chain 
(the CONTAM Panel). The consultation was web-based and lasted 10 weeks and ran between 
1 July 2014 and 15 September 2014. It was very limited in its scope, considering only the 
identification and characterisation of any hazard, and specifically any toxicity or 
carcinogenicity, drawing on evidence from studies carried out on humans and animals. It did 
not propose any regulations, did not address whether there should be binding or non-binding 
maximum levels of acrylamide in food, and did not call for more stringent controls. Nor did it 
seek to quantify any health impact at population level or possible mitigation measures.  In its 
technical report of the public consultation, EFSA states that questions related to the 
evaluation of remedial action fall squarely under the remit of the European Commission 
(European Food Safety Authority, 2015). 
Even before the EFSA Scientific Opinion was published in its final form, however, the 
Commission had adopted a further Recommendation 2013/647/EU on investigations into 
levels of acrylamide in food (European Commission, 2013). That Recommendation endorsed 
the existing monitoring system, but in a more targeted manner, and with a review of the 
indicative levels used to select manufacturers for inspections. The industry had also acted, 
developing a toolbox designed to facilitate control and reduction of acrylamide in food, since 
updated several times (Food Drink Europe, 2014). In 2014, the Commission organised a 
workshop on acrylamide at which relevant industry sectors were asked to present in detail 
how the FDE-toolbox was being implemented in the production process. Consumer 
organisations were also asked to present their initiatives to make consumers aware of the 
importance of good cooking practices to keep acrylamide levels in home-prepared foods to a 
minimum (European Commission, 2014b). The Toolbox is an example of self-regulation 
intended to curtail the introduction of more stringent regulatory measures at EU-level. 
The documents 
Twenty-three parties submitted comments (European Food Safety Authority, 2015), from 
academia, industry and industry associations, national agencies/ authorities, and other 
105 
 
organisations and individuals in a private capacity. Only 17 could be identified; there were six 
submissions whose source could not be ascertained and which were impossible to assign to 
any single entity. This reflected the reporting format of the contributions in the Technical 
Report (i.e. by chapter of consultation and not in their totality). 
The respondents are presented in Table 6-1, clustered in two groups. The first includes the 
food industry and associated bodies and the second includes public health bodies.  Potential 
linkages between the actors are shown in appendix 3. The process yielded 120 comments. 
Some submissions took the form of abstract feedback only, whilst others were more 
comprehensive as the authors had submitted comments under different sections of the 
consultation. I combined all those from the same stakeholder and excluded chapter-based 
anonymous submissions, as it was impossible to assign them a) an identity and b) a specific 
stakeholder position. 
I added the draft scientific opinion, the final scientific opinion and the stakeholder review 
report containing a brief summary of the comments received and an explanation of how they 
were addressed by the Panel on Contaminants in the Food Chain (CONTAM Panel) to the 17 
texts sent in by the 17 identified parties, increasing the total to 20 texts. Unlike in the previous 
case study which represented a pilot for the other case studies, the full texts of the scientific 
opinions were more representative than their executive summaries and were therefore used 
in their full length.  
The analysed texts represented 9 industry texts including those from innovation-oriented 
companies, 7 public health contributions (PH), one was a ghost (anomalous) submission and 
three texts were neutral or their positions were to be tested. I use the term “anomalous” (or 
“ghost submission”) to refer to text that is irregular, or deviates significantly from its 
surrounding context (Guthrie, 2008). 
Analysis 
I ran Jfreq and the Wordscores algorithm in STATA for the 20 text files in the consultation 
(including the draft and the final EFSA scientific opinion and the technical report of the 
consultation). The scaling algorithm Wordscores was used (Costa et al., 2014, Laver et al., 
2003). Wordscores infers policy positions in new documents – so-called virgin texts – by 
calculating scores for these documents based on the scores of reference texts. Scores are 
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derived from the frequency of words in a document relative to the total number of words. 
Given the polarisation of perspectives between industry and public health, for running 
Wordscores in STATA I devised a scale using texts from Food Drink Europe and European 
Coffee Federation as reference texts for industry and Kantonales Labor Zuerich and the 
Austrian Public Health Institute as reference texts for public health organisations. 
First, I converted documents from portable document format to more manageable text files. 
In this case, since the submissions were published in the Technical Report annex, I simply had 
to collate the contributions by author. The template headings were retained (e.g. “Abstract”, 
“Summary”, “Conclusions and recommendations”). Bibliographic references were retained as 
the bibliography that stakeholders quote reveals their interests; the links in references were 
also kept in.  
I then created a frequency matrix using the programme Jfreq in R, which estimated the 
frequency distribution of words across documents, reduced words to their roots and removed 
capitals, stop words, numbers and symbols. Hence, all pre-processing options were ticked. 
This proved useful as there are fewer columns with unique word roots in the end. Jfreq is 
useful to detect errors in sanitation of the data (spacing problems, words lumped together, 
etc). Typos (although few) were corrected to the extent possible. 
I built the MV scores in Excel and presented precision estimates (95% confidence interval) in 
a box on sensitivity analysis and robustness. However, one of the reference texts for public 
health, from the Austrian Agency for Health and Food Safety, is comparatively much shorter, 
which may limit its suitability as reference text. Thus, another algorithm was run in which the 
industry reference texts were kept constant and the Chilean Food Quality and Safety Agency 
replaced the Austrian Public Health Institute. This was to have a longer reference text (as 
measured by a higher word count) with a low STATA raw score. The Chilean Food Quality and 
Safety Agency fitted these criteria. However, the draft EFSA scientific opinion and the 
scientific opinion both yielded raw scores lower than each of the public health advocacy 
reference texts (which was not the case in the previous scenario). Hence this test was 
dismissed as having low face validity. 
I then ran one further iteration, replacing the Chilean Food Quality and Safety Agency 
submission with that from the Instituto Superiore de Sanita (ISS) while keeping the others 
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constant. Again, the EFSA draft scientific opinion and the scientific opinion yielded raw scores 
lower than one of the reference texts (in this case, that of Kantonales Labor Zuerich). On the 
same principle as before, this test was dismissed as having low face validity. 
A final iteration employed the same algorithm, with the same public health reference texts as 
in the first attempt (Kantonales Labor Zuerich and the Austrian Public Health Institute) and 
for industry – Food Drink Europe and the National Coffee Association US (NCFUS), the latter 
instead of the European Coffee Federation text. As in the first scenario, these results 
appeared to have acceptable face validity, with raw scores of the EFSA draft scientific opinion 
and final scientific opinion marginally higher than those of both public health reference texts. 
However, the first test was the one adopted as the final iteration did not present any 
additional advantages over the first and the first appeared to have more face validity based 
on initial results. 
MV (the Martin-Vanberg) transformation compensates for the tendency of non-
discriminating words to pull scores towards the middle of the scale, rendering the alignment 
less visible and clear. I calculated 95% confidence intervals based on standard deviations in 
score frequencies across documents. Then I compared the score of the EFSA scientific opinion 
document before and after the consultation. For this point, I used the entire report, not solely 
the Executive Summary of the scientific opinion as Wordscores allows for this and a variation 
was sought after the pharmaceutical pricing case study focused only on the Executive 
Summaries of the draft study report.  
The Margin-of-Exposure Model 
To interpret the findings, it is necessary to explain something of the Margin-of-Exposure 
(MoE) concept. This is an internationally established method for the estimation of the 
potential risk genotoxic and carcinogenic substances pose to human health. This concept 
underpins EFSA’s Scientific Opinion on acrylamide and puts forward a harmonized approach 
for the risk assessment of substances in food with genotoxic and carcinogenic properties. 
However, not all stakeholders participating in the public consultation clearly espouse this 
concept in the wording of their submissions. 
According to a recent paper that I translated from German (Andres et al., 2017), the MoE 
value is a dimensionless number, which describes the ratio of an active dose in which a slight 
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but measurable adverse effect is observed, and estimates the level of exposure to the 
substance in question, taking into account different consumption patterns. A critical 
observation is that in this case, such a ratio is calculated based on data retrieved via animal 
experiments only. This approach attempts to compare the extent of possible risks posed by 
different genotoxic carcinogens occurring in foodstuffs. It hinges on the assumption that the 
course of the risk curve is comparable to the relationship between carcinogenic activity and 
dose in the different substances. 
In line with EFSA’s proposition, two parameters can be calculated for the reference values of 
the active dose on the basis of the animal experiments carried out to date:  
· One is the benchmark dose “BMDL10” (“benchmark dose-lower confidence limit 10%”), 
in which the incidence of cancer in a particular tissue is 10% higher. The calculation is 
based on a mathematical model of the dose-effect relationship and is only useful or 
possible if sufficient data across different dosages is available. To ensure that the concern 
about a possible cancer risk is low for humans, a BMDL10-related MoE value should be 
greater than 10,000 (Andres et al., 2017).  
· Another reference value for the active dose, a so-called “T25” value can also be 
determined which indicates the dose which causes cancer in a particular tissue within the 
life span of 25% of the animals studied. In the calculation, a correction must be made with 
regard to the spontaneously occurring cancer rate in this tissue. To ensure that the 
concern about a possible cancer risk is low or negligible for humans, a T25-related MoE 
value should be greater than 25,000. The lower the MoE value of a given substance is 
below the above-mentioned value, the greater the health concerns for a cancer risk for 
humans (Andres et al., 2017). 
As shown in table 6-1, the following submissions display unquestionable evidence of adoption 
of the MoE model: the Chilean Food Quality and Safety Agency; the Joint Submission by the 
Technical University of Denmark (DTU), the French Agency for Food, Environmental and 
Occupational Health & Safety (ANSES), and the Swedish National Food Agency (NFA Sweden); 
Instituto Superiore di Sanita; Kantonales Labor Zurich; and the Joint submission by the UK 
Committee on Toxicity (COT) and UK Committee on Carcinogenicity (COC).
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Table 6-1 Overview of all textual submissions by stakeholder & neutral texts 
Text acronym in 
STATA 
Stakeholder name (acronym) Raw 
score in 
STATA 
Wordcount 
score in 
STATA 
Industry or 
public 
health? 
Evidence of the 
Margin of 
Exposure 
model being 
adopted? 
Evidence of 
the industry 
“toolbox” 
being referred 
to 
Evidence of the 
enzyme-based 
solution 
“asparaginase” being 
referred to 
Evidence of 
“yeast” 
being 
referred to 
AT.txt Austrian Agency for Health and Food 
Safety AGES 
0.2337 135 PH – Ref. 
text 
No 0 0 0 
CHOPRABISCO.txt The Royal Belgian Association of the 
Biscuit, Chocolate, Pralines and 
Confectionary (Choprabisco) 
0.3564 197 Industry No 0 0 0 
CL.txt Chilean Food Quality and Safety 
Agency (ACHIPIA) 
0.3681 1669 PH Yes 0 0 0 
BDSI.txt Association of the German 
Confectionary Industry (BDSI) 
0.3412 235 Industry  No 1 0 0 
DKSE.txt Joint Submission by the Technical 
University of Denmark (DTU), the 
French Agency for Food, 
Environmental and Occupational 
Health & Safety (ANSES), and the 
Swedish National Food Agency (NFA 
Sweden) 
0.3745 554 PH Yes 0 0 0 
ECF.txt European Coffee Federation 0.7504 1910 Industry – 
Ref. text  
No 1 0 0 
EFSADraft.txt EFSA Draft Scientific Opinion 0.2838 79080 Test Yes 17 0 0 
EFSASciOp.txt EFSA Final Scientific Opinion 0.2837 88777 Test Yes 19 3 0 
EPPA.txt European Potato Processors’ 
Association (EUPPA) 
0.3864 189 Industry No 1 0 0 
ES.txt Spanish National Research Council 
(CSIC) 
0.3406 259 PH No 0 0 0 
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Text acronym in 
STATA 
Stakeholder name (acronym) Raw 
score in 
STATA 
Wordcount 
score in 
STATA 
Industry or 
public 
health? 
Evidence of the 
Margin of 
Exposure 
model being 
adopted? 
Evidence of 
the industry 
“toolbox” 
being referred 
to 
Evidence of the 
enzyme-based 
solution 
“asparaginase” being 
referred to 
Evidence of 
“yeast” 
being 
referred to 
FoodDrinkEurope.txt Food Drink Europe (FDE) 0.7361 3805 Industry – 
Ref. text  
No 3 0 0 
FPP.txt Frozen Potato Products Institute (FPPI) 0.384 466 Industry  No 0 0 0 
ISS.txt Instituto Superiore di Sanita 0.3572 745 PH Yes 0 0 0 
Kantonales.txt Kantonales Labor Zurich 0.2799 2736 PH – Ref. 
text 
Yes 1 3 0 
LTDH.txt LTD H-Group 0.2718 80 Ghost/ 
snap/ 
anomalous 
N/A 0 0 0 
NCFUS.txt National Coffee Federation/ 
Association USA (NCA) 
0.6215 645 Industry No 0 0 0 
Novozymes.txt Novozymes A/S 0.3236 337 Industry No 3 12 0 
Renaissance.txt Renaissance BioScience Corp. 0.3069 370 Industry No 3 0 18 
TechnicalReport.txt* Technical Report of the Public 
Consultation 
0.3799 13268 Test Yes 3 3 1 
UK.txt Joint submission by the UK Committee 
on Toxicity (COT) and UK Committee 
on Carcinogenicity (COC) 
0.3708 1005 PH Yes 0 0 0 
         
N.B. the Technical Report contained the individual contributions in an annex that was removed from the text of the technical report analysed to avoid 
duplication. 
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Results from Jfreq and comparative reading via corpus analysis  
· The longest submissions have the highest use of the article “the” (the EFSA Draft Opinion 
and Final Draft, the Technical report, etc); 
· References to the “MOE model” mentioned by DKSE, UK, Kantonales, CL, ISS as well as by 
the Technical Report and the draft and final scientific opinion; 
· “Toolbox” used by Food Drink Europe, BDSI, ECF, Novozymes, Renaissance as well as by 
the Technical Report and the draft and final scientific opinion; 
· “Asparaginase” was used only by Novozymes, by Kantonales and by the EFSA Final 
Scientific Opinion; 
· “Yeast” used only by Renaissance, a company that advocates a solution to reduce 
acrylamide based on yeast replacement and by the Technical Report who picks this notion 
up in summarising the consultation results; 
· “Mitigation” (truncated “mitig”) used notably (4 times) by the Association of the German 
Confectionary Industry which focuses on the German signal values in order to explore the 
effectiveness of mitigation measures, but also by CL and EPPA, FoodDrinkEurope, FPPI, 
Kantonales (5 times), Novozymes, Renaissance, CHOPRABISCO, Technical Report (22 
times) and the draft (14 times) and final Scientific Opinion (19 times); 
· “Home” used by Renaissance, Kantonales, EPPA, CL and the EFSA draft and final scientific 
opinion as well as the Technical Report; 
· “Elimination” (truncated “elimin”) used by the Technical Report, the draft and final 
scientific opinion as well as by Renaissance and Kantonales; 
· “Guidelines” (truncated “guidelin”) used mostly by the draft and final scientific opinion 
and by the Technical Report (with one occurrence also in the AT submission). 
Therefore, JFREQ offers a good overview of the type of critical concepts that underpin sub-
sets of submissions and the solutions put forward by them. For example, the “yeast”-based 
technology belonging to Renaissance Bioscience and Novozymes’s enzyme-based solution 
“asparaginase” for bakery products clearly identify the owner of the intellectual property 
rights and the proponent of the solution, as the two mostly overlap. For a more nuanced view, 
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an in-depth analysis of the textual changes between the draft and final versions of the 
abstracts of EFSA’s scientific opinion is offered in box 6-1. 
Box 6-1 Textual changes between draft and final versions of the abstracts of EFSA’s 
Scientific Opinion on Acrylamide, 2015 
The following textual changes between the draft and final versions of EFSA’s Scientific Opinion 
Abstract on Acrylamide illustrate: (i) textual expansions linked to the addition of attributes 
invoking the weak quality of evidence e.g. insertion of the qualifier “based on animal 
evidence”; (ii) use of more specific descriptions of conditions and characteristics e.g. “low 
moisture” and “solid (coffee)” and (iii) usage of the phrase “epidemiological associations” 
instead of “(MoEs) across dietary surveys and age groups”. 
The draft version of the scientific opinion abstract included: 
(1a) AA was found at the highest levels in “Coffee and coffee substitutes” followed by “Potato 
crisps and snacks” and “Potato fried products”; 
(2a) The CONTAM Panel evaluated 43 419 analytical results from food commodities collected 
and analysed since 2010; 
(3a) The data from human studies were not adequate for dose-response assessment. 
In the final version of the scientific opinion, these were amended to (changes in italics): 
(1b) AA was found at the highest levels in solid coffee substitutes and coffee, and in potato 
fried products; (…) the main contributor to total dietary exposure was generally the category 
“Potato fried products (except potato crisps and snacks)”; 
(2b) The CONTAM Panel evaluated 43 419 analytical results from food commodities; 
(3b) The data from human studies were inadequate for dose-response assessment. 
Results from the STATA analysis 
As in the previous case study, the findings that positions of stakeholders having similar 
interests (e.g. on the one hand, ECF and FoodDrinkEurope and AT and Kantonales on the 
other) translate into scores with similar values are confirmed. ECF and FoodDrinkEurope 
converge around the 0.74 value and AT and Kantonales around 0.25. 
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Table 6-2  Comparative Analysis of Scores of Stakeholder clusters 
Stakeholder Word count Unique 
words 
scored 
Raw score LBG score MV score 
Industry 
ECF 1910 313 0.7504 1.8391 1 
FoodDrinkEurope 3805 719 0.7361 1.7817 0.972324 
NCFUS 645 97 0.6215 1.3236 0.750532 
BDSI 235 111 0.3412 0.2022 0.208051 
Novozymes 337 123 0.3236 0.1319 0.173989 
Renaissance 370 109 0.3069 0.0649 0.141668 
      
Advocacy 
AT 135 93 0.2337 -0.2279 0 
Kantonales 2736 886 0.2799 -0.0431 0.089414 
DKSE 554 166 0.3745 0.3354 0.272499 
CL 1669 326 0.3681 0.3098 0.260112 
ISS 745 187 0.3572 0.2663 0.239017 
UK 1005 259 0.3708 0.3206 0.265338 
 
The analyses of submissions confirmed that it was possible not only to differentiate, 
quantitatively, responses from industry and the public health community, but also to 
differentiate innovators in industry proposing solutions from those whose manufacturing 
processes were being questioned. Therefore, Novozymes and Renaissance have raw scores, 
LBG scores and MV scores that are much closer to the advocacy cluster than to the industry 
cluster. They are proposing asparaginase technology and improved enzyme solutions to 
reduce acrylamide occurrence in foods. Unlike the rest of the industry, they are less reticent 
to accept regulatory change, in general. In these circumstances, the first mover advantage 
can be interpreted as a pre-emptive strike against the industrial competitors. 
The analysis also made it possible to identify anomalous submissions, i.e. entries whose 
content is irrelevant to the questions asked rather than illegible or empty. These are 
characterised by having wide confidence intervals with low word-count and low raw scores 
(in this case, LTDH is the case in point). The fact that LTDH is an anomalous submission is 
confirmed by the Technical Report: “The CONTAM Panel notes that the content of this 
comment is outside the scope of this risk assessment on AA in food”, where AA is an 
abbreviation for “acrylamide” (European Food Safety Authority, 2015). 
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Table 6-3 summarises the results from the STATA analysis. The movement of the text 
consulted upon (the draft scientific opinion) is very marginally in the direction of the public 
advocacy (raw score of 0.2838 to 0.2837; LBG score of -0.0272 to -0.0277 and MV score of 
0.09696 to 0.09676). ECF, FoodDrinkEurope and NCFUS have very similar scores given that not 
only their positions are similar, but also large parts of their submissions are copy-pasted, 
duplicated or shared. AT and Kantonales have equally similar scores, on the other end of the 
scale, approaching the 0 MV value (assigned to AT). The technical review Report scores are: 
0.3799 (raw), 0.3572 (LBG) and 0.2829 (MV), hence closer to the advocacy, than to the 
industry group. 
Table 6-3   Comparative Analysis of the Draft and Final Scientific Opinion 
compared to the industry and public health texts  
Stakeholder or 
version of report 
Word 
count 
Unique 
words 
scored 
Raw 
score 
LBG 
score 
MV score Lower 
limit 
MV 
score CI 
Upper 
limit 
MV 
score 
CI 
Industry   
ECF 1910 313 0.7504 1.8391 1 0.9825 1.0174 
FoodDrinkEurope 3805 719 0.7361 1.7817 0.972324 0.9593 0.9853 
NCFUS 645 97 0.6215 1.3236 0.750532 0.7176 0.7834 
BDSI 235 111 0.3412 0.2022 0.208051 0.1688 0.2472 
Novozymes 337 123 0.3236 0.1319 0.173989 0.1429 0.2050 
Renaissance 370 109 0.3069 0.0649 0.141668 0.1131 0.1702 
Neutral   
Pre-consult (Draft 
Scientific Opinion) 
79080 1043 0.2838 -0.0272 0.096961 0.0949 0.0989 
Post-consult 
publication 
(Scientific Opinion) 
88777 1059 0.2837 -0.0277 0.096768 0.0947 0.0987 
Technical Report 
of the stakeholder 
review 
13268 889 0.3799 0.3572 0.282949 0.2771 0.2887 
Advocacy   
AT 135 93 0.2337 -0.2279 0 -0.0359 0.0359 
Kantonales 2736 886 0.2799 -0.0431 0.089414 0.07858 0.1002 
DKSE 554 166 0.3745 0.3354 0.272499 0.24580 0.2992 
CL 1669 326 0.3681 0.3098 0.260112 0.24492 0.2753 
ISS 745 187 0.3572 0.2663 0.239017 0.21657 0.2614 
UK 1005 259 0.3708 0.3206 0.265338 0.24524 0.2854 
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Plotting of the scores containing the Martin-Vanberg transformation results and their 
confidence intervals clearly shows that the industry (ECF, NCFUS, FoodDrink Europe, EPPA, 
FPP) is situated closer to 1 than the advocacy groups (AT, Kantonales, CL, ES, UK, ISS, DKSE), 
which are closer to 0. Innovators such as Novozymes and Renaissance have MV scores around 
the 0.2 value which situates them in the public advocacy cluster (since they are deliberately 
favouring a tighter regulation of acrylamide levels in food), compared to their competitors in 
the industry, labelled as “laggards”. Choprabisco and BDSI, also belonging to the industry 
cluster, have MV values that situate them between the two innovators Novozymes and 
Renaissance and the rest of the industry cluster, on a “middle ground”. 
As for anomalous or ghost submissions, LTDH has the widest confidence interval in the 
diagram and is adjacent to the public advocacy reference texts, rendering it a perfect 
candidate for a spurious or anomalous submission. The fact that its word count is also rather 
low (80 total words scores, as per Appendix I, Table 2) confirms with certitude its anomalous 
nature.  
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Figure 6-1 Stakeholder position based on MV scores and their confidence intervals 
 
 
 
In summary, analyses of submissions to the EFSA consultation on safety of acrylamide 
confirmed that it was possible not only to differentiate, quantitatively, responses from 
industry and the public health community, but also to differentiate innovators in industry 
proposing solutions from those whose manufacturing processes were being scrutinised (i.e. 
the laggards). The analyses offered important insights into how the issues were being framed 
by each group. I summarised these insights in Figure 6-2 using summary measures for industry 
(laggards vs. innovators), a summary measure for advocacy groups, and plotting the MV scores 
of the neutral texts (the Technical Report of submissions, the EFSA Scientific Opinion Draft as 
Proposed and the EFSA Scientific Opinion as Adopted), including the anomalous submission 
(LTDH). 
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Figure 6-2  Stakeholder position based on MV scores and their confidence 
intervals (summary measures) 
 
 
In the figure 6-2 above, the green triangle represents the summary measure of MV scores for 
that stakeholder category, neutral text or anomalous submission, the red square represents 
the lower limit of the 95% confidence interval and the blue diamond the upper limit of the 
same confidence interval. Hence, the green triangle is always at the half-way point between 
the red square and the blue diamond. The figure illustrates how the advocacy summary 
measure just undercuts the 0.2 score, the industry laggard summary measure undercuts the 
0.6 value and the industry innovator summary value is inferior to the 0.2 score, being plotted 
to the left of the advocacy group measure. This may reflect the fact that innovators are even 
more supportive of regulation than are advocacy groups.  
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Moreover, the technical consultation report giving an overview of submissions is anchored 
around the 0.3 mark, whereas the pre-consultation version of the scientific opinion is slightly 
above 0.1 with the post-consultation version marginally, yet visibly towards the 0 value. This 
effectively means that the post-consultation version moved in the direction of the advocacy 
scores, rather than being pulled into the direction of the much higher industry laggards’ score. 
The implications of the results above will be teased out further in the discussion chapter. 
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Chapter 7. The Directive on Patients’ Rights in Cross-border Healthcare 
The issue 
Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare sets out 
the conditions under which a patient may travel to another EU Member State to receive 
medical care and have the cost reimbursed by their own health insurance scheme. It also 
encourages cooperation between national healthcare systems. 
The European Treaties have given the EU a limited role in health policy. Article 168 of the 
Treaty on the Functioning of the European Union notes that Member States have 
responsibility for “the definition of their health policy and for the organisation and delivery of 
health services and medical care.” The same article also states that: “The responsibilities of the 
Member States shall include the management of health services and medical care and the 
allocation of the resources assigned to them.” Historically, therefore, there was considered to 
be virtually no EU dimension to policy around the management and provision of health 
services. In recent years that view has changed, for a number of reasons.  
Firstly, EU legislation originating from other policy areas – for example, the Directive 
2003/88/EC concerning certain aspects of the organisation of working time and Directive 
2005/36/EC on the recognition of professional qualifications – has had significant impacts on 
health services. 
Secondly, over a number of years, the European Court of Justice has developed the principle 
that healthcare was a service within the meaning of the Treaty on the Functioning of the 
European Union, and that the principles of the free movement of services therefore apply to 
health services, albeit with important safeguards. 
The EU institutions and the Member States are therefore faced with a series of questions 
about how these principles apply to health services, and what this means in practice for health 
systems. 
Directive 2011/24/EU was the first step towards answering some of these questions. This 
Directive codified and clarified the jurisprudence of the Court with regard to the rights of 
patients to be reimbursed for healthcare received in another Member State. The Directive did 
not just deal with the rights to reimbursement, but also introduced a number of significant 
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flanking measures to ensure that patients could use these rights in practice. As part of this 
there is now, for the first time, a minimum set of requirements which apply to all health 
providers and all healthcare provided within the EU. These requirements relate to 
transparency, information to patients, and safety and quality of care. 
The intention in this case study is to examine whether and how the initial text proposed by 
the European Commission has been altered following the opinion of the European Parliament 
and the General Approach of the Council in the two readings of the co-decision procedure. 
Regulatory environment and the decision being discussed  
EU involvement in health goes back to the 1950s when standards for Health and Safety at 
Work were laid out in the Treaty of Rome and in the EURATOM and Coal and Steel Community 
origins (Bowis, 2016). Health was enshrined in the Treaty of Maastricht, signed in 1992. That 
Treaty widened the competence of the Community to cover new areas such as education, 
culture, public health, consumer protection, trans-European networks, industry, and the 
environment. Since then, a compendium of directives and regulations on matters relevant to 
public health has been adopted, addressing, among others, dangerous substances, pollution, 
waste disposal, water and air and soil quality, food safety and product liability.  
Between 1991 and 2006 a succession of rulings by the European Court of Justice in 
Luxembourg expanded the role of health in the EU. In the landmark case of Kohll and Decker 
in 1998 (two Luxembourg citizens), the ECJ established that, under the Treaties, citizens had 
the right to travel to another Member State of the EU to receive medical treatment (to receive 
orthodontic treatment and to obtain spectacles respectively) (Kanavos et al., 1999). It further 
ruled that the patient should not bear the medical treatment cost alone, as long as the 
treatment was normally available in the home country and the reimbursable cost was no more 
than would have been assumed in the home country by the responsible health insurance.  
The EU-regulated patient mobility provisions prior to the Kohll and Decker ruling were 
restricted to three procedures: first, the E111 form, which has now become the European 
Health Insurance Card – the traditional cross-border social security path, covering medical 
treatment in Europe for citizens on holiday, studying or working abroad. Second, a bilateral 
block-grant system of lump-sum transfers between countries to support the healthcare needs 
of retirees living in Malta, Spain, or Cyprus. The third route was the E112 form system, which 
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allowed citizens to travel to another EU country specifically for treatment. This system 
required a prior-authorisation form which de facto (except for some notable exceptions in 
small Luxembourg and liberal Sweden) was rarely granted by the home authorities to their 
applicants and hence rarely applied for. Awareness of the existence of such a system has been, 
up to the present, generally low (European Commission, 2015b). 
With the ECJ ruling on spectacles and orthodontic treatment, the question of whether such 
services were limited to those provided as outpatient, non-hospital services was asked. 
Subsequent cases, such as those of Geraerts-Smits and Peerbooms (C-157/99), two Dutch 
citizens, revealed that hospital treatment could also be included within the scope of the 
previous judgment (these cases related to Parkinson’s disease treatment in Germany and 
coma therapy in Austria). In 2003, in the ruling on the case of Muller Fauré and Van Riet (C-
385/99), the ECJ stated that prior authorisation was not necessary for non-hospital treatment. 
Last but not least, in 2006, in the case of Yvonne Watts (C-372/04), the Court questioned 
whether a health authority could refuse a patient prior-authorisation by retrospectively 
reducing the waiting time for treatment and even challenged the pre-existing requirement for 
prior-authorisation for inpatient hospital treatment (in this case, a hip replacement in France 
to avoid long waiting times in England).  
Following this body of ECJ rulings in a relatively short space of time, the European Parliament 
demanded legal certainty and procedural clarity. The Commission published a Communication 
on the ECJ judgments following a high-level reflection process on patient mobility (European 
Commission, 2004) and the European Parliament undertook a study on legislative proposals 
on patient mobility (European Parliament, 2008).  
The process culminated in the European Commission’s long-awaited legal proposal published 
in July 2008 on “The Application of Patients’ Rights in Cross-border Healthcare” (European 
Commission, 2008). There were widespread calls for the case law on the application of the 
principle of free movement of goods and services in the field of health to be codified in a new 
Directive. The proposed Directive therefore included provisions on the regime of quality and 
safety to be applicable for cases of cross-border healthcare, the creation of information 
systems (National Contact Points) to offer information to citizens and further provisions that 
went beyond the ECJ rulings regarding e-Health, e-prescriptions, health technology 
assessment or centres of excellence for rare diseases. 
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Actors 
The majority of delegations in the preparatory debate of the Council recommended that the 
Regulation on the coordination of social security systems (Council of Ministers, 2004) and its 
clearing house system of payments (bilateral lump-sum payments for retirees settled abroad 
and yearly bilateral settlements between countries triggered by the use of the European 
Health Insurance Card) should be incorporated within the Directive on cross-border 
healthcare and that a “third method” of reimbursement should be avoided. It is not the 
purpose of this case study to focus in detail on the different views expressed in the Council 
and therefore the Council will be treated as a unitary body (although de facto it is not, a 
contrario).  
Five institutional actors submitted amendments, press releases or papers on the European 
Commission draft, including the EDPS (European Data Protection Supervisor Authority), the 
EESC (European Economic and Social Committee), the CoR (the Committee of the Regions), 
the EP (European Parliament), and the Council (both in its more formal ministerial function in 
EPSCO Employment, Social Policy, Health and Consumer Affairs Council and in the more basic 
Council of Ministers configuration).  
The analyses of submissions confirmed that it was possible not only to differentiate, 
quantitatively, responses from the European Parliament and the Council, but also to 
differentiate early contributors proposing solutions from those who contributed later on in 
the decision-making chain – a reinterpretation of the “first-mover advantage” is therefore put 
forward.  For a list of the actors, appendix 3 discussed a stakeholder analysis in detail. 
Context 
Against the legal regulatory background presented in the sections above, a political dispersion 
of interests and views formed during the co-decision procedure negotiations.  
During the negotiations, the ministers asked that Member States should be able to make the 
use of cross-border healthcare subject to prior authorisation or to apply the “gatekeeping” 
principle (Council of Ministers, 2008), for example by the attending physician. This envisaged 
that the patient could only be reimbursed for care provided following a referral to a provider 
abroad. 
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Council delegations also wanted the Member State providing the healthcare to be responsible 
for giving patients information on the mechanisms by which they ensured the quality and 
safety of healthcare provided within their own jurisdiction. 
Ultimately, a balance was struck between the rights of patients and of Member States. 
Mandatory reimbursement by a Member State should not exceed the level provided for by its 
own system. Particularly sensitive topics included the management of incoming patient flows, 
the definition of healthcare and the quality of care. 
In parallel, the Council held a first exchange of views on the proposal for a Council 
Recommendation on a European action in the field of rare diseases (Council of Ministers, 
2009). The Ministers agreed that the particular nature of rare diseases made this an area in 
which Europe could bring substantial added value. 
The European Union initiated a policy in this area with the adoption in 1999 of the Regulation 
on orphan medicinal products. Then an overall strategy was published in the Commission 
Communication “Rare Diseases: Europe’s challenges”. These allowed the Council to adopt a 
common approach based on best-practice to combating rare diseases, working jointly with 
patient organisations.  
A common definition of rare diseases throughout the European Union was also requested in 
the Communication. The latter also called for the Commission to cooperate with the World 
Health Organisation (WHO) in its work on codification of rare diseases. Lastly, Member States 
were invited via the Communication to promote the sharing of expertise via European 
reference centres, which have in the meantime been set up under the name “European 
Reference Networks”. 
The consultation  
The inter-institutional consultation on the draft Directive on cross-border healthcare lasted 
just under 3 years and ran between 2nd July 2008 and until 9 March 2011. The Directive 
entered into force on the 20th day following its publication in the Official Journal (hence, in 
April 2011) and the deadline for its transposition into national law was 25 October 2013. 
Since institutional consultation does not specifically entail questions formulated by the 
organiser of the consultation process as would be the case in a standard public consultation, 
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the draft proposal for the Directive in all its parts was subject to the consultation. No parts 
were excluded and the basis for the consultation was the draft Directive text and the impact 
assessment accompanying it.  
Methods 
I ran Jfreq and the Wordscores algorithm in STATA for the 15 text files in the consultation 
(including the draft and the final Directive text and the Impact Assessment accompanying the 
draft proposal for a Directive). For the draft text of the Directive, the corrigendum version was 
considered, published on 16 July 2008 (European Commission, 2008), not the initial version 
adopted on 2 July 2008 (European Commission, 2008).  
One publicly retrieved document that was initially considered but eventually dropped from 
the word scoring analysis was the Council Document adopted by the French Presidency after 
a  Presidency-run public policy debate in the Council on the proposal for the Directive on the 
basis of a progress report and a Presidency questionnaire (Council of Ministers, 2008). I 
decided to deliberately exclude the latter from the analysis due to its short length (under 1 
page) and to the fact that it was more of a political statement of support rather than a 
milestone in the adoption process. The score (extremely small) would have skewed the 
results, had it been included in the analysis. 
The intention is to examine whether and how the initial text proposed by the European 
Commission has been altered following the opinion of the European Parliament and the 
General Approach of the Council in the two readings of the co-decision procedure. 
Results 
The analysis confirmed that it was possible not only to differentiate, quantitatively, responses 
from the Council from the European Parliament and other institutional partners, but also to 
differentiate early contributors proposing solutions from those who contributed later on in 
the decision-making chain. The analyses offered important insights into how the issues were 
being framed by each group. 
The results precluded the identification of anomalous submissions in this case study, i.e. 
entries whose content is irrelevant to the questions asked. Also, it is important to mention 
that no questions were asked per se within the remit of the consultation run in this case study. 
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Therefore, in this case study I ask whether and how the draft text of the Directive on patients’ 
rights in cross-border healthcare proposed by the European Commission shifted towards 
positions that could be seen to favour the Council, European Parliament and other institutions’ 
perspectives against a more prescriptive regulation of patient rights and patient flows. 
The scaling algorithm Wordscores was used as before (Costa et al, Stuckler et al, Laver, Benoit 
and Gary, etc). Wordscores infers policy positions in new documents – so-called virgin texts – 
by calculating scores for these documents based on the scores of reference texts. Scores are 
derived from the frequency of words in a document relative to the total number of words. 
First, I converted documents from portable document format to more manageable text files. 
Then I manually removed superfluous information i.e. headers and certain footers, yet left 
contact details and citations in. Then I created a frequency matrix using the programme Jfreq 
in R, which estimated the frequency distribution of words across documents, reduced words 
to their roots and removed stop words, numbers and symbols. Given the polarisation of views 
(opinions) between institutional stakeholders, I devised a scale using texts from the European 
Parliament first reading and second reading as reference texts for the European Parliament 
views and the Council first reading press release and the Council first reading as reference 
texts for the Council’s perspectives. However, the Council first reading press release is 
comparatively much shorter and so its suitability as reference text will be analysed in the 
Discussion section of this Chapter. 
As explained in the previous case studies, MV (the Martin-Vanberg) transformation 
compensates for the tendency of non-discriminating words to pull scores towards the middle 
of the scale, rendering the alignment less visible and less clear. I calculate 95% confidence 
intervals based on standard deviations in score frequencies across documents. Then the score 
of the Directive text document before and after the consultation is compared.  
I combined texts by iteration and identified stakeholder and collated all contributions 
according to stakeholder, e.g. in the case of the EPSCO text, the political agreement and the 
background text were combined into one manageable text file and for the Council first 
reading, the Draft statement of the Council’s reasons and the Legislative Act were combined 
into one text. 
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The following table shows the 15 texts included in the analysis and the number of hits in Jfreq 
for a number of concepts explained above in the context section of this Chapter, also 
representing critical control points further discussed in the preliminary observations below.
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Table 7-1    Overview of all submissions by stakeholder with critical control points identified  
Text acronym in STATA Stakeholder 
submission full 
name 
(acronym) 
Raw 
score 
in 
STATA 
Wordcoun
t score in 
STATA 
Type of text 
or 
stakeholder 
cluster 
affiliation? 
Evidence of 
“gatekeeping
” being 
referred to 
Evidenc
e of 
“rare” 
being 
referred 
to 
(“rare” 
or 
“rarer”) 
Evidence of 
“authorisation
” being 
referred to 
(pre-
authoris*/ 
unauthoris*/ 
authoris) 
Evidenc
e of 
“quality
” being 
referred 
to 
Evidenc
e of 
“safety” 
being  
referred 
to 
COMoriginal.txt Commission 
original 
proposal 
0.435 21 359 Test text 0 0 48 40 24 
IA.txt Commission’s 
Impact 
Assessment 
accompanying 
the original 
proposal 
0.395 27940 Commissio
n 
0 5 41 69 36 
EDPSopinion.txt Opinion of the 
European Data 
Protection 
Supervisor 
0.396
2 
29334 Inst. 
Partners 
0 0 12 13 2 
EESCopinion.txt Opinion of the 
European 
Economic and 
Social 
Committee 
0.406
9 
3450 Inst. 
Partners 
0 0 6 8 3 
CoRopinion.txt Opinion of the 
Committee of 
the Regions 
0.374
2 
41270 Inst. 
Partners 
0 1 20 73 25 
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Text acronym in STATA Stakeholder 
submission full 
name 
(acronym) 
Raw 
score 
in 
STATA 
Wordcoun
t score in 
STATA 
Type of text 
or 
stakeholder 
cluster 
affiliation? 
Evidence of 
“gatekeeping
” being 
referred to 
Evidenc
e of 
“rare” 
being 
referred 
to 
(“rare” 
or 
“rarer”) 
Evidence of 
“authorisation
” being 
referred to 
(pre-
authoris*/ 
unauthoris*/ 
authoris) 
Evidenc
e of 
“quality
” being 
referred 
to 
Evidenc
e of 
“safety” 
being  
referred 
to 
EPfirstreading.txt First Reading of 
the European 
Parliament 
0.399
1 
77878 EP – Ref. 
text  
1 15 209 135 94 
EPSCO.txt EPSCO 
Background 
and Political 
Agreement 
Text 
0.475
5 
13455 CONS 0 0 38 18 22 
EPSCOpress.txt EPSCO First 
Reading Press 
Release 
0.541
8 
1322 CONS 1 0 4 4 3 
CONSfirstreading.txt General 
Approach of 
the Council in 
the First 
Reading 
0.498
5 
16602 CONS – Ref. 
text 
1 0 55 22 28 
CONSfirstreadingpress.txt Press release 
on the General 
Approach 
0.644
4 
948 CONS – Ref. 
text 
1 0 3 5 3 
COMonCONSfirstreading.txt Commission 
Communicatio
n on the 
0.482
0 
3437 Commissio
n 
0 1 24 15 16 
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Text acronym in STATA Stakeholder 
submission full 
name 
(acronym) 
Raw 
score 
in 
STATA 
Wordcoun
t score in 
STATA 
Type of text 
or 
stakeholder 
cluster 
affiliation? 
Evidence of 
“gatekeeping
” being 
referred to 
Evidenc
e of 
“rare” 
being 
referred 
to 
(“rare” 
or 
“rarer”) 
Evidence of 
“authorisation
” being 
referred to 
(pre-
authoris*/ 
unauthoris*/ 
authoris) 
Evidenc
e of 
“quality
” being 
referred 
to 
Evidenc
e of 
“safety” 
being  
referred 
to 
Council First 
Reading 
EPsecondreading.txt Second 
Reading of the 
European 
Parliament 
0.457
9 
15520 EP – Ref. 
text  
0 11 48 25 22 
COMonEPsecondreading.txt Commission 
Opinion on EP 
Second 
Reading 
0.492
9 
470 Commissio
n 
0 0 0 1 0 
CONSonEPamendmentspress.t
xt 
Press Release 
Council 
Approval of EP 
Amendments 
0.543
0 
793 CONS 0 1 3 3 5 
DirectiveAdoptedText.txt Text of 
Directive as 
Adopted 
0.465
7 
14386 Test text 0 9 45 20 19 
          
N.B. The Press Release for the 2916th Council Meeting of the Employment, Social Policy, Health and Consumer Affairs Council of 17 and 18 December 2008 
was not included in the analysis since the directly relevant text was too short (under 1 page). The press release simply marked a public policy debate on the 
proposal for a Directive on the application of patients’ rights in cross-border healthcare on the basis of a progress report and a questionnaire rolled out to 
the Member States by the French Presidency (the Directive had been proposed by the Commission under the French Presidency of the Council).  
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Results from Jfreq and comparative reading 
The longest submissions have the highest use of the article “the” (the EPfirstreading, the 
CoRopinion, the EDPSopinion, the IA, the COM original, the CONSfirstreading, etc); 
- References to the “gatekeeping” container concept (meaning a referral by a local 
General Practitioner as being necessary for accessing cross-border healthcare), 
mentioned by EPfirstreading (once), EPSCOpress (once), CONSfirstreading (once), 
CONSfirstreadingpress (once); 
- “Rare” or “rarer” used by IA (five times), EPfirstreading (15 times), 
COMonCONSfirstreading (once), EPsecondreading (11 times), 
CONSonEPamendmentspress (once) and DirectiveTextAdopted (nine times); 
- “Authoris” (from “pre-authorisation”, “unauthorised” or “authorise/ authorisation”) 
was used 48 times in the COMoriginal, 41 times in the IA, 12 times in the EDPSopinion, 
six times in EESCopinion, 20 times in CoRopinion, 209 times in EPfirstreading, 38 times 
in EPSCO, 4 times in EPSCOpress, 55 times in CONSfirstreading, three times in 
CONSfirstreadingpress, 24 times in COMonCONSfirstreading, 48 times in 
EPsecondreading, three times in CONSonEPamendmentspress and 45 times in 
DirectiveAdoptedText;  
- “Quality” used 40 times by COMoriginal, 69 times by the IA, 13 times by EDPSopinion, 
eight times by EESCopinion, 73 times by CoRopinion, 135 by EPfirstreading, 18 times 
by EPSCO, four times by EPSCOpress, 22 times by CONSfirstreading, five times by 
CONSfirstreadingpress, 15 times by COMonCONSfirstreading, 25 times by 
EPsecondreading, once by COMonEPsecondreading, three times by 
CONSonEPamendmentspress, 20 times by DirectiveAdoptedText;  
- “Safety” used 24 times by COMoriginal, 36 times by the IA, twice by EDPSopinion, 
three times by EESCopinion, 25 times by CoRopinion, 94 times by EPfirstreading, 22 
times by EPSCO, three times by EPSCOpress, 28 times by CONSfirstreading, three times 
by CONSfirstreadingpress, 16 times by COMonCONSfirstreading, 22 times by 
EPsecondreading, 5 times by CONSonEPamendmentspress, 19 times by 
DirectiveAdoptedText; 
- “Right” used by EPfirstreading (195 times), COMoriginal and EDPSopinion (67 times), 
IA (65 times), CoRopinion (60 times), CONSfirstreading (38 times), EPsecondreading 
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(35 times), DirectiveAdoptedText (33 times), EPSCO (31 times), EESCopinion (21 
times), COMonCONSfirstreading (18 times), EPSCOpress (9 times), 
CONSfirstreadingpress (8 times), CONSapprovalEPamendments (5 times), 
COMopinionEPsecondreading (4 times); 
- “Ehealth” used by COMonCONSfirstreading (8 times), EPsecondreading (7 times), 
DirectiveAdoptedText (6 times), CONSfirstreading (3 times), EDPSopinion (twice) and 
once by IA, EPSCO and COMopinionEPsecondreading; not used in the COMoriginal 
proposal. 
In conclusion, the first reading in the European Parliament introduced a number of concepts 
that did not appear explicitly in the original Commission Directive text:  gatekeeping and rare 
(diseases), and to a lesser extent, quality and safety.  
The following table presents the raw, LBG and MV score in the following groupings:  on the 
one hand, Commission and European Parliament (containing the IA text, the EPfirst reading 
text, the COMonCONSfirst reading text, the EPsecondreading text and the COMonEPsecond 
reading) versus on the other hand the Council and other institutional partners (containing the 
EDPSopinion, the EESCopinion, the CoRopinion, the EPSCO, the EPSCOpress, the 
CONSfirstreading, the CONSfirstreadingpress and the CONSonEPamendmentspress). The 
word count and the unique words scored are also included in Table 7-2. 
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Table 7-2  Comparative Analysis of Scores of Stakeholder clusters without Test 
Texts 
Stakeholder Word 
count 
Unique 
words 
scored 
Raw score LBG score MV score 
Commission and European Parliament 
IA 27 940 1747 0.395 0.1101 0.130953 
EPfirstreading 77 878 4935 0.3991 0.0775 0 
COMonCONSfirstreading 3 437 710 0.482 0.5856 0.392479 
EPsecondreading 15 520 1892 0.4579 0.3929 0.239706 
COMonEPsecondreading 470 162 0.4929 0.6729 0.492608 
      
Council and Other Institutional Partners 
EDPSopinion 29 334 1861 0.3962 0.1008 0.155756 
EESCopinion 3 450 762 0.4069 0.0149 0.181939 
CoRopinion 41 270 2 204 0.3742 0.2766 0.098668 
EPSCO 13 455 1 556 0.4755 0.5332 0.333015 
EPSCOpress 1 322 412 0.5418 1.0638 0.707816 
CONSfirstreading 16 602 1 950 0.4985 0.7178 0.405218 
CONSfirstreadingpress 948 342 0.6444 1.8845 1 
CONSonEPamendmentspress 793 315 0.543 1.0737 0.662171 
 
The box below discusses the textual changes between the draft and final versions of the 
Commission Directive proposal, in light of the consultation. 
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Box 7-1  Textual changes between draft and final versions of the original 
Commission Directive proposal 
Box 7-1: Textual changes between draft and final versions of the original 
Commission Directive proposal 
The following notable textual changes between the draft and final versions of the 
Commission Proposal for a Directive on the application of patients’ rights in cross-border 
healthcare illustrate: (i) textual additions linked to the definitions article (originally 
Article 4, finally Article 3 of the Directive 2011/24/EU) e.g. insertion of the definition for 
“telemedicine”, “medical records” and “health technology” and removal of the definition 
of “harm” (i.e. adverse outcomes or injuries stemming from the provision of healthcare); 
(ii) extension of the deadline for transposition into national law from one year to 2.5 years 
in favour of Member States and (iii) more recurrent reporting obligations bestowed on 
the European Commission on the operation of this Directive (reporting recurrent every 3 
years) rather than once after 5 years of implementation. 
The draft version of the original Commission proposal included: 
(1a) Non-hospital care was not subject to the prior-authorisation scheme: “The Member 
State of affiliation shall not make the reimbursement of the costs of non-hospital care 
provided in another Member State subject to prior authorisation, where the cost of that care, 
if it had been provided in its territory, would have been paid for by its social security system”; 
(Article 7, Original Commission Proposal); 
(2a) The COM was expected to update a list of “specialised and hospital” healthcare: “This 
list shall be set up and may be regularly updated by the Commission. Those measures, 
designed to amend non-essential elements of this Directive by supplementing it, shall be 
adopted in accordance with the regulatory procedure with scrutiny referred to in Article 
19(3)”; 
(3a) “Member States shall, when setting out the time limits within which requests for the use 
of healthcare in another Member State must be dealt with, take into account: (a) the specific 
medical condition, (b) the patient's degree of pain, (c) the nature of the patient's disability, 
and (d) the patient's ability to carry out a professional activity” (article 9 (4)(d) of Original 
Commission Proposal); 
134 
 
(4a) “The Commission may, in accordance with the procedure referred to in Article 19(2), 
develop a standard Community format for the prior information referred to in paragraph 1” 
(article 10(3) of the Original Commission Proposal); 
(5a) “The Commission shall, in accordance with the procedure referred to in Article 19(2), 
adopt: (c) guidelines on information to patients provided for in paragraph 2(a) of this 
Article.” (article 12(3)(c) of Original Commission Proposal); 
(6a) “Member States shall facilitate the development of the European reference networks of 
healthcare providers. Those networks shall at all times be open for new healthcare providers 
which might wish to join them, provided that such healthcare providers fulfil all the required 
conditions and criteria” (article 15(1) of Original Commission Proposal); 
(7a) “The Commission shall within five years after the date referred to in Article 22(1) draw 
up a report on the operation of this Directive and submit it to the European Parliament and 
to the Council.” (Article 20(1) of Original Commission Proposal); 
(8a) “Member States shall bring into force the laws, regulations and administrative 
provisions necessary to comply with this Directive by … [one year after its entry into force].” 
(Article 22 (1) of Original Commission Proposal) – N.B. . entry into force was to be 
established as being April 2011 following negotiations. 
In the final version of the Directive, these were amended to (changes in italics): 
(1b) The article was entirely removed; 
(2b) The article was replaced with “Member States shall notify the categories of healthcare 
referred to in point (a) to the Commission”, whereby point (a) read “Healthcare that may 
be subject to prior authorisation shall be limited to healthcare which:  
(a) is made subject to planning requirements relating to the object of ensuring 
sufficient and permanent access to a balanced range of high-quality treatment in the 
Member State concerned or to the wish to control costs and avoid, as far as possible, any 
waste of financial, technical and human resources and: 
(i) involves overnight hospital accommodation of the patient in question for 
at least one night; or 
  (ii) requires use of highly specialised and cost-intensive medical 
infrastructure or medical equipment”; 
(3b) “the patient's ability to carry out a professional activity” was replaced with “the history 
and probable course of the patient’s illness” and “the nature of the patient’s disability at the 
time when the request for authorisation was made or renewed”;  
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(4b) More specificity was added: e.g. “In order to enable patients to make use of their rights 
in relation to cross-border healthcare, national contact points in the Member State of 
treatment shall provide them with information concerning healthcare providers, including, 
on request, information on a specific provider’s right to provide services or any restrictions 
on its practice, information referred to in Article 4(2)(a), as well as information on patients’ 
rights, complaints procedures and mechanisms for seeking remedies, according to the 
legislation of that Member State, as well as the legal and administrative options available to 
settle disputes, including in the event of harm arising from cross-border healthcare” (Article 
6(3) of the Adopted Directive) and “National contact points in the Member State of 
affiliation shall provide patients and health professionals with the information referred to 
in Article 5(b)” (Article 6(4) of the Adopted Directive); 
(5b) Article dropped from the Adopted Directive in its entirety; 
(6b) “The Commission shall support Member States in the development of European 
reference networks between healthcare providers and centres of expertise in the Member 
States, in particular in the area of rare diseases. The networks shall be based on voluntary 
participation by its members, which shall participate and contribute to the networks’ 
activities in accordance with the legislation of the Member State where the members are 
established and shall at all times be open to new healthcare providers which might wish to 
join them, provided that such healthcare providers fulfil all the required conditions and 
criteria referred to in paragraph 4.” (Article 12(1) of the Adopted Directive); 
(7b) “The Commission shall by 25 October 2015 and subsequently every 3 years thereafter, 
draw up a report on the operation of this Directive and submit it to the European Parliament 
and to the Council” (Article 20(1) of the Adopted Directive); 
(8b) “Member States shall bring into force the laws, regulations and administrative 
provisions necessary to comply with this Directive by 25 October 2013.” (Article 21(1) of the 
Adopted Directive) – N.B. entry into force was to be established as being April 2011 
following negotiations. 
 
Results from STATA 
As in the previous case studies, the findings that positions of stakeholders having similar 
interests (e.g. on the one hand, the Council and EPSCO and, on the other, the European 
Parliament and the Commission) translate into scores with similar values are confirmed.  
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The analyses of submissions confirmed that it was possible not only to differentiate, 
quantitatively, responses from the European Parliament and the Council, but also to 
differentiate first movers proposing solutions from those who intervened later in the 
consultation process.  
Consequently, EDPSopinion, EESCopinion and CoRopinion have raw scores, LBG scores and 
MV scores that are much closer to the European Parliament cluster than to the Council cluster. 
Unlike the Council, the three institutional partners are less reticent to regulatory change. 
The analysis did not allow me to identify anomalous submissions, i.e. entries whose content 
is irrelevant to the questions asked rather than illegible or empty. As distinctive features, 
anomalous submissions tend to have large confidence intervals with low word-count and low 
raw scores (in the pharmaceutical products case study, LTDH was the case in point). 
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Table 7-3   Comparative Analysis of the Draft and Final Directive text 
Stakeholder or version 
of Directive 
Word 
count 
Uniqu
e 
words 
scored 
Raw 
score 
LBG 
score 
MV score Lower 
limit 
MV 
score CI 
Upper 
limit 
MV 
score CI 
Commission, European Parliament and Other Institutional Partners    
IA 27 940 1747 0.395 0.1101 0.130953 0.1252 0.1367 
EDPSopinion 29 334 1861 0.3962 0.1008 0.155756 0.1499 0.1616 
EESCopinion 3 450 762 0.4069 0.0149 0.181939 0.1654 0.1984 
CoRopinion 41 270 2 204 0.3742 0.2766 0.098668 0.0940 0.1033 
EPfirstreading 77 878 4935 0.3991 0.0775 0 -0.0035 0.0035 
COMonCONSfirstreadi
ng 
3 437 710 0.482 0.5856 0.392479 0.3756 0.4093 
EPsecondreading 15 520 1892 0.4579 0.3929 0.239706 0.2337 0.2456 
COMonEPsecondreadi
ng 
470 162 0.4929 0.6729 0.492608 0.4436 0.5416 
 
Test Texts 
COMoriginal 21 359 1 744 0.435 0.2091 0.208767 0.2029 0.2147 
DirectiveAdoptedText 14 386 1 661 0.4657 0.4547 0.275309 0.2693 0.2813 
 
Council    
EPSCO 13 455 1 556 0.4755 0.5332 0.333015 0.3269 0.3391 
EPSCOpress 1 322 412 0.5418 1.0638 0.707816 0.6752 0.7405 
CONSfirstreading 16 602 1 950 0.4985 0.7178 0.405218 0.3990 0.4114 
CONSfirstreadingpres
s 
948 342 0.6444 1.8845 1 0.9634 1.0366 
CONSonEPamendmen
tspress 
793 315 0.543 1.0737 0.662171 0.6208 0.7035 
 
The table above shows again the raw, LBG and MV score as well as precision estimates for the 
calculated MV scores. The test texts (COMoriginal and DirectiveAdoptedText) show a 
movement to the right in all scores (raw, LBG and MV) of the draft text submitted to 
consultation. Moreover, in this iteration, the scores of EDPS, EESC and CoR opinions fit much 
better the European Parliament cluster than the EPSCO and Council cluster, hence the 
regrouping as per Table 7-3 above. Figure 7-1 presents a visual representation of the MV 
results, illustrating also the direction of travel of the test text to the right.  
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Figure 7-1 Stakeholder text position based on MV scores & their confidence intervals 
 
 
Before moving on to the summary measure graph, it is worth highlighting that the first mover 
advantage is confirmed and translates into MV scores closer to the reference text score of the 
EP first reading (i.e. a score of 0) for the opinions of the first inter-institutional partners (i.e. 
EDPS, EESC, CoR all yielding scores under the value of 0.2) and for rather more right-oriented 
plotting of the texts towards the top of the graph, which were submitted chronologically later 
in the consultation process (for example, values around the score 0.65 for 
CONSonEPamendmentspress). This movement represents a rapprochement towards the 
CONSfirstreading and CONSfirstreadingpress values, 0.4 and respectively 1. 
In terms of overall travel, the original Commission proposal migrated to the right from a value 
of 0.2 to just undercutting a score of 0.3 as adopted text. However, given the rather more 
extreme positions of the Council (mostly with values over 0.6 except for EPSCO and 
CONSfirstreading), this test text travel may be considered as surprisingly minimal. 
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Figure 7-2  Stakeholder text position based on MV scores and their confidence 
intervals (summary measures) 
 
In Figure 7-2, the green triangle represents the summary measure of MV scores for that 
stakeholder category or neutral text, the red square represents the lower limit of the 95% 
confidence interval and the blue diamond the upper limit of the same confidence interval. 
Hence, the green triangle is always at the half-way point between the red square and the blue 
diamond. The figure reveals that the Commission’s original proposal is only slightly over the 
0.2 score, the Commission, EP and institutional partners other than the Council summary 
measure undercuts the 0.25 value and the Council texts summary value is just over the 0.6 
score, being plotted to the right of the Commission, EP and other institutional partners 
summary measure. This may reflect the fact that the Council has entirely different views from 
the EP and the other institutional partners. Last but not least, the adopted Directive text 
migrates to the right, approaching a score of 0.3. These results will be discussed in the next 
chapter. 
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Chapter 8. Discussion 
Limitations of the case studies and of the thesis 
There are a number of limitations to the present study, not least the assumptions that were 
made (e.g. importance of word choice in conveying a political position) but also the limited 
number of case studies and parameters chosen for the analysis. This means that the findings 
are subject to certain caveats. First, the case studies use recent examples and cannot be 
generalised to the whole population of public consultations. Nevertheless, future work should 
aim to extend the research into other policy areas and consultations. Also, a small number of 
translations were carried out by myself, introducing the possibility of bias. The translation 
process is important. In an ideal case, the translation would be conducted “blind” by someone 
who is not fully familiar with the main distinctions driving the research. 
 
A number of questions to better understand the implications of the research findings to the 
theoretical basis of a public consultation process are outlined in Appendix B. The concern 
related to relationships of trust within a public consultation’s design and conduct has also 
been cited in previous research. Thus, it is necessary to recognise that the scale of undue 
influence of interest groups is likely underestimated here on account of the fact that the pre-
consultation text may already have been under the influence of a certain group, or the text 
going out for consultation may have already incorporated a degree of compromise. This 
however cannot be examined via the methods employed in this thesis. 
 
A further discussion point would revolve around the concept of what counts as a meaningful 
shift in the consultation document. This can equally well be conceptualised as distance 
covered (as measured by Wordscores or MV scores) in the direction of travel of the 
consultation document, i.e. towards industry texts or rather towards public health advocacy 
texts. One significant aspect pertains to the shift from the pre-consultation text to the 
consultation text and then, importantly, from the consultation version to the published 
version and how much of that shift may be perceived as random noise. 
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Finally, the opportunities and challenges of QTA have already been highlighted in the 
introductory chapters of this thesis (Table 3 - 1 provides more details). One particular 
opportunity arises from the theoretical framework chosen to underpin the present research. 
By combining dialogical theory with framing research and discourse analysis, the thesis 
explores the inner working of public consultation processes, through a number of constructs 
that are summarised and revisited below. 
 
Observing and examining public consultations as knowledge encounters between 
stakeholders (and the wider public) through a dialogical lens allowed me to analyse whose 
voices are heard in different variants of consultations. “Knowledge” constructed in 
communication refers not just to technical knowledge but also to cultural, social, and political 
functions, which apply equally, leading to a plurality of knowledge, thus informing policy, 
through negotiation. 
 
The findings discussed below support my contention that frames and discourse, alongside 
beliefs and narrative can be viewed as “ordering devices”, which explain how policy makers 
and stakeholders structure reality to gain a handle on practical questions. Acknowledging and 
handling ambivalence is therefore essential for prudent action (Hajer and Laws, 2006). This 
ambiguity was highlighted at length via the qualitative analysis of the texts before and after 
consultation in each of the three case studies (see notably boxes 6-1 and 7-1 for details). 
 
The present research also corroborated findings from past alcohol pricing research (Hawkins 
and Holden, 2013) as acrylamide regulation, just as alcohol pricing policy, was not seen as a 
simple dichotomy between public health activists and a uniform, monolithic industry on the 
other. The industry was rather split between innovators and laggards. 
 
Last but not least, this thesis contributes by making a recommendation for improvement. By 
endowing open consultation with greater visibility, public consultation managers 
(organisations, governments, or knowledge brokers) strengthen the level of policy literacy 
(civic educational attainment) and of policy performance in a jurisdiction. Such openness 
could, at least in theory, reduce the risk of regulatory capture by well financed groups of 
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interest or by groups with a deep legislative knowledge (Rodrigo and Amo, 2006). However, 
this will only be possible with full disclosure of responses to consultations, so they can be 
critiqued, and the reduction, and ideally elimination, of hidden mechanisms by which 
powerful interests exert influence. Some encouragement can be taken from the evidence 
presented in Chapters 2 and 3, from the original data analysis in Chapter 5 and especially the 
work of Stuckler et al on the process of guideline development on sugar by the WHO, where 
it seemed that industry influence was avoided at the stakeholder consultation stage. 
Publication of  individual submissions to public consultations are essential, to make it possible 
to reduce the risk of spurious or anomalous texts under the guise of credible, legitimate 
submissions, which have in the past been criticised for unsettling or disrupting the public 
consultation process (e.g. the consultation on the Natura 2000 network recognising the 
importance of nature conservation in a living and changing landscape where crowd-surfing 
was used to intercede in the consultation process and burden it with duplicated 
contributions).  
 
There is a further reason why anomalous submissions erode the quality of public 
consultations. Since public consultation credentials (dictated by previously published 
submissions, not by stakeholder background) send a signal to the public about stakeholder 
abilities, equality of opportunity becomes deeper and more meaningful, increasing the 
information value of the credential. In a scenario where there is a level playing field, 
credentials tell citizens and the public more about a stakeholder’s ability to represent their 
interests competently and fairly than in a context where opportunities for exercising one’s 
consultation abilities are a privilege rather than a meritocratic exercise. 
 
The inclusiveness of consultation (not least via use of plain, accessible language and an ability 
to dissect issues of technical complexity) alongside capacity to disseminate detailed and timely 
information on regulations can both provide a rationale for the emergence of open public 
consultations as a normative prescription and act as a plausible framing mechanism going 
forward.  
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Pharmaceutical pricing models 
This case study showed that the QTA method can successfully be applied in an effective and 
insightful manner to consultations on a technical study: it reveals clear patterns of interest 
representation in the European policy process. The results show some migration of the 
executive summary score towards the industry end of the spectrum but elicited no association 
between consultation-ensued bias and policy direction, as the study was simply exploratory 
and did not invite any concrete policy action in the short term. Findings are robust and the 
suitability of advocacy reference texts (HAI and BEUC to be specific) in view of their 
comparative length (shorter than the industry reference texts) has not proven to be 
problematic per se.  
The initial raw score range is 0.2878 for BEUC and 0.6987 for EGA. In this case study, no ghost 
or anomalous submissions were identified nor discussed (identifiable as having low word 
counts, low word scores, and broad confidence intervals). 
The fact that the executive summary is closer to the industry cluster than to the advocacy 
cluster following the consultation is revealing. One may however argue that this is the only 
viable direction of travel given the already low score of the executive summary text to start 
off with. Although it can only be speculative, the observation that the movement is minimal 
could be attributable to one or several of the following three main observations: 
1. The baseline executive summary started off as a much more public health-oriented text 
than an industry-oriented text given the nature and interests of the report author (in 
this case, Gesundheit Oesterreich); 
2. The consultation organiser, i.e. Gesundheit Oesterreich, as the Public Health Institute 
of Austria is de facto a knowledge-intensive organisation more public health-oriented 
than most stakeholders in the field and in its role of honest broker, remained 
unconvinced of the arguments put forward by the industry; 
3. The public health stakeholders mobilised enough to counterbalance the arguments of 
the industry and the minimal movement in the score of the report’s executive summary 
denotes the level playing field that exists in this particular case study. 
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Certain authors have remarked that policy evaluations are often sponsored by the very 
organisations that designed and implemented the intervention in the first place (Vaganay, 
2014) or strong allies of the latter. Such conflict of interest threatens the acquisition of valid 
and robust results. Research in the area of clinical trials has consistently shown that this type 
of arrangement creates a moral hazard and may lead to overestimates of the effect of 
treatment (Vaganay, 2014). Yet, the question remains whether social interventions or health 
economics policy interventions are also subject to such ‘confirmation bias’, notably, in our 
case, re-evaluations of the EPR system. I take the view that this confirmation bias does not 
apply to a similar extent in this present case study as EPR is not an EU-driven policy and the 
study consultation was merely exploratory in nature. Neither the consultation manager nor 
the body commissioning the research needed to defend EPR to the extent that they created a 
reputational risk since it is merely a practice and not a policy anchored in a legal text of the 
EU. 
The “reward for innovation” argument or discourse/ frame was identified as one of the 
strongest in the industry camp. However, challenges to the reward for innovation argument 
are receiving more and more attention lately, not least via reservation and even scepticism 
against the Innovative Medicines Initiative, Europe’s largest public-private initiative aiming to 
speed up the development of better and safer medicines for patients. Shining a light on “the 
pharmaceutical lobby’s firepower, and deconstructing its agenda, is a crucial step in serving 
genuine public health needs, and truly facilitating access to essential medicines the world over” 
(CEO, 2015). 
To conclude, the objective of this case study was twofold. Firstly, it assessed whether 
innovative methods of text analysis reveal patterns of interest representation in the European 
policy process. This has proven to be the case. Secondly, it examined whether various public 
consultation norms/ frames, constellations and mechanisms endemic in knowledge brokering 
help to decrease the relative disadvantage of public health advocacy groups in the policy 
arena. These issues will be explored further in the following sections. 
Cross-border Healthcare Directive case study 
The ordinary legislative procedure example shows that the adopted Directive text more 
closely resembles the Commission proposal and the EP amendments than the Council’s 
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General Approach. Secondary findings concerned the First Mover Advantage (those who 
engage earliest in the process are able to exert most influence), and confirmed that, also in 
this case study, opinions of institutions consulted in a first instance (e.g. EDPS, CoR, EESC) 
more closely resembled or reflected the stance of the Commission than Council counterparts 
did. 
When analysing the pathways and the determining factors in the direction of the movement 
of the draft text for consultation, the pre-consultative version of text (in this case, the proposal 
draft Directive) is crucial in and of itself. As it kept the patient interest at heart, it leaned more 
heavily toward the European Parliament instead of the Council, to start off with. 
The initial raw score range is 0.3742 for CoR opinion and 0.6444 for CONSfirstreadingpress, 
indicating polarised views which are less pronounced than in the other case studies. 
In this case study, no ghost or anomalous submissions were identified. These can be 
distinguished by the combination of a low word count, low word scores and broad confidence 
intervals. 
Further questions for future research therefore are: 
· Is the position of the pre-consultative text in relation to the European 
Parliament/ Council a prompt for the final result (more likely to drag it to one 
side or another) or if neutral – is it likely to stay as it is?  
· Is there an incentive for pre-consultative documents to be middle-ground 
upfront i.e. to compress the compromise? 
· What can be done to counter or mitigate this incentive going forward? 
Incidentally, one of the chosen reference texts was indeed rather short by comparison to 
other chosen reference texts (948 words in the CONSfirstreadingpress as opposed to 16 602 
words in the CONSfirstreading), yet this is not considered so low as to harm the face value 
validity of the case study. 
This case study shows that the QTA method can successfully be applied in an effective and 
insightful manner to consultations run as part of an inter-institutional process: it reveals vivid 
patterns of interest representation in the European policy process. The results show some 
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movement as measured by the mild migration to the right of the post-consultation Directive 
text score towards the Council scores.  
The fact that the adopted text of the Directive is found to be closer to the European Parliament 
cluster than to the Council cluster following the consultation is revealing. One may however 
argue that this is the only viable direction of travel given the already low score of the draft 
Directive text to start with (and its proximity to the European Parliament text scores). The 
observation that the movement is minimal (from 0.2 MV score to 0.3 MV score) might be 
attributable to one or several of the following three observations: 
1) The draft Directive started off as a much more patient-, public health-oriented text 
than an industry-oriented one given the nature and interests of the Directive’s 
main author (in this case, the European Commission); 
2) The consultation organiser, the European Commission is de facto a knowledge-
intensive organisation that is more public health-oriented than most stakeholders 
in the field. In its role of honest broker, it remained unconvinced of the arguments 
put forward by the industry via the Council; the organiser seemed rather more 
concerned with clarifying the jurisprudence of the Court and acting in the patient’s 
best interest, no matter which Member State the patient happens to call home; 
3) The European Parliament’s movement from one reading to another (from MV 0 to 
MV 0.25) in the scores on the Directive’s adoption denotes the level playing field 
that exists in this particular case study. 
In conclusion, findings are robust and the suitability of advocacy reference texts in view of 
their comparative length (shorter for the CONSfirstreadingpress Council reference text) has 
not proven to be problematic per se.  
Acrylamide case study 
The case study focusing on acrylamide is the one which enabled the detection of anomalous 
submissions, notably identified via a low word count, low word scores and broad confidence 
intervals. One should acknowledge that there may, of course, be instances of public 
consultations where anomalous submissions come with a high word count – these should be 
screened and carefully considered for future investigation. 
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The initial raw score range is 0.2337 for AT and 0.7504 for ECF, the largest range of the three 
case studies. This case study is also the one where the test text leans more towards public 
advocacy and innovators than towards the industry laggards, who resist more stringent 
regulation of acrylamide.  
In this case study, I experimented somewhat with the choice of reference texts. At first, I chose 
the submissions of the Austrian Agency for Health and Food Safety and of Kantonales Labor 
Zurich as the public health reference and the texts of Food Drink Europe and National Coffee 
Federation (US) as the industry reference. However, this choice resulted in the European 
Coffee Federation’s raw Wordscores score being in between the scores of the two industry 
reference texts (Appendix 2, Table 3). I therefore decided to run the algorithm again, by re-
estimating the scores with Food Drink Europe and European Coffee Federation as industry 
reference texts and keeping the same public health reference texts as in the previous 
iteration. This resulted in a sound alignment of virgin texts, without any interference between 
the two industry reference texts (Appendix 2, Table 4). This distinction is explained in the 
Manual (Appendix 4), particularly in the part entitled “The Top Ten Mistakes Analysts Make” 
(points 8 and 9). 
Questions that remain for future research are: 
1) Is the pre-consultative version of text important in and of itself? Is it significant 
whether it leans toward public health advocacy or industry to start off with? 
2) Is the position of the pre-consultative text in relation to advocacy/ industry a prompt 
for the final result (more likely to drag it to one side or another) or if neutral – is it likely to 
stay as it is? Is there an incentive for pre-consultative documents to be middle-ground upfront 
i.e. to compress the compromise? 
3)  If the tools proposed by the thesis become standard (i.e. incorporated into official 
reviews of submissions), can the industry game it? Can the industry be successful by 
employing tactical games? It is beyond the scope of this thesis to assess such a risk, but it 
should be noted that the potential for gaming will only increase with the greater use of 
artificial intelligence. 
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In conclusion, findings are robust and the suitability of advocacy reference texts in view of 
their comparative length (shorter for the AT public health advocacy reference text) has not 
proven to be problematic per se.  
Overview 
The section above discussed in detail the results from each of the three case studies, the 
validation of the methods, and how the findings may be used to understand stakeholder 
positions. I examined whether various public consultation norms/ frames, constellations and 
mechanisms in knowledge brokering help to decrease the relative disadvantage of public 
health advocacy groups in the policy arena and whether a more mature policy dialogue can 
be developed via public consultation, taking into account the Overton window of realistic 
potential futures, also known as the window of discourse. The so-called “Overton Window of 
Political Possibilities” derives from a concept named after Joseph P. Overton and is based on 
the assumption that any collection of public policies within a policy area can be arranged in 
order from more free to less free. At any given time, some group of adjacent policies along 
the freedom spectrum fall into a “window of political possibility”. Policies inside the window 
are politically acceptable, meaning office-holders believe they can support the policies and 
survive the next election (Szalek, 2013). 
When I started this research, only a few QTA projects had published results. However, 
meanwhile, I learned that a synergy of QTA and qualitative methods via a mixed methods 
approach can achieve maximum impact. Moreover, I am convinced QTA can improve 
stakeholder analysis, by attributing positions to stakeholders based on text production.  
This thesis sought to answer two research questions:  
· Can innovative methods of text analysis reveal patterns of interest representation in the 
European policy process? 
· Can the various public consultation norms, constellations and mechanisms that 
characterise knowledge brokering help to decrease the relative disadvantage of public 
health advocacy groups in the policy arena? 
The thesis successfully mapped policy positions onto written submissions. Secondly, it showed 
that constellations of positions can be distinguished (non-monolithic views of industry, first 
mover advantage, movement of text prior and after the consultation). The present work 
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furthermore identified anomalous or ghost submissions. The movement of text before and 
after the consultation was noted and discussed in all the three case studies, whilst the non-
monolithic views of industry (laggards versus innovators) were highlighted in the acrylamide 
case study. The first mover advantage was discussed both in the Cross-border Healthcare 
Directive and in the acrylamide case study.  
I argued that QTA, alongside qualitative methods, provides a lens through which value systems 
underlying contributions to public debate can be monitored, traced, and analysed over time 
and across policy fields and through which anomalous, irregular, or spurious submissions to 
public consultations can be identified and examined (for example, the LTDH submission under 
the acrylamide case study). I made a case that language is central to expressing political 
opinion and that public consultation norms and frames can help to decrease the disadvantage 
that certain policy groups have in the policy arena, by distinguishing the first mover advantage, 
detecting anomalous submissions and by carefully comparing scores of texts before and after 
consultation. The use of text mining, comprising quantitative and qualitative text analysis, as 
described in the thesis, has the potential to optimise the mechanisms of public consultation, 
to render them more inclusive by encouraging a greater diversity of submissions and to 
ultimately facilitate the resolution of protracted policy controversies, for example around 
issues pushed for by front groups protecting corporate views.  
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Chapter 9. Conclusions 
The generic outputs of this thesis include an expansion of the so far sparse literature on the 
use of QTA to study influences on policy processes and guidance for others in its use. The 
specific output is the generation of evidence on the nature and impact of industry or advocacy 
influence on public consultations covering EU policies. 
The objectives of this thesis were twofold. Firstly, it assessed whether innovative methods of 
text analysis reveal patterns of interest representation in the European policy process. This 
has proven to be the case. Secondly, it examined whether various public consultation norms/ 
frames, constellations and mechanisms endemic in knowledge brokering help to decrease the 
relative policy arena disadvantage of certain consulted groups and help the playing field to 
evolve. The intention is to help policy entrepreneurs and policy shapers to cope better with 
their risk management and policy-making tasks, taking into account the Overton window of 
realistic potential futures, also known as the window of discourse.  
What this study adds to the research to date – the “differentia specifica” 
The relationship between QTA and qualitative text analysis is often touched upon, yet remains 
fundamentally unexplored. Past research has been largely qualitative (Ulucanlar et al., 2014), 
some of the quantitative research has included stakeholder analyses (Proksch and Slapin, 
2010), and some has focussed on examining leaks of emails. Very little has been written about 
how open public consultation works in practice (Bunea, 2014), what it means to those involved 
and how they experience the process. The present work seeks to overcome the distrust that 
may exist in public consultation processes by revealing the inner workings of a relatively new 
tool to assess submissions: quantitative text analysis and its synergies with qualitative text 
analysis, as the parallel use of the two methods (qualitative and quantitative, as per the 
Manual in appendix 4) is greater than the analytical contribution of either method used in 
isolation.  
Quantitative metrics help focus attention on quantifying influence expressed in a text that 
belongs to a series of texts in a public consultation, whilst qualitative methods, pioneered in 
sociological research, help identify the critical control points for best interpreting the metrics 
obtained previously. On the one hand, this thesis examines interest representation/ lobbying/ 
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industry/ public health activists in order to contribute to the evolution of the playing field and 
on the other, it draws on theory in order to inform the future development of public 
consultation and especially the development of a generic reference tool such as QTA, which 
can upgrade the tools used to perform stakeholder mapping and analysis as well as qualitative 
text analysis.  
My thesis successfully demonstrated that industry views are non-monolithic (innovators 
differentiating themselves from laggards) and confirmed “the first mover advantage”, as well 
as the possibility to detect anomalous submissions. 
Doubtless, synthesising findings of complex evidence has the potential to provide knowledge 
and decision support to important questions being asked by healthcare policy-makers and 
managers. Advances in computing offer scope for mainstream usage of QTA in governmental 
institutions, drawing on text mining, computational linguistics and STATA-driven word-count 
analysis. This strand of work could be linked to perceptual signatures and mathematical 
modelling employed to distinguish and recognise gait, voice, movement and visual features.  
Implications for policy and research: Production of a Manual and beyond 
The implications for policy and research are three-fold: first, at the level of theoretical 
conceptualisation, the first mover advantage (non-monolithic views of industry) and 
anomalous submissions detection.  
Secondly, in terms of strategic response, everyone can game the mainstreaming of such a QTA 
tool by changing meaning or standard interpretation of concepts and by inventing new policy 
constructs. However, to mitigate these effects, as concept use becomes more blurred, new 
dichotomies emerge which can be tracked (meaning change e.g. “Brexit”, “agreement”, etc). 
Last but not least, the thesis also makes an original contribution to knowledge in the form of 
a manual (see appendix 4). The manual was pilot tested on a colleague and reviewed for 
clarity. The manual consists of a Step-by-step protocol for data sanitation and analysis, a 
sample STATA code for running the Wordscores algorithm, a set of FAQs on the strengths and 
weaknesses of QTA and a “Top 10 Mistakes analysts make when rolling out this QTA 
methodology” guidance document. 
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Avenues for further research 
Future research should address two main needs: one revolving around methodological 
research and a second one geared towards policy research. In terms of policy research, further 
work should focus on propositions for developing a system of checks and balances to counter 
and mitigate tactics coined and documented in the literature (Moodie, 2017b), with a view to 
rendering decision-making systems and playing fields immune to non-direct influence or 
confrontation tactics from any vested interest or advocacy group. Further methodological 
research could focus on testing the main hypotheses presented here (the first mover 
advantage and the anomalous submission detector) and developing data visualisation 
techniques for better and clearer presentation of results. Further policy research could equally 
apply the technique to other policy fields and public consultations or look into ways to better 
identify industry front groups or how texts going out for public consultation may already have 
compressed the compromise before being subject to public consultation, a belief held by 
many in the field. 
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APPENDICES 
A. Overview of research aims, objectives, questions and methods  
Objectives Research Questions Data Collection 
methods 
A. Landscape analysis of 
political/scientific texts submitted 
for public consultation  
To assess the feasibility of applying 
different methods of textual analysis 
to written responses to EU 
consultations and determine whether 
they can differentiate material from 
different sources. 
Policy analysis, text 
analysis and QTA 
B. Detecting patterns 
(constellations of stakeholder 
mapping) 
 
To determine whether the positions of 
individual texts and constellations of 
texts relate to the positions of the 
parties to a negotiation (interest 
representation in the policy process) 
and whether it is possible, 
quantitatively, to identify significant 
shifts in the content (and thus the 
underlying expression of interests) 
during the course of a consultation? 
Mostly QTA via 
Wordscores 
C. To develop further ways of 
visual analytics that are 
representative and meaningful for 
capturing QTA results (Dropped) 
 
How can the results of text analytics be 
rendered visual to best effect? 
How could this field be improved in the 
future? 
Gapminder software 
 
Wordgraphing software 
 
Stakeholder 
Consultation 
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B. Questions of generalisability based on incidental observations  
 
This thesis will ask the following questions to better understand the implications of the 
research findings to the theoretical basis of a public consultation process: 
· How could relationships of trust and knowledge encounter be improved within a public 
consultation’s design and conduct? E.g. the Natura case where crowd-surfing was used to 
interfere with the consultation process and burden it with duplicated contributions 
· What is specific about EU Public Health that might well not apply to public consultation 
more generally? 
· What is specific about the three case studies chosen that might not apply to other 
contexts? 
· Which analytical aspects may be applicable to other contexts? 
 
Based on the answers provided to these questions, the present work will add to the evidence 
base and enhance the dialogue between marginalised stakeholder groups and the regulatory 
affairs system. 
C. Brief account of public consultations in US, EU, Member States 
 
In Europe, the process known as the European Semester ushered in health country-specific 
recommendations (Földes, 2016) and examinations based on textual analysis e.g. mentioning 
words related to “health” (Azzopardi-Muscat et al., 2015). 
In the United States, public consultations have been running for decades (Evans-Cowley and 
Hollander, 2010). Since advocates in the 1960s first brought widespread public participation 
into the planning process, there have been many innovations and improvements. Today, 
technology allows for an entirely new generation of forms and practices of public participation 
that promise to elevate the public discourse in an unprecedented manner while providing an 
interactive, networked environment for decision-making. This is occurring with various 
communities interacting with one another on a variety of planning subjects, which allows for 
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what may be a more democratic more meaningful participation. In their paper, Evans-Cowley 
et al review the ways in which today’s web-based virtual worlds, like Facebook, provide 
platforms for public participation in planning in a manner distinct from previous formats. The 
paper explores the different ways that citizens and communities are using web-based 
technologies for citizen participation, including the use of Facebook for community organising 
around planning issues and of Second Life for virtual workshops. The paper concludes by 
exploring the contribution that virtual participation can make to planning and examines the 
challenges that it poses. 
Highly sensitive public policy fields such as public health genomics are therefore all the more 
good examples of where public consultations can help the effort of reaching a truly 
participatory form of regulatory decision-making (Modell and Citrin, 2012). 
D. Access and participation in public consultations in the EU 
 
A typical consultation strategy designed for use within the European Commission is an 
elementary document, which requires the endorsement of an Inter-Service Group or, 
alternatively, of the Secretariat-General / concerned Directorate-General. It must contain at 
least a Stakeholder Analysis.  
The purpose of the consultation strategy is to encompass all the consultation methodologies 
and tools as well as all the initiatives aiming at stakeholder feedback that will be part and 
parcel of the strategy. It also serves as a checklist for a comprehensive consultation strategy, 
it will support the drafting of the consultation document and should contain relevant 
information on human and financial resource planning.  
A potential table of contents for the consultation strategy would contain: 
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(1) Setting consultation objectives. 
(2) Developing a stakeholder analysis or at least stakeholder mapping that is conducive to 
determining who should be targeted. It should be further defined who would have access to each 
part of the consultation. 
(3) A determined consultation method, tools and how accessibility would be ensured  (physically and 
linguistically). Relevant documents or initiatives on which stakeholders need to be consulted or to 
provide feedback have to be defined. 
a. Method: open or targeted (at least one open question is compulsory under the current 
guidelines) 
b. Tools: internet (EU Survey), email, telephone, workshops, etc. 
c. Type of initiatives: 
i.4 weeks request for feedback on the roadmap (compulsory) 
ii.12 weeks public online consultation (compulsory) 
iii.Other (workshop, surveys, stakeholder conference, etc) 
 
Consultation documents are important documents that frame the debate and serve as 
background to support the consultation. They are presently not compulsory for all initiatives. 
They must be no more than 10 pages long and should be easy to understand. 
(4) A planning team should be established including the contractor developing a feasible timeline for 
the different consultation methods. It is paramount to coordinate carefully with the contractor to 
understand how to run the consultation and what is expected from each party. 
(5) A consultation webpage should be created that has all the relevant information (including the 
consultation strategy containing the planned dates of the different consultation activities). 
(6) The stakeholder consultation should be documented as Annex 2 of the Staff Working Document 
drafted for the evaluation, with Annex 1 containing procedural information concerning the 
evaluation process and Annex 3 focusing on Methods and analytical models used in preparing the 
evaluation. A brief summary of the consultation strategy/ process should be provided in Annex 2 – 
including details of how, who and on what consultation took place and an explanation of how it 
was ensured that all relevant stakeholders had a possibility to provide inputs. More specifically, it 
should be documented which groups of stakeholders have been consulted, at what stage in the 
process and how (via public or via targeted consultations). 
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Dates for consultation will equally be included in the Commission’s Consultation Planning 
Calendar, compiled by the Secretariat-General and published in «Your voice in Europe ». 
The Better Regulation Toolbox 
A toolbox to complement the Better Regulation Guidelines has also been published and 
presented in the form of a single document structured around eight chapters containing 
individual tools that are ultimately available as downloadable web tools on the dedicated 
website. The Toolbox presents a comprehensive array of additional guidance to assist 
practitioners in the application of better regulation principles. 
The Toolbox contains 8 main chapters and introduces a standardized terminology as well as a 
specific rationale for EU policy-making, which is to reduce the administrative burden on 
political and economic systems as well as to increase the efficiency of law-making at EU level. 
Key to this undertaking is the improvement of the dialogue with stakeholders that are now 
more extensively consulted at different intervals in the process. We will look at this section in 
more detail further on. 
Chapter 1 defines key principles and concepts underpinning Better Regulation at the European 
Commission while Chapter 2 relates to tools for carrying out an Impact Assessment (IA). 
Chapter 3 presents tools for assessing specific impacts, whether they are estimated 
prospectively in the context of an IA or retrospectively when carrying out evaluations or 
Fitness Checks (i.e. specific evaluation exercises spanning all the regulation applicable in a 
given sector). 
Chapters 4, 5 and 6 provide a short summary of how to facilitate and verify the transposition 
and conformity of EU law, they describe how to establish monitoring systems which is a clear 
innovation in EU policy-making and provide guidance on how to carry out Evaluations and 
Fitness Checks. 
Chapter 7 lays out how to consult stakeholders in the context of Better Regulation. A clear 
innovation is again here the need defined to dispose of a stakeholder consultation strategy 
that is collectively approved and based on a specific stakeholder analysis. The Commission 
intends with the emphasis on this tool to streamline the consultation process and to ensure 
that important parts of the stakeholder communities are not ignored or marginalised in the 
process. 
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In practical terms, all documents pertaining to a public consultation are published on a website 
that is linked to automatic alerts to subscribers allowing stakeholders to react in good time to 
the documents under consultation. The time allowed for the process has also been 
considerably extended, the minimum currently being 12 weeks. 
Chapter 8 summarises methods to identify, assess and quantify costs and benefits of 
legislation. The tools are comprehensive and are expected to cover the relevant aspects of all 
initiatives and policy interventions.  
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Appendix 1. Supplementary material from Chapter 5 
Section   A. Full STATA results and sensitivity analysis  
Appendix table 1 Full Results from STATA without Martin-Vanberg Scores  
 
 
 
 
 
 
 
 
Unique Trans- Trans- Total %
Virgin Raw Raw Scored formed formed Transformed Words Tot True Raw
Text Score SE Words Score SE [95% Conf. Interval] Scored Sc'd score
tBEUC 0.2878 0.0098 264 -1.1041 0.0686 -1.2414 -0.9668 479 100 0.2878
tHAI 0.356 0.005 737 -0.6248 0.0349 -0.6946 -0.555 2,088 100 0.356
tepha 0.4511 0.0146 141 0.0433 0.1024 -0.1615 0.2481 286 82.7 0.545466
tgavi 0.5762 0.0228 84 0.9225 0.1603 0.6019 1.243 137 87.8 0.656264
tWHO 0.5154 0.0164 125 0.4954 0.1152 0.265 0.7259 238 82.6 0.623971
tbmg 0.5099 0.0163 123 0.4567 0.1142 0.2282 0.6851 269 82.8 0.615821
tBE 0.4988 0.0156 119 0.3784 0.1099 0.1585 0.5983 244 81.6 0.611275
tCH 0.4542 0.072 16 0.0651 0.5061 -0.9472 1.0774 16 66.7 0.68096
tIE 0.6181 0.0298 52 1.2172 0.2093 0.7986 1.6359 79 89.8 0.688307
tFI 0.5201 0.0324 46 0.5285 0.2275 0.0736 0.9835 75 83.3 0.62437
tHR 0.5009 0.0246 70 0.3935 0.1729 0.0477 0.7393 113 89 0.562809
tES 0.5009 0.0253 60 0.3935 0.1775 0.0385 0.7485 96 85 0.589294
tLT 0.4924 0.0502 28 0.3334 0.3527 -0.3721 1.0389 33 76.7 0.641982
tHU 0.5327 0.0094 271 0.6168 0.0658 0.4852 0.7483 726 86.2 0.617981
tSK 0.5066 0.01 253 0.4338 0.0703 0.2932 0.5744 794 86.8 0.583641
tMT 0.5323 0.0245 77 0.6141 0.1724 0.2694 0.9588 117 88 0.604886
tSE 0.4732 0.0323 57 0.199 0.2266 -0.2542 0.6522 74 74.7 0.633467
tNO 0.588 0.019 109 1.0051 0.1337 0.7376 1.2725 191 88 0.668182
tTR 0.4732 0.0318 38 0.1988 0.2236 -0.2484 0.6461 56 77.8 0.608226
tEGA 0.6987 0.0066 499 1.783 0.0467 1.6896 1.8763 1,275 100 0.6987
taok 0.5081 0.0112 225 0.4442 0.0787 0.2868 0.6015 588 76.6 0.663316
tAIM 0.5502 0.0217 93 0.7395 0.1526 0.4343 1.0448 162 82.2 0.669343
tAmgen 0.6125 0.0037 1,223 1.1774 0.0258 1.1257 1.2291 5,367 96.1 0.637357
tEFPIA 0.6576 0.0024 2,482 1.4943 0.0167 1.4609 1.5277 12,855 100 0.6576
tpreconsult 0.5379 0.0054 599 0.6531 0.0382 0.5768 0.7295 2,260 92.3 0.582774
tReport 0.5112 0.0051 579 0.4656 0.0361 0.3934 0.5378 2,717 85.9 0.595111
tpublic 0.5421 0.0052 627 0.6826 0.0363 0.61 0.7552 2,432 92.2 0.587961
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Appendix table 2 Full STATA results with Martin Vanberg scores and estimates of 
precision (95% CIs) 
 
The standard unit, according to equation 2 of the classical Martin Vanberg paper (Martin and 
Vanberg, 2007) is 2.43668. To perform a sensitivity analysis for the Martin-Vanberg 
transformation scores and obtain estimates of precision for each document scanned via the 
algorithm, I recalculated the MV transformation using the formal transformation in equation 
4 of the classical Martin-Vanberg paper (Martin and Vanberg, 2007). We then recalculate the 
variance for these scores and transform this variance using the equation on page 360 in a 
critical methodological review paper (Lowe, 2008). This then results in estimates which are 
tight around the point estimates just as the original standard errors. 
  
Unique Trans- Trans- Total %
Virgin Raw Raw Scored formed formed Transformed Words Tot True Raw
Text Score SE Words Score SE [95% Conf. Interval] Scored Sc'd score Difference
Standard 
Unit Variance MV Variance MV SE MV low 95 MV high 95
tBEUC 0.2878 0.0098 264 -1.1041 0.0686 -1.2414 -0.9668 479 100 0.2878 0 2.433682161 0 0.002593 0.004420124 0.012795 -0.02507791 0.0250779
tHAI 0.356 0.005 737 -0.6248 0.0349 -0.6946 -0.555 2,088 100 0.356 0.0682 2.433682161 0.165977 0.000675 0.001423251 0.00726 0.151746795 0.1802075
tepha 0.4511 0.0146 141 0.0433 0.1024 -0.1615 0.2481 286 82.7 0.545466 0.1633 2.433682161 0.39742 0.005755 0.015376944 0.023865 0.350645792 0.4441948
tgavi 0.5762 0.0228 84 0.9225 0.1603 0.6019 1.243 137 87.8 0.656264 0.2884 2.433682161 0.701874 0.014036 0.04789988 0.04212 0.619319311 0.7844286
tWHO 0.5154 0.0164 125 0.4954 0.1152 0.265 0.7259 238 82.6 0.623971 0.2276 2.433682161 0.553906 0.007262 0.022167851 0.028654 0.497744911 0.6100672
tbmg 0.5099 0.0163 123 0.4567 0.1142 0.2282 0.6851 269 82.8 0.615821 0.2221 2.433682161 0.540521 0.007174 0.021664651 0.028327 0.485000733 0.5960409
tBE 0.4988 0.0156 119 0.3784 0.1099 0.1585 0.5983 244 81.6 0.611275 0.211 2.433682161 0.513507 0.006571 0.019411859 0.026813 0.460952697 0.5660612
tCH 0.4542 0.072 16 0.0651 0.5061 -0.9472 1.0774 16 66.7 0.68096 0.1664 2.433682161 0.404965 0.139968 0.376533485 0.118092 0.173504689 0.6364247
tIE 0.6181 0.0298 52 1.2172 0.2093 0.7986 1.6359 79 89.8 0.688307 0.3303 2.433682161 0.803845 0.023977 0.087777408 0.057018 0.692090577 0.9155999
tFI 0.5201 0.0324 46 0.5285 0.2275 0.0736 0.9835 75 83.3 0.62437 0.2323 2.433682161 0.565344 0.028344 0.087310878 0.056866 0.453887105 0.6768016
tHR 0.5009 0.0246 70 0.3935 0.1729 0.0477 0.7393 113 89 0.562809 0.2131 2.433682161 0.518618 0.016339 0.048474432 0.042372 0.435569406 0.6016659
tES 0.5009 0.0253 60 0.3935 0.1775 0.0385 0.7485 96 85 0.589294 0.2131 2.433682161 0.518618 0.017282 0.051272389 0.043577 0.433206244 0.6040291
tLT 0.4924 0.0502 28 0.3334 0.3527 -0.3721 1.0389 33 76.7 0.641982 0.2046 2.433682161 0.497931 0.068041 0.198434399 0.085729 0.329902979 0.6659598
tHU 0.5327 0.0094 271 0.6168 0.0658 0.4852 0.7483 726 86.2 0.617981 0.2449 2.433682161 0.596009 0.002386 0.007527138 0.016697 0.563283047 0.6287345
tSK 0.5066 0.01 253 0.4338 0.0703 0.2932 0.5744 794 86.8 0.583641 0.2188 2.433682161 0.53249 0.0027 0.008101336 0.017322 0.498538661 0.5664407
tMT 0.5323 0.0245 77 0.6141 0.1724 0.2694 0.9588 117 88 0.604886 0.2445 2.433682161 0.595035 0.016207 0.051095202 0.043502 0.509771574 0.680299
tSE 0.4732 0.0323 57 0.199 0.2266 -0.2542 0.6522 74 74.7 0.633467 0.1854 2.433682161 0.451205 0.028169 0.078948024 0.054074 0.345219571 0.5571898
tNO 0.588 0.019 109 1.0051 0.1337 0.7376 1.2725 191 88 0.668182 0.3002 2.433682161 0.730591 0.009747 0.033945015 0.035457 0.661095003 0.8000878
tTR 0.4732 0.0318 38 0.1988 0.2236 -0.2484 0.6461 56 77.8 0.608226 0.1854 2.433682161 0.451205 0.027303 0.07652273 0.053237 0.346860207 0.5555491
tEGA 0.6987 0.0066 499 1.783 0.0467 1.6896 1.8763 1,275 100 0.6987 0.4109 2.433682161 1 0.001176 0.004867098 0.013426 0.973684645 1.0263154
taok 0.5081 0.0112 225 0.4442 0.0787 0.2868 0.6015 588 76.6 0.663316 0.2203 2.433682161 0.53614 0.003387 0.010192406 0.019429 0.498058811 0.5742215
tAIM 0.5502 0.0217 93 0.7395 0.1526 0.4343 1.0448 162 82.2 0.669343 0.2624 2.433682161 0.638598 0.012714 0.041431584 0.039173 0.56181964 0.7153768
tAmgen 0.6125 0.0037 1,223 1.1774 0.0258 1.1257 1.2291 5,367 96.1 0.637357 0.3247 2.433682161 0.790217 0.00037 0.001340914 0.007047 0.776404021 0.8040292
tEFPIA 0.6576 0.0024 2,482 1.4943 0.0167 1.4609 1.5277 12,855 100 0.6576 0.3698 2.433682161 0.899976 0.000156 0.000605725 0.004736 0.890692156 0.9092592
tpreconsult 0.5379 0.0054 599 0.6531 0.0382 0.5768 0.7295 2,260 92.3 0.582774 0.2501 2.433682161 0.608664 0.000787 0.002508306 0.009638 0.589772495 0.6275553
tReport 0.5112 0.0051 579 0.4656 0.0361 0.3934 0.5378 2,717 85.9 0.595111 0.2234 2.433682161 0.543685 0.000702 0.002126291 0.008874 0.526291153 0.561078
tpublic 0.5421 0.0052 627 0.6826 0.0363 0.61 0.7552 2,432 92.2 0.587961 0.2543 2.433682161 0.618885 0.00073 0.002344108 0.009318 0.600622758 0.637148
Reeves 
MV 
transfor
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Section   B. Glossary of terminology 
Generic drugs can be: 
- Branded generics (generics with a specific trade name) 
- Unbranded generics (using the international non-proprietary name and the name of 
the company) 
Generic drugs, according to European legislation are pharmaceutical products which have the 
same qualitative and quantitative composition in active substances and the same 
pharmaceutical form as a reference medicinal product, and whose bioequivalence with the 
reference medicinal product is evidenced by appropriate bioavailability studies. However, it 
should be noted that there is a variety of different, sometimes overlapping, definitions of the 
term ‘generics’ due to differences in the requirements for registration of generics between 
countries, especially related to the degree and proof of therapeutic equivalence and the fact 
that they can be sold under brand (branded generics) or International Nonproprietary Name 
(unbranded generics). The World Health Organization (WHO) defines generics as multi-source 
pharmaceutical products that are therapeutically equivalent, not taking into consideration of 
whether or not the ‘originator’ molecule is, or was, under patent protection.  
Biological medicines are medicines that are made by or derived from a biological source, such 
as a bacterium or yeast.  
A biosimilar is a biological medicine that is similar to another biological medicine that has 
already been authorized for use. 
Specialty medicines do not benefit from a unique definition. They usually include injectable 
and biologic agents used to treat complex conditions such as rheumatoid arthritis, multiple 
sclerosis and cancer and often require special handling or delivery mechanisms. 
Orphan drugs refer to medicines developed for rare conditions. 
The categories of pharmaceuticals above refer to retail pharmaceuticals, delivered to patients 
via pharmacies and other retail outlets. Pharmaceuticals can also be dispensed in other care 
settings – primarily the hospital inpatient sector – where the pharmaceuticals used are 
considered as an input to the overall service treatment and not separately accounted. Present 
health accounts do allow for additional reporting items to monitor a total pharmaceutical 
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spending estimate covering all modes of provision (inpatient and retail). Currently though, 
only a handful of countries report such figures to OECD. 
Section   C. Stakeholder analysis 
I performed a stakeholder analysis, based on Schmeer’s methodology (Schmeer, 1999), which 
I linked to the findings of my corpus analysis of the submissions. The diagram below provides 
an illustration of the average raw scores that emerged for each submission. The diagram 
results from an additional layer of generalisation and abstraction, which runs counter to the 
conventional wisdom that stakeholders should be analysed at the level of individual topics or 
subjects, notwithstanding the need to take into account their heterogeneity.  
We refer to: 
· Position/ Interest, along the x-axis, whether the stakeholder supports, opposes or is 
neutral with regard to a more stringent regulation of pharmaceuticals; 
· Power/ Influence, along the y-axis, the stakeholder’s ability to influence the 
pharmaceutical-related policy. 
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Key messages that emerge from the analysis include: 
· The key stakeholders are those in the top right quadrant, which have both a high level of 
interest in the more stringent regulation of pharmaceuticals, and some level of influence 
over its implementation. These are the innovators or the “first movers” who have a 
“natural” interest in acting as policy entrepreneurs and supporting the push for tighter 
regulation and more equitable access to pharmaceuticals. 
· The groups in the bottom right quadrant are potentially interested, but their influence is 
limited due to small national markets, which translates into their engagement being 
strategically important yet less vocal. 
· The stakeholders in the top left quadrant are of note, as their high level of influence 
coincides with relatively low levels of interest in tighter regulation – they are the 
exponents of the industrial core. 
High Influence, Low Stake: 
KEEP INFORMED
HANDLE WITH CARE
- EFPIA
- EGA
- Amgen
- AIM
High Influence, High Stake: 
MANAGE CLOSELY
- WHO
-HAI
-BEUC
-EPHA
Low Influence, Low Stake: 
MONITOR
-Turkey
-Iceland
- Norway
Low Influence, High Stake:
NEED HELP TO HAVE A SAY
- Ireland
- Luxembourg
- Hungary
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· Finally, the bottom left quadrant contains the stakeholders that combine low levels of 
interest with a low level of influence over EU policy and they are the governmental 
agencies regulating pharmaceuticals outside of the EU bloc.  
  
165 
 
Appendix 2. Supplementary material from Chapter 6 
Appendix table 3 STATA, LBG and MV Transformation results with AT, Kantonales, 
FoodDrink Europe and NCFUS as reference texts 
 
The standard unit, according to equation 2 of the classical Martin Vanberg paper (Martin and 
Vanberg, 2007) is 1.67729. I decided against using these values. 
To test the robustness of my results, I re-estimated word scores using a different classification 
method for the texts. I first used as reference texts only the four documents from the Austrian 
Agency for Health and Food Safety, Kantonales Labor Zurich on the one hand and 
FoodDrinkEurope and European Coffee Federation on the other to classify the policy positions 
of the other stakeholders in the confectionary, coffee and food industry and the public health 
bodies. 
 
 
 
 
 
 
Unique Trans- Trans- Total % True Raw
Virgin Raw Raw Scored formed formed Words Tot score Difference
Standard 
Unit Variance MV VarianceMV SE MV low 95 MV high 95
Text Score (STATA)SE Words Score SE Scored Sc'd
tAT 0.2071 0.0187 93 -0.2721 0.0678 -0.4076 -0.1366 135 100 0.2071 0 1.67729 0 0.006994 0.004075 0.014274 -0.0279767 0.027977
tCHOPRABISCO 0.3777 0.0196 77 0.3462 0.0709 0.2044 0.4881 197 69.1 0.546599 0.1706 1.67729 0.286146 0.007683 0.008164 0.020204 0.24654573 0.325745
tCL 0.3639 0.0066 329 0.2961 0.0239 0.2484 0.3439 1,674 76.3 0.476933 0.1568 1.67729 0.262999 0.000871 0.000892 0.006678 0.24991022 0.276088
tBDSI 0.3411 0.0178 111 0.2135 0.0645 0.0844 0.3426 235 73.7 0.462822 0.134 1.67729 0.224757 0.006337 0.006081 0.017437 0.1905805 0.258933
tDKSE 0.355 0.0115 168 0.2639 0.0418 0.1803 0.3475 556 74.2 0.478437 0.1479 1.67729 0.248071 0.002645 0.002642 0.011493 0.22554553 0.270597
tECF 0.7154 0.006 308 1.5703 0.0219 1.5265 1.614 1,904 99.7 0.717553 0.5083 1.67729 0.852566 0.00072 0.001449 0.008512 0.83588265 0.86925
tEFSADraft 0.2928 0.001 1054 0.0383 0.0037 0.0309 0.0457 80,348 58.2 0.503093 0.0857 1.67729 0.143744 0.00002 1.65E-05 0.000908 0.14196482 0.145523
tEFSASciOp 0.2925 0.001 1,070 0.0371 0.0035 0.0301 0.0441 90,178 58.1 0.503442 0.0854 1.67729 0.143241 0.00002 1.65E-05 0.000907 0.14146254 0.145019
tEPPA 0.371 0.0207 102 0.3218 0.0752 0.1714 0.4722 189 77.1 0.481193 0.1639 1.67729 0.274908 0.00857 0.008945 0.021148 0.23345805 0.316357
tES 0.337 0.0172 112 0.1986 0.0624 0.0738 0.3233 260 75.4 0.44695 0.1299 1.67729 0.21788 0.005917 0.00561 0.016748 0.1850547 0.250705
tFoodDrinkEurope 0.7128 0.0044 719 1.5607 0.016 1.5287 1.5927 3,805 100 0.7128 0.5057 1.67729 0.848205 0.000387 0.000776 0.006231 0.83599291 0.860418
tFPP 0.3696 0.0131 162 0.3169 0.0473 0.2223 0.4115 465 73.7 0.501493 0.1625 1.67729 0.27256 0.003432 0.003569 0.013358 0.24637763 0.298741
tISS 0.3454 0.01 192 0.229 0.0363 0.1565 0.3016 751 66.9 0.516293 0.1383 1.67729 0.231969 0.002 0.001943 0.009858 0.21264833 0.25129
tKantonales 0.2768 0.0054 886 -0.0198 0.0196 -0.059 0.0194 2,736 100 0.2768 0.0697 1.67729 0.116907 0.000583 0.000454 0.004765 0.10756721 0.126247
tLTDH 0.2746 0.032 39 -0.0277 0.1161 -0.2598 0.2045 80 61.1 0.449427 0.0675 1.67729 0.113217 0.02048 0.015821 0.028126 0.05809004 0.168344
tNCFUS 0.8033 0.0077 120 1.8888 0.0277 1.8333 1.9443 715 100 0.8033 0.5962 1.67729 1 0.001186 0.00268 0.011575 0.97731213 1.022688
tNovozymes 0.321 0.0145 124 0.1407 0.0524 0.0359 0.2455 338 66.1 0.485628 0.1139 1.67729 0.191043 0.004205 0.003797 0.013779 0.16403576 0.218051
tRenaissance 0.3099 0.0137 109 0.1002 0.0495 0.0011 0.1992 370 63.2 0.490348 0.1028 1.67729 0.172425 0.003754 0.003273 0.012792 0.14735299 0.197498
tTechnicalReport 0.3672 0.0025 898 0.3081 0.009 0.2901 0.326 13,314 71.8 0.511421 0.1601 1.67729 0.268534 0.000125 0.000129 0.002541 0.26355375 0.273514
tUK 0.3606 0.0088 265 0.2841 0.0318 0.2206 0.3476 1,011 74.8 0.482086 0.1535 1.67729 0.257464 0.001549 0.001571 0.008863 0.24009155 0.274836
Reeves 
MV 
transforTransformed
[95% Conf. Interval]
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Appendix table 4  STATA, LBG and MV Transformation results with AT, Kantonales, 
FoodDrinkEurope and ECF as reference texts 
 
The standard unit, according to equation 2 of the classical Martin Vanberg paper (Martin and 
Vanberg, 2007) is 1.935359. I decided to retain these values. 
Section   D. Sensitivity Analysis for all texts under the Martin-Vanberg 
Transformation 
To perform a sensitivity analysis for the Martin-Vanberg transformation scores and obtain 
estimates of precision for each document scanned via the algorithm, I recalculated the MV 
transformation using the formal transformation in equation 4 of the classical Martin-Vanberg 
paper (Martin and Vanberg, 2007). We then recalculate the variance for these scores and 
transform this variance using the equation on page 360 in a critical methodological review 
paper (Lowe, 2008). This then results in estimates which are tight around the point estimates 
just as the original standard errors. 
  
Unique Trans- Trans- Total % True Raw
Virgin Raw Raw Scored formed formed Words Tot score Difference
Standard 
Unit Variance MV VarianceMV SE MV low 95 MV high 95
Text Score (STATA)SE Words Score SE Scored Sc'd
tAT 0.2337 0.0196 93 -0.2279 0.0784 -0.3847 -0.0711 135 100 0.2337 0 1.935359 0 0.007683 0.006725 0.018338 -0.0359421 0.035942
tCHOPRABISCO 0.3564 0.0191 77 0.2632 0.0765 0.1101 0.4162 197 69.1 0.515774 0.1227 1.935359 0.237469 0.007296 0.00974 0.022068 0.19421519 0.280722
tCL 0.3681 0.0066 326 0.3098 0.0266 0.2566 0.363 1,669 76.1 0.483706 0.1344 1.935359 0.260112 0.000871 0.001201 0.00775 0.24492272 0.275302
tBDSI 0.3412 0.0177 111 0.2022 0.0708 0.0605 0.3439 235 73.7 0.462958 0.1075 1.935359 0.208051 0.006266 0.008008 0.02001 0.1688322 0.24727
tDKSE 0.3745 0.0115 166 0.3354 0.0461 0.2431 0.4276 554 74 0.506081 0.1408 1.935359 0.272499 0.002645 0.00371 0.01362 0.24580285 0.299194
tECF 0.7504 0.0053 313 1.8391 0.0213 1.7964 1.8817 1,910 100 0.7504 0.5167 1.935359 1 0.000562 0.001579 0.008886 0.98258434 1.017416
tEFSADraft 0.2838 0.001 1043 -0.0272 0.004 -0.0353 -0.0191 79,080 57.3 0.495288 0.0501 1.935359 0.096961 0.00002 2.13E-05 0.001031 0.09494068 0.098982
tEFSASciOp 0.2837 0.001 1,059 -0.0277 0.0038 -0.0353 -0.0201 88,777 57.2 0.495979 0.05 1.935359 0.096768 0.00002 2.13E-05 0.001031 0.0947475 0.098788
tEPPA 0.3864 0.0209 102 0.3829 0.0836 0.2158 0.55 189 77.1 0.501167 0.1527 1.935359 0.295529 0.008736 0.012644 0.025144 0.24624799 0.344811
tES 0.3406 0.0171 111 0.1997 0.0684 0.0629 0.3366 259 75.1 0.453529 0.1069 1.935359 0.20689 0.005848 0.007461 0.019314 0.16903376 0.244746
tFoodDrinkEurope 0.7361 0.004 719 1.7817 0.0161 1.7494 1.8139 3,805 100 0.7361 0.5024 1.935359 0.972324 0.00032 0.000882 0.006642 0.95930631 0.985342
tFPP 0.384 0.0128 163 0.3734 0.0512 0.2711 0.4758 466 73.9 0.519621 0.1503 1.935359 0.290884 0.003277 0.004713 0.015351 0.26079647 0.320972
tISS 0.3572 0.0099 187 0.2663 0.0397 0.1869 0.3458 745 66.3 0.538763 0.1235 1.935359 0.239017 0.00196 0.002623 0.011451 0.21657241 0.261461
tKantonales 0.2799 0.0054 886 -0.0431 0.0217 -0.0865 0.0003 2,736 100 0.2799 0.0462 1.935359 0.089414 0.000583 0.000611 0.005529 0.07857649 0.100251
tLTDH 0.2718 0.0318 39 -0.0755 0.1274 -0.3303 0.1792 80 61.1 0.444845 0.0381 1.935359 0.073737 0.020225 0.02059 0.032086 0.01084894 0.136625
tNCFUS 0.6215 0.011 97 1.3236 0.044 1.2355 1.4117 645 90.2 0.689024 0.3878 1.935359 0.750532 0.00242 0.005634 0.016783 0.71763715 0.783427
tNovozymes 0.3236 0.0144 123 0.1319 0.0577 0.0165 0.2473 337 65.9 0.491047 0.0899 1.935359 0.173989 0.004147 0.005027 0.015854 0.14291569 0.205062
tRenaissance 0.3069 0.0136 109 0.0649 0.0544 -0.044 0.1737 370 63.2 0.485601 0.0732 1.935359 0.141668 0.003699 0.004252 0.014581 0.11308876 0.170248
tTechnicalReport 0.3799 0.0025 889 0.3572 0.0098 0.3375 0.3768 13,268 71.5 0.531329 0.1462 1.935359 0.282949 0.000125 0.000178 0.002982 0.27710438 0.288795
tUK 0.3708 0.0087 259 0.3206 0.0348 0.251 0.3901 1,005 74.4 0.498387 0.1371 1.935359 0.265338 0.001514 0.002102 0.010253 0.24524185 0.285434
Reeves 
MV 
transforTransformed
[95% Conf. Interval]
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Appendix table 5  Full STATA results including sensitivity analysis for individual 
MV scores 
Stakeholder or 
version of report 
Word 
count 
Unique 
words 
scored 
Raw 
score 
LBG 
score 
MV score Lower 
limit MV 
score CI 
Upper 
limit MV 
score CI 
Industry   
ECF 1910 313 0.7504 1.8391 1 0.9825 1.0174 
FoodDrinkEurope 3805 719 0.7361 1.7817 0.972324 0.9593 0.9853 
NCFUS 645 97 0.6215 1.3236 0.750532 0.7176 0.7834 
BDSI 235 111 0.3412 0.2022 0.208051 0.1688 0.2472 
Novozymes 337 123 0.3236 0.1319 0.173989 0.1429 0.2050 
Renaissance 370 109 0.3069 0.0649 0.141668 0.1131 0.1702 
BE 197 77 0.3564 0.2632 0.237469 0.19421 0.28072 
FPP 466 163 0.384 0.3734 0.290884 0.26079 0.32097 
EPPA 189 102 0.3864 0.3829 0.295529 0.24624 0.34481 
Neutral   
Pre-consult (Draft 
Scientific Opinion) 
79080 1043 0.2838 -0.0272 0.096961 0.0949 0.0989 
Post-consult 
publication 
(Scientific Opinion) 
88777 1059 0.2837 -0.0277 0.096768 0.0947 0.0987 
Technical Report of 
the stakeholder 
review 
13268 889 0.3799 0.3572 0.282949 0.2771 0.2887 
Advocacy   
AT 135 93 0.2337 -0.2279 0 -0.0359 0.0359 
Kantonales 2736 886 0.2799 -0.0431 0.089414 0.07858 0.1002 
DKSE 554 166 0.3745 0.3354 0.272499 0.24580 0.2992 
CL 1669 326 0.3681 0.3098 0.260112 0.24492 0.2753 
ISS 745 187 0.3572 0.2663 0.239017 0.21657 0.2614 
UK 1005 259 0.3708 0.3206 0.265338 0.24524 0.2854 
ES 259 111 0.3406 0.1997 0.20689 0.16903 0.2447 
 
Section   E. Stakeholder Analysis Acrylamide Case Study Submissions 
I performed a stakeholder analysis, based on Schmeer’s methodology (Schmeer, 1999), which 
I linked to the findings of my corpus analysis of the submissions. The diagram below provides 
an illustration of the average raw scores that emerged for each submission. The diagram 
results from an additional layer of generalisation and abstraction, which runs counter to the 
conventional wisdom that stakeholders should be analysed at the level of individual topics or 
subjects, notwithstanding the need to take into account their heterogeneity.  
We refer to: 
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· Position/ Interest, along the x-axis, whether the stakeholder supports, opposes or is 
neutral with regard to a more stringent regulation of acrylamide; 
· Power/ Influence, along the y-axis, the stakeholder’s ability to influence the 
acrylamide-related policy. 
 
 
Key messages that emerge from the analysis include: 
· The key stakeholders are those in the top right quadrant, which have both a high level 
of interest in the more stringent regulation of acrylamide, and some level of influence 
over its implementation. These are the innovators or the “first movers” who have a 
“natural” interest in acting as policy entrepreneurs and supporting the push for tighter 
regulation. 
· The groups in the bottom right quadrant are potentially interested, but their influence 
is limited, which translates into their engagement being strategically less important. 
High Influence, Low Stake: 
KEEP INFORMED
HANDLE WITH CARE
- NCFUS
- ECF
- FoodDrinkEurope
High Influence, High Stake: 
MANAGE CLOSELY
- Kantonales Labor Zurich
- Austrian Agency for Health 
and Food Safety
Low Influence, Low Stake: 
MONITOR
- BDSI
- CHOPRABISCO
- EUPPA 
- FPPI
Low Influence, High Stake:
NEED HELP TO HAVE A SAY
- Renaissance
- Novozymes
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· The stakeholders in the top left quadrant are of note, as their high level of influence 
coincides with relatively low levels of interest in tighter regulation – they are the 
exponents of the industrial core. 
· Finally, the bottom left quadrant contains the stakeholders that combine low levels of 
interest with a low level of influence and they are the smaller federations of industrial 
producers (often sectorial and national in nature).  
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Appendix 3: Supplementary material from Chapter 7 
Appendix table 6  STATA, LBG and MV Transformation results with EPfirstreading, 
EPsecondreading, CONSfirstreading and CONSfirstreadingpress as reference texts  
 
Appendix table 7  STATA, LBG and MV Transformation results with EPfirstreading, 
EPsecondreading, CONSfirstreading and CONSfirstreadingpress as reference texts  
 
Section   F. Stakeholder Analysis Directive Case Study  
I performed a stakeholder analysis, based on Schmeer’s methodology (Schmeer, 1999), which 
I linked to the findings of my corpus analysis of the submissions. The diagram below provides 
an illustration of the average raw scores that emerged for each submission. The diagram 
results from an additional layer of generalisation and abstraction, which runs counter to the 
conventional wisdom that stakeholders should be analysed at the level of individual topics or 
subjects, notwithstanding the need to take into account their heterogeneity.  
We refer to: 
Unique Trans Trans Trans Trans Total      % %
Virgin Raw Raw Scored formed formed Transformed Words Tot True Raw
Text Score SE Words Score SE [95% Conf. Interval] Scored Sc'd score
Diffe
rence
Standard 
Unit Variance MV Variance MV SE MV low 95 MV high 95
tCOMoriginal 0.435 0.0011 1,744 0.2091 0.0085 0.192 0.2262 21,359 96.6 0.45031056 0.04 4.076641 0.146351406 0.00001815 0.00013121 0.00296 0.140554506 0.152148
tIA 0.395 0.0011 1,747 0.1101 0.0089 -0.128 -0.0922 27,940 91.6 0.43122271 0.00 4.076641 -0.01671423 0.00001815 0.00011915 0.00282 -0.02223818 -0.01119
tEPfirstreading 0.3991 0.0007 4,935 0.0775 0.0057 -0.0889 -0.0661 77,878 100 0.3991 0.00 4.076641 0 0.00000735 4.875E-05 0.0018 -0.00353344 0.003533
tEPsecondreading 0.4579 0.0011 1,892 0.3929 0.0092 0.3746 0.4112 15,520 100 0.4579 0.06 4.076641 0.239706482 0.00001815 0.00013812 0.00303 0.233758953 0.245654
tEPSCO 0.4755 0.0011 1,556 0.5332 0.0089 0.5155 0.551 13,455 98.9 0.48078868 0.08 4.076641 0.311455361 0.00001815 0.00014343 0.00309 0.305394609 0.317516
tEPSCOpress 0.5418 0.0054 412 1.0638 0.0429 0.9781 1.1495 1,322 94.6 0.57272727 0.14 4.076641 0.581736649 0.0004374 0.00393843 0.0162 0.549977286 0.613496
tEESCopinion 0.4069 0.0031 762 0.0149 0.025 -0.0649 0.0351 3,450 91.7 0.44372955 0.01 4.076641 0.031797799 0.00014415 0.00097478 0.00806 0.015997545 0.047598
tEDPSopinion 0.3962 0.0011 1,861 0.1008 0.0085 -0.1178 -0.0838 29,334 90.6 0.43730684 0.00 4.076641 -0.01182226 0.00001815 0.00011951 0.00282 -0.01735459 -0.00629
tCoRopinion 0.3742 0.0009 2,204 0.2766 0.0076 -0.2918 -0.2614 41,270 88.4 0.42330317 -0.02 4.076641 -0.10150836 0.00001215 7.5559E-05 0.00224 -0.10590735 -0.09711
tCONSfirstreading 0.4985 0.0011 1,950 0.7178 0.0087 0.7003 0.7352 16,602 100 0.4985 0.10 4.076641 0.4052181 0.00001815 0.00015036 0.00317 0.3990125 0.411424
tCONSfirstreadingpress 0.6444 0.0057 342 1.8845 0.0454 1.7937 1.9754 948 100 0.6444 0.25 4.076641 1 0.00048735 0.00521917 0.01865 0.963439583 1.03656
tCOMonCONSfirstreading 0.482 0.003 710 0.5856 0.0243 0.537 0.6343 3,437 97.3 0.49537513 0.08 4.076641 0.337953526 0.000135 0.0010814 0.00849 0.321311611 0.354595
tCONSonEPamendmentspress 0.543 0.0069 315 1.0737 0.055 0.9637 1.1837 793 96.7 0.56153051 0.14 4.076641 0.586628618 0.00071415 0.00644457 0.02073 0.546002294 0.627255
tCOMonEPsecondreading 0.4929 0.0085 162 0.6729 0.0677 0.5374 0.8083 470 94.8 0.51993671 0.09 4.076641 0.382388912 0.00108375 0.00887754 0.02433 0.334706649 0.430071
tDirectiveAdoptedText 0.4657 0.0011 1,661 0.4547 0.0088 0.4371 0.4724 14,386 99.8 0.46663327 0.07 4.076641 0.27150428 0.00001815 0.00014047 0.00306 0.26550631 0.277502
Reeves MV 
transformed 
scored
Unique Trans Trans Trans Total      % %
Virgin Raw Raw Scored formed formed Transformed Words Tot True Raw
Text Score SE Words Score SE [95% Conf. Interval] Scored Sc'd score
Differ
ence
Standard 
Unit Variance MV Variance MV SE MV low 95 MV high 95
tCOMoriginal 0.435 0.0011 1,744 0.2091 0.0085 0.192 0.2262 21,359 96.6 0.450311 0.05 4.076641 0.208767 1.82E-05 0.000135829 0.003009 0.202869023 0.21466509
tIA 0.395 0.0011 1,747 0.1101 0.0089 -0.128 -0.0922 27,940 91.6 0.431223 0.03 4.076641 0.130953 1.82E-05 0.000130072 0.002945 0.125181064 0.13672442
tEPfirstreading 0.3991 0.0007 4,935 0.0775 0.0057 -0.0889 -0.0661 77,878 100 0.3991 0.00 4.076641 0 7.35E-06 4.87499E-05 0.001803 -0.00353344 0.00353344
tEPsecondreading 0.4579 0.0011 1,892 0.3929 0.0092 0.3746 0.4112 15,520 100 0.4579 0.06 4.076641 0.239706 1.82E-05 0.000138119 0.003034 0.233758953 0.24565401
tEPSCO 0.4755 0.0011 1,556 0.5332 0.0089 0.5155 0.551 13,455 98.9 0.480789 0.08 4.076641 0.333015 1.82E-05 0.000145023 0.003109 0.326921028 0.33910975
tEPSCOpress 0.5418 0.0054 412 1.0638 0.0429 0.9781 1.1495 1,322 94.6 0.572727 0.17 4.076641 0.707816 0.000437 0.004163241 0.01666 0.675162797 0.74046927
tEESCopinion 0.4069 0.0031 762 0.0149 0.025 -0.0649 0.0351 3,450 91.7 0.44373 0.04 4.076641 0.181939 0.000144 0.001063011 0.008418 0.165438831 0.19843849
tEDPSopinion 0.3962 0.0011 1,861 0.1008 0.0085 -0.1178 -0.0838 29,334 90.6 0.437307 0.04 4.076641 0.155756 1.82E-05 0.000131907 0.002965 0.149943327 0.16156783
tCoRopinion 0.3742 0.0009 2,204 0.2766 0.0076 -0.2918 -0.2614 41,270 88.4 0.423303 0.02 4.076641 0.098668 1.22E-05 8.54737E-05 0.002387 0.093988904 0.10334634
tCONSfirstreading 0.4985 0.0011 1,950 0.7178 0.0087 0.7003 0.7352 16,602 100 0.4985 0.10 4.076641 0.405218 1.82E-05 0.000150365 0.003166 0.3990125 0.4114237
tCONSfirstreadingpress 0.6444 0.0057 342 1.8845 0.0454 1.7937 1.9754 948 100 0.6444 0.25 4.076641 1 0.000487 0.00521917 0.018653 0.963439583 1.03656042
tCOMonCONSfirstreading 0.482 0.003 710 0.5856 0.0243 0.537 0.6343 3,437 97.3 0.495375 0.10 4.076641 0.392479 0.000135 0.001111406 0.008608 0.375607886 0.40935036
tCONSonEPamendmentspress 0.543 0.0069 315 1.0737 0.055 0.9637 1.1837 793 96.7 0.561531 0.16 4.076641 0.662171 0.000714 0.006664502 0.021078 0.62085712 0.70348456
tCOMonEPsecondreading 0.4929 0.0085 162 0.6729 0.0677 0.5374 0.8083 470 94.8 0.519937 0.12 4.076641 0.492608 0.001084 0.009364498 0.024986 0.443635317 0.54158041
tDirectiveAdoptedText 0.4657 0.0011 1,661 0.4547 0.0088 0.4371 0.4724 14,386 99.8 0.466633 0.07 4.076641 0.275309 1.82E-05 0.000140753 0.003063 0.269304895 0.28131285
Reeves 
MV 
transfor
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Position/ Interest, along the x-axis, whether the stakeholder supports, opposes or is neutral 
with regard to a more stringent regulation of patient flows; 
· Power/ Influence, along the y-axis, the stakeholder’s ability to influence the cross-
border healthcare policy. 
 
 
Key messages that emerge from the analysis include: 
· The key stakeholders are those in the top right quadrant, i.e. the European Parliament, 
which have both a high level of interest in the more stringent regulation of patient 
flows and patient rights, and some level of influence over its implementation. These 
are the innovators or the “first movers” who have a “natural” interest in acting as 
policy entrepreneurs and supporting the push for tighter regulation, without 
precluding more vigorous action in the field of rare diseases. 
High Influence, Low Stake: 
KEEP INFORMED
HANDLE WITH CARE
- Council first reading
- Council second reading
High Influence, High Stake: 
MANAGE CLOSELY
- European Parliament first 
reading
-European Parliament 
second reading
Low Influence, Low Stake: 
MONITOR
- EDPS
Low Influence, High Stake:
NEED HELP TO HAVE A SAY
- CoR
- EESC
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· The groups in the bottom right quadrant are potentially interested, but their influence 
is limited, which translates into their engagement being strategically less critical, yet 
imperative. 
· The stakeholders in the top left quadrant are of note, as their high level of influence 
coincides with relatively low levels of interest in tighter regulation – they are the 
exponents of the industrial core, represented in the interests of Member States 
reunited in the Council. 
· Finally, the bottom left quadrant contains the stakeholders that combine low levels of 
interest with a low level of influence (often sectorial, i.e. data protection oriented, in 
nature).  
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Appendix 4: A Manual for Quantitative Text Analysis in Policy 
Development 
Step-by-step Protocol for Data Sanitat ion and Analysis  
 
 
A systematic review is a review that strives to comprehensively identify, track down and appraise all 
the literature on a specific topic (Petticrew, 2003). Similarly, quantitative text analysis (QTA) is a tool 
used to review texts based on word frequencies in order to comprehensively identify, track down and 
appraise word usage by different actors, authors or stakeholders on a specific policy topic.  
In 1979, human coders coded 2,500 party manifestos issued by 632 different parties in 52 countries. 
The undertaking “Comparative Manifestos Project” was well underway and it lasted 20 years. It yielded 
a mammoth data set generated by hand. The analytical team developed categories for a classification 
scheme, half classified as “pro regulation” and half as “anti-regulation”. All statements that could not 
be allocated to one of these categories were grouped into an “others” category. The units of analysis 
were natural sentences. First, the percentage of pro and anti-regulation categories in the total number 
of coded statements per text were calculated. Then, the pro percentage was subtracted from the anti-
regulation percentage. Negative scores represented one camp positions and positive scores 
represented the other camp positions. Drawing on this pioneering manually run project, automated 
content analysis software has helped QTA methods to evolve considerably over the years.  
In this manual, QTA is applied via running JFREQ and the Wordscores algorithm in STATA v14.0. Based 
on the underlying assumption that agents with different policy positions use different wording and 
different concepts that reflect their stance, Wordscores uses the frequency of words in each 
document, relative to the total number of words in a text to output scores for each examined 
document.  
The five basic steps set out below are further detailed on the next page in a table presenting process 
workflow items and remarks or observations that can be of use to the operator.  
 
Five steps to conducting QTA (Quantitative Text Analysis) 
1. Collect written evidence per stakeholder, decide on a policy dimension fitting the case study  
2. Sanitise data and prepare for analysis 
3. Run JFREQ and in parallel, the Wordscores algorithm in STATA 
4. Optional: Calculate estimates of precision for Martin-Vanberg transformations (in Excel) 
5. Interpret the data, disambiguate and plot positions based on scores in a graph 
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The In-depth Step-by-Step Guide: 
Process workflow item Remarks/ observations Date completed 
   
1. Decide on a policy 
dimension fitting your 
case study 
E.g. tobacco regulation (more or less 
regulation along an axis) – against tobacco 
control at one extremity and for tobacco 
control at the other 
 
 
2. Collect documents and 
convert files to text 
format (.txt) and 
classify files. Translate 
from any other 
languages into English 
further text 
contributions 
. 
Different text formats (email, template, 
translate if found in other languages).  
 
Important to also include the test text (pre 
and post consultation or official legislation 
at two or three points in time) into the 
analysis.  
 
3. Manually remove 
interest group names, 
headers and footers, 
contact details, address 
formulae (“Dear”) and 
citations; remove the 
template headings 
(Chapter, Comment, 
Suggested Change), the 
title of the study, the 
email subject phrase 
“draft report for 
written review” 
Remove all text pertaining to the template 
of the consultation. Proceed to creating the 
text files. Combine these per stakeholder. 
 
Bibliographic references are kept as the 
bibliography stakeholders choose to quote 
reveals their interests. It is important to 
keep these in. Individual page numbers and 
chapters quoted in the templates are 
furthermore removed. 
 
Links in references are kept. Correct typos 
so that results are accurate. 
 
 
4. Run JFREQ (create a 
frequency matrix – this 
allows an examination 
of the word count data 
per word used in Excel 
format). 
It is more beneficial to tick all pre-
processing options (no numbers or no 
currency, no stop-words in all files, no 
capitals) – this proves more useful as there 
are fewer columns with unique word roots 
in the end. 
JFREQ is extremely useful to detect errors 
in the sanitation of the data (spacing 
problems, words lumped together, etc). 
For instance, it is interesting to verify if the 
industry uses with a higher frequency 
words like “agreement”, 
“competitiveness”, “innovation”. 
 
 
5. Run Stata Wordscores 
(see code example in 
this manual) 
Examine scores. Reselect reference texts if 
scores do not appear aligned. Examine 
texts to decide on potential clusters (public 
health, industry) and skim through texts for 
critical control points. 
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6. Re-run JFREQ and re-
run Stata (if need be) 
JFREQ is very useful in deciding on critical 
control points. Put together a table without 
test texts with incipient stakeholder 
clusters.  
 
 
7. Optional : Validation 
via the Martin-Vanberg 
transformation in Excel 
and building its 
respective 95% 
confidence interval 
Simple re-scaling of texts to the original 
scale (as LBG transformation rescales the 
estimated raw scores to have the same 
variance as the original reference score), 
based on the most extreme values to 
render text scores directly comparable 
with reference texts. Calculate in Excel. 
  
 
8. Optional: create a box 
on sensitivity analysis, 
robustness check and 
plots/ confidence 
interval bar graph 
Put together a diagram plotting the scores 
and a table including test texts and refine 
the stakeholder clusters. 
 
9. Interpretation of 
results 
Look for anomalous submissions (low 
STATA raw score, low word count and a 
relatively broad confidence interval 
compared to other texts for the LBG 
transformation) and first mover advantage 
(innovators versus laggards, with the 
laggards closer to the industry reference 
score and the innovators visibly closer to 
the public health reference score). 
 
 
Points to consider prior and during Wordscores analysis: 
1. If after an iteration, the two test texts (e.g. the text consulted upon prior to the consultation 
and the text following the consultation) yield raw scores lower than either of the Public Health 
advocacy reference texts, the test needs to be dismissed on grounds of low face validity and 
the public health reference texts need to be re-selected. 
 
2. If two reference texts are chosen per stakeholder cluster (advocacy and industry), these should 
ideally be the ones with the two lowest and the two highest raw scores according to the Stata 
algorithm Wordscores. 
 
3. If the text consulted upon (the text for which the public consultation is run) has a much higher 
word-count than any of the other submissions, then the direction of travel and the travel 
achieved per se on the axis through the consultation is expected to be minimal. 
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Sample STATA Code for running the 
Wordscores algorithm 
~with special thanks to Dr. Helia Costa for the code 
net install http://www.tcd.ie/Political_Science/wordscores/wordscores, replace 
*net install wordscores 
*Change the directory to the folder where you have your texts (in txt format) 
cd "E:\Meeting21-07\Texts" 
*\\manor-road.ox.ac.uk\Store\Staff\Sociology\Data\myfolder 
*Transform the documents into frequency counts: 
wordfreq TRI2012.txt CONS.txt COM.txt PAR.txt 1.txt 2.txt 3.txt 4.txt 5.txt 7.txt 8.txt 9.txt 10.txt 
11.txt 12.txt 13.txt 14.txt 15.txt 16.txt 17.txt 18.txt 19.txt 20.txt 21.txt 22.txt A6.txt A7.txt A8.txt  
A9.txt A11.txt A14.txt  A15.txt A16.txt A17.txt A18.txt  
*Describe data: 
describetext tTRI2012 tCONS tCOM tPAR t1 t2 t3 t4 t5 t7 t8 t9 t10 t11 t12 t13 t14 t15 t16 t17 t18 t19 
t20 t21 t22 tA6 tA7 tA8 tA9 tA11 tA14 tA15 tA16 tA17 tA18 
*Classify position papers: texts 16 and 17 have known policy position situated at -1; 20 and 21 at 1 
setref t16 0  t17 0 t20 1 t21 1 
*Create scores for words based on these reference texts: 
wordscore nameofestimation 
*nameofestimation is the name you want to give to this scoring (eg. scoring1) 
*Score other texts based on the word scores previously calculated: 
textscore nameofestimation tTRI2012 tCONS tCOM tPAR t1 t2 t3 t4 t5 t7 t8 t9 t10 t11 t12 t13 t14 t15 
t18 t19 t22 tA6 tA7 tA8 tA9 tA11 tA14 tA15 tA16 tA17 tA18 
*Include the reference texts as virgins (useful for rescaling  ֠step 7): 
textscore nameofestimation tTRI2012 tCONS tCOM tPAR t1 t2 t3 t4 t5 t7 t8 t9 t10 t11 t12 t13 t14 t15 
t16 t17 t18 t19 t20 t21 t22 tA6 tA7 tA8 tA9 tA11 tA14 tA15 tA16 tA17 tA18 
*nameofestimation will be stored, so each time you want to classify more tests based on the same 
reference texts you can; otherwise use: 
*clear nameofestimation 
*Note that here we included the reference texts as virgin texts again - this is useful 
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Strengths and Weaknesses of QTA 
Frequently Asked Questions (FAQ) 
Capitalis ing on exist ing Methods for Quant itat ive Text Analysis when  
Examining Policy-related Texts 
 
I. General Background 
Wordscores in STATA v14.0 is an algorithm that infers policy positions, or scores, for new plain text 
documents, i.e. “virgin texts” on the basis of plain text documents with known scores, i.e. “reference 
texts”. It measures positions along an axis, for example right or left wing party manifestos or press 
releases for or against specific health regulations. 
JFREQ7 (previously integrated  in the statistical analysis programme R, now available as a stand-alone) 
is a quantitative text analysis programme taking plain text documents, counting words within them 
and producing a word frequency matrix across the sample. It is useful for identifying the most 
commonly used words across a sample of texts and hence, for identification of reference texts for the 
Wordscores code. 
1) What’s the purpose of QTA? 
QTA is applied via running JFREQ and the Wordscores algorithm in STATA v14.0. Based on the 
underlying assumption that agents with different policy positions use different wording and 
different concepts that reflect their stance, Wordscores uses the frequency of words in each 
document, relative to the total number of words in a text to output scores for each examined 
document.  
2) What’s the purpose of the manual?  
The manual consists of three guidance documents: the present FAQ on the strengths and 
weaknesses of QTA, the “Top Ten Mistakes Analysts Make” and the Protocol “QTA in Policy 
Development” step-by-step guide. The purpose of this manual is to guide users into mainstreaming 
QTA run via JFREQ and Wordscores in analysing texts for policy-related purposes. Coding syntax is 
included as an example. 
3) How can QTA help to examine written texts? 
Extracting policy positions from political texts using words as data has already been employed in 
the specialist literature, with varying rates of success. For an extensive list of relevant literature, 
the reference section of the present thesis provides a good introduction. QTA using Wordscores 
has been used previously in studies by Stuckler et al and Costa et al, as well as Kluever to quantify 
industry influence in environmental issues. 
  
                                                   
7 http://conjugateprior.org/software/jfreq/ 
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4) Who is the target user of the manual? 
The target user of the manual is any public health researcher, knowledge broker, policy 
entrepreneur or decision support analyst interested in tracking policy documents over time or 
capturing shifts in documents mapping the policy process. The initial review has identified 
Wordscores used jointly with JFREQ as having the greatest potential in selected fields of public 
health. 
5) How will the manual be used? 
The manual represents basic guidance that is made available together with the present thesis to 
help the research community in mainstreaming the use that is made of QTA for policy monitoring 
purposes. 
6) What kind of added value is expected from the manual? 
The added value in the manual refers mostly to the innovation brought by the present thesis and 
its differentia specifica. Advances in computing offer scope for mainstream usage of QTA in 
governmental institutions, drawing on text mining, computational linguistics and STATA-driven 
word-count analysis. 
7) How was the manual put together? 
The manual was drafted by the author as an aid to help uptake of the quantitative and mixed 
methods described in the thesis.  
II. What to do specifically? 
 
1) Am I expected to follow all the steps in the Manual/ Step-by-step Protocol ? 
It is advisable to follow the steps described in the guide as they are evidence-based and have been 
empirically tested and pilot tested with volunteers. However, tailoring is possible.  
2) Am I expected to systematically check that I avoid the “Top 10 Mistakes QTA analysts 
make”? 
The errors outlined in the document referred to above should significantly increase the chances of 
the operationalisation being accurate and rigorous. They have been selected on the basis of their 
significance and severity, as assessed by the author.  
3) How  am I expected to help improve the manual based on my experience? 
Outlining benefits and limitations of the present method is helpful – as is further guidance on how 
the method can be tested, refined and mainstreamed. 
III. Other potential questions on strengths and weaknesses of QTA 
 
1) Strengths: What is QTA particularly sensitive to? 
There is a premium on conciseness. QTA is well equipped for anomalous submission detection 
(illegible, empty or irrelevant submissions) and it is sensitive to the first mover advantage, it can 
distinguish between laggards in industry versus innovators. It is also sensitive enough to detect 
certain stakeholders by their school of thought (corporate interests vs. public health interests). 
2) Weakneses: What is QTA blind to? What disparities can it not explain? 
QTA is blind to legalese, pharmish, bankspeak and any other possibly distracting jargon. QTA is 
equally blind to tone, nuance and minor as opposed to severe wordiness.  
3) Is there an alternative to Wordscores and how does it compare to Wordscores? 
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Wordfish is a possible alternative to Wordscores. Both are driven by the frequency distributions of 
words. Wordfish does not require reference values, Wordscores having this extra assumption, 
however in the health policy field this is relatively easy to establish (see above). Wordfish requires 
R or R studio. Wordscores runs in Stata v14.0. Moreover, Wordfish is more appropriate for analysis 
of party manifestos, where words are quite different, rather than for public consultation 
processes. 
4) How does the Martin-Vanberg transformation compare to the LBG (Laver, Benoit and Gary) 
transformation included in the Wordscores algorithm? 
The LBG transformation automatically applied by Wordscores to the raw score has good face 
validity based on this study. The main criticism of the LBG transformation is: 
a) the LBG-transformed score are non-robust to the selection of virgin texts (they depend on the 
combination of virgin texts scored and the dispersion of the raw scores, the standard deviation);  
b) the LBG transformation fails to place the virgin texts on the same metric as the reference 
texts.    
Therefore, the Martin-Vanberg transformation is not a sine qua non for obtaining robust results. 
However, for a nuanced view, the MV transformation may be helpful. 
5) What limitations are expected? 
As with any statistical analysis tool, there will be limitations. The key assumption underlying the 
analysis is that stakeholders with different policy positions will use wording that reflects their 
ideology or stance. However, industry may seek to mimic the language of public health or vice 
versa. Also, it is statistically more difficult to prove that there was no influence rather than an 
adverse influence. Moreover, no large empirical data sets on the policy positions of interest groups 
are available yet (Kluever, 2009). The ultimate selection of sources remains the sole responsibility 
of the author.  
6) What further research to help improve the manual and shed further light on its benefits and 
limitations is expected? 
Further research is welcome and especially knowledge on benefits and limitations is in a position 
to help improve the manual. Future work should aim to extend the research to other policy areas 
and consultations elsewhere. This literature is based on recent studies and cannot be generalised 
to the whole population of public consultations. 
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The Top Ten Mistakes Analysts Make 
 
This document sets out the top ten mistakes analysts make when rolling out the QTA methodology set 
out in the manual to a set of policy-related texts. The intention is to draw attention to these common 
errors so that operators and practitioners are aware of them and can thus avoid them in future 
practice. 
Analysts of Jfreq and STATA make the following frequent mistakes in result interpretation, sensitivity 
analysis and confidence interval construction: 
1. Not ticking all pre-processing options for Jfreq in order to obtain a robust frequency matrix 
This may seem commonplace, but ticking all pre-processing options ensures that the text files are 
cleansed of numbers, currency, symbols, stop-words and capitals. This proves useful as there are fewer 
columns with unique word roots in the final frequency matrix output file. 
 
2. Not starting by skimming through the summary consultation document 
Reading the summary consultation document or the most balanced overview document primes the 
analyst to better assess the policy problem at hand, beliefs held by stakeholders, potential interests at 
play and likely concepts of note as well as initial clustering of stakeholders and their espoused policy 
positions. 
 
3. Not skimming through the submitted texts searching for critical control points 
It is good practice to skim through submitted texts so that: 
a) The stakeholder clustering (industry vs. public advocacy) becomes clearer. 
b) The reference texts for each cluster crystallise. 
c) The concepts promoted and the spin put on them (the specific framing of the problem) 
becomes clearer to the analyst. 
d) The analyst is in a position to identify any potential anomalous submissions.  
 
 
4. Not performing a stakeholder analysis after initially skimming the texts 
It is of considerable benefit to produce a rough stakeholder analysis as a first draft after an initial 
reading of the submitted texts, if the number of texts submitted are relatively limited and the task is 
feasible. If not, selecting a representative sample from each stakeholder cluster (industry vs. public 
advocacy or consumer groups) is of interest. The stakeholders in the selected sample should then be 
plotted on a basic stakeholder diagram. 
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5. Not refining the stakeholder analysis throughout the analysis 
Needless to say, the stakeholder analysis can be iteratively and manually refined as the STATA 
algorithm Wordscores is run and perfected. 
 
6. Not carrying out the anomalous submission test 
The anomalous submission test consists in seeking out texts that obtain a low STATA raw score, a low 
Wordcount and a relatively broad confidence interval compared to other texts for the LBG 
transformation. This step is important as otherwise, anomalous submissions may be mistaken for 
reference texts for one stakeholder group or another – whereas they are merely anomalous or snap 
submission texts. 
 
7. Not using Jfreq to decide on critical control points 
When constructing the comparison data tables, Jfreq estimates the frequency distribution of words 
across documents and hence critical words can be picked out and included in the extracted data tables 
(as per the case studies in this thesis).  
 
8. Not critically examining raw STATA scores and LBG and MV scores 
The Wordscores algorithm should be run several times, varying the reference texts chosen. The STATA 
raw scores, LBG scores and MV scores should be examined via dedicated tables and an executive 
decision taken whether the virgin or the test texts yield raw scores lower than either of the two 
reference texts for the advocacy group cluster (or mutatis mutandis, higher than either of the industry 
reference texts). If this is the case, then this iteration should be dismissed on grounds of low face 
validity. A different pair of advocacy group reference texts (or mutatis mutandis, industry reference 
texts) should be chosen and a new iteration of the Wordscores algorithm run.   
 
9. Not repositioning texts via coding and experimenting with the assignment of reference texts 
if the scores do not appear aligned at first glance 
If after an iteration, the virgin or test texts yield raw scores inferior to either of the advocacy group 
reference texts (or higher than either of the industry reference texts), then the test needs to be 
discontinued based on questionable face validity and re-run with a different set of reference texts for 
the advocacy group (or for the industry group). 
 
10. Not interpreting the results and not performing the sensitivity analysis for MV scores 
This last important step is necessary as underlying assumptions in the choice of critical control points 
may reflect analyst or reviewer bias in the parameters chosen for analysis. It is likely that the scale of 
undue influence of interest groups is underestimated via QTA performed as per the manual, since the 
text submitted for consultation may already have compressed the compromise. 
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